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1 INTRODUCTION 
1.1 Methotrexate 
Methotrexate (MTX, amethopterin) was introduced as a folate antagonist into 
cancer therapy more than 50 years ago. Since then it has gained widespread 
use also in the treatment of nonmalignant disorders such as rheumathoid 
arthritis, psoriasis, asthma and graft-versus-host disease where low doses 
(5-25 mg/week) have been shown to be beneficial. In the therapy of 
malignant diseases it is the most widely used antifolate. In conventional 
doses (< 100 mg/m2) it still plays an important role in the treatment of breast 
cancer, choriocarcinoma, squamous cell tumours of the head and neck and 
bladder cancer. However, progress in the treatment of acute lymphoblastic 
leukaemia (ALL), lymphoma, medulloblastoma and osteosarcoma was 
achieved after the introduction of high doses (1 - 33.6 g/m2) of MTX followed 
by calcium folinate rescue. Because of the efficacy of MTX, a central nervous 
system (CNS) directed administration was introduced for prevention of overt 
ALL relapses. Since then the intrathecal (i.th.) administration of low doses 
(8-12 mg) of MTX plays an important role in ALL and lymphoma protocols. 
 
1.1.1 Chemical structure 
MTX is a folate analogue and consists of a pteridine ring, p-amino benzoic 
acid and glutamic acid. The pteridine ring and the p-amino benzoic acid 
together form the pteroic acid. The difference in chemical structure between 
MTX and the naturally occuring folic acid is the presence of the amino group 
in position 4 and the methylation of nitrogen in position 10 of the pteroyl 
rest (see Fig. 1.1). 
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Fig. 1.1: Chemical structure of MTX (4-amino-N10-methyl-pteroylglutamic acid). 
 
1.1.2 Biochemical mechanisms of methotrexate activity 
Since MTX is a folate analogue its primary target is the cellular folate 
pathway. The entrance into a mammalian cell occurs via at least two different 
transport systems. The first one is the reduced folate carrier which has high 
affinity for reduced folates and MTX whereas the other utilises a folate 
receptor which has higher affinity for folic acid compared to reduced folates1. 
At high extracellular concentrations MTX may enter the cell by passive 
diffusion2. 
In the cell, MTX is, in analogy with cell folates, partly polyglutamated by the 
enzyme folylpolyglutamate synthetase3 which adds up to six or seven 
glutamic acid residues. Both mono- and polyglutamated MTX inhibit the 
enzyme dihydrofolate reductase (DHFR) with the same affinity4. However, 
MTX-polyglutamates remain bound to the enzyme for a longer period of 
time5 and are therefore retained in the cell. As a consequence of the 
inhibition of DHFR the conversion of dihydrofolates (DHF) into 
tetrahydrofolates (THF) is disabled leading to a depletion of reduced folates 
(see Fig. 1.2). In that way MTX indirectly affects the pyrimidine and purine  
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Fig. 1.2: Intracellular folate metabolism. 
Abbreviations: AICART: 5-aminoimidazole-4-carboxamide ribonucleotide 
transformylase; DHF: dihydrofolate; DHFR: dihydrofolate reductase; GART: 
glycineamide ribonucleotide transformylase; Hcy: homocysteine; Met: 
methionine; MTX-PG: methotrexate polyglutamate; THF: tetrahydrofolate; TS: 
thymidilate synthase.  
Red crosses indicate targets of MTX and MTX-PG whereas the interrupted 
arrow indicates indirect conversion. 
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synthesis since 5,10-methylene-THF is required for the thymidylate synthesis 
while 10-formyl-THF is important for the purine synthesis. Furthermore, MTX 
indirectly interferes with other metabolic pathways since 5-methyl-THF, the 
most important transport form of reduced folates, is also the methyl donor 
for the conversion of homocysteine to methionine. In conjuction with the 
depletion of reduced folates, dihydrofolates accumulate and are 
polyglutamated to a higher extent.  
MTX polyglutamates and DHF polyglutamates directly affect the pyrimidine 
synthesis by inhibiting the enzyme thymidilate synthase6, which is 
responsible for the conversion of uridine monophosphate (dUMP) to 
thymidine monophosphate (dTMP). Furthermore, the two enzymes of the 
purine synthesis glycineamide ribonucleotide (GAR) transformylase and 
5-aminoimidazole-carboxamide ribonucleotide (AICAR) transformylase are 
inactivated by polyglutamates of MTX and DHF7 (see Fig. 1.2). 
 
1.1.3 High-dose administration of methotrexate 
Since its introduction into clinical practice MTX has shown efficacy in the 
treatment of childhood ALL. However, therapy with conventional doses 
revealed to be unsuccessful in patients with CNS disease. Therefore, the 
administration of high-dose MTX (≥ 1 g/m2) was considered. The theoretical 
background for this approach was the postulation that more MTX would pass 
across the blood-brain barrier into the CNS and thus improve therapeutic 
outcome. 
However, the limiting factor for the administration of high doses was 
toxicity. A breakthrough occured with the pioneering work of Goldin et al.8 
who showed that delayed administration of calcium folinate could rescue 
nonmalignant cells from MTX toxicity without diminishing the cytotoxic 
effect of the drug on tumour cells. After that, it was possible to investigate 
the outcome of elevated doses of MTX in the treatment of ALL. 
The aim of high-dose therapy was to provide a prolonged CSF exposure to 
the MTX concentration of 1 µM9 which was determined to be cytotoxic in 
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vitro10. High-dose MTX was administered as a continuous infusion often 
preceeded by a loading dose.  
It had already been shown that after doses of 500 mg/m2 only a low 
cytotoxic concentration of MTX (0.1 µM) was achieved in the CSF11. 
Therefore, further attempts were made with more intensive dose regimens 
including 1-33.6 g/m2. Balis et al.12 reported concentrations of 10 µM in the 
CSF after an infusion of 33.6 g/m2, while Pitman et al.13 showed that the 
cytotoxic concentration of 1 µM was achieved after 3-7.5 g/m2. The 
introduction of high-dose MTX was accompanied with a notable decrease of 
systemic relapse rate in children with ALL compared to conventional doses14. 
Furthermore, Evans et al.15 showed that a relationship existed between the 
obtained steady-state serum concentration of MTX and the probability of 
remaining in remission. A serum concentration ≥ 16 µM was associated with 
a decreased relapse rate. However, the steady-state concentration obtained 
after 1 g/m2 was very variable (9.3-25.4 µM) and therefore the optimal dose 
of MTX in the therapy of childhood ALL still remains to be established.  
A benefit of high-dose MTX therapy followed by calcium folinate rescue was 
also shown in patients with primary central nervous system lymphoma 
(PCNSL). This is a rare but highly agressive non-Hodgkin’s lymphoma which 
often involves the leptomeninges, the eye and rarely the spinal cord16. 
Initially, PCNSL patients where treated with whole-brain irradiation and the 
median survival was 12-18 months with a 5-year survival rate of less than 5%. 
When high-dose MTX-based regimens were applied prior to radiotherapy the 
median survival increased to 60 months. However, such protocols were 
associated with considerable long-term neurological complications especially 
in elderly patients (> 65 years)17. In an attempt to reduce the toxicity 
preserving the efficacy of treatment, a polychemotherapy regimen alone 
based on high-dose infusions and intraventricular administration of MTX was 
proposed18. It was shown that response rates and duration after 
polychemotherapy were comparable to polychemotherapy combined with 
cranial irradiation (CI). Magnetic resonance imaging (MRI) revealed white 
matter changes in one third of the treated patient population but clinical 
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symptoms were not present. Altogether, there was less neurotoxicity in the 
polychemotherapy group since there was no substantial decline of cognitive 
function in patients who did not receive cranial irradiation. 
Initially, the administration of high-dose MTX in the therapy of malignant 
diseases was associated with considerable toxicity as well as drug-related 
deaths attributed mainly to severe myelosuppression and renal failure19. 
However, today high-dose MTX is considered to be generally well-tolerated 
when accompanied by an adequate hydratation, alkalisation, avoidance of 
drug interactions, drainage of the third space fluids (when present), 
pharmacodynamic monitoring and administration of an appropriate dosage 
of folinate rescue therapy20.  
Rescue mechanisms after high-dose methotrexate administration 
The role of rescue therapy which follows high-dose MTX administration is to 
minimise or even prevent the systemic toxicity of the drug while preserving 
its cytotoxic efficacy in tumour cells. Since MTX is an antifolate, folates were 
considered to be appropriate as antidotes. Several agents have been 
suggested for this role but the most widely used is the calcium salt of folinic 
acid (N5-formyltetrahydrofolic acid, Leucovorin®) due to its chemical stability 
(see Fig. 1.3).  
 
 
 
 
 
 
 
 
Fig. 1.3: Chemical structure of N5-formyltetrahydrofolic acid. 
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The exact mechanism by which calcium folinate rescues normal cells from 
toxicity is not well understood. However, several hypotheses have been 
suggested: (a) Calcium folinate is easiliy converted into other reduced folates 
thus restoring the intracellular pool of tetrahydrofolates and thereby 
circumventing the MTX-induced inhibition of folate metabolism (see Fig. 1.2). 
(b) As a reduced folate calcium folinate is transported into the cell via the 
reduced folate carrier and can thereby competitively inhibit the entrance of 
MTX. (c) By competing at the level of folylpolyglutamate synthetase it could 
decrease the polyglutamation of MTX. (d) A direct competition and 
displacement of MTX at the level of DHFR has also been suggested21. 
However, the inhibition of DHFR is sustained in the presence of MTX 
polyglutamates22.  
The efficacy of calcium folinate rescue is influenced by its administered dose, 
the extracellular concentration of MTX and the duration of exposure to 
cytotoxic concentrations of the drug21. Since elevated plasma concentrations 
of MTX require an intensified rescue it is common clinical practice to monitor 
plasma levels of MTX after high-dose infusion and adjust the dosage of 
calcium folinate if necessary. Another important aspect is the time of rescue 
initiation. A delayed rescue has been associated with irreversible toxicity23 
whereas an early administration may rescue tumour cells as well. It has been 
suggested that starting rescue 36-42 h after the beginning of the high-dose 
MTX infusion would provide a sufficient exposure to MTX with minimal 
toxicity23, 24.  
 
1.1.4 Intrathecal administration of methotrexate 
Although high-dose MTX therapy followed by rescue is well tolerated there is 
an intensive systemic exposure to the drug. Therefore, an attempt to 
circumvent the blood-brain barrier in order to avoid systemic drug exposure 
was made by intrathecal administration of MTX. Since this is a form of local 
chemotherapy, high concentrations of the drug in the CSF can be obtained 
with relatively low doses.  
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Initially, the dose of intrathecally administered MTX was based on body 
surface area similarly to high-dose MTX. However, Bleyer et al.25 proposed an 
age-related dosage regimen based on the results obtained in 
pharmacokinetic studies. They showed that a fixed dose provided 
significantly less variability in the CSF concentration of MTX. This could be 
explained by a more rapid enlargement of the CSF volume in children (where 
intrathecal MTX is distributed) compared to the body surface area. Since 
children at the age of 3 years reach the CSF volume of an adult, the body 
surface area did not correlate with the volume in which MTX was distributed.  
After intrathecal administration of low doses (6-12 mg) the concentration of 
MTX in the CSF is 100 times higher compared to plasma. Although low doses 
are injected intrathecally the drug is released slowly from the CSF and 
therefore a prolonged systemic exposure to the drug was observed when 
compared to an equivalent dose administered intravenously26. Nevertheless, 
compared to a high-dose infusion, intrathecal administration provided a 
reduced systemic exposure to the drug and considerably less systemic 
toxicity27. 
The introduction of the intrathecal administration of MTX was a major 
advance in the treatment of ALL patients with meningeal relapse. This led to 
a prophylactic or adjuvant use of intrathecally administered MTX in all ALL 
patients. In combination with cranial irradiation the use of intrathecal MTX 
reduced the incidence of meningeal relapse to less than 10%28, 29. 
Lumbar puncture  
The common mode of intrathecal administration of cytotoxic drugs is lumbar 
puncture. There are several disadvantages of this administration method. 
First, a leakage out of the subarachnoid space (where CSF flows) into the 
surrounding subdural or epidural space is possible30. Second, because of the 
slow unidirectional flow of CSF the distribution within the CNS is limited. It 
was shown that only 10% of the concentration of MTX in the lumbar CSF was 
simultaneously present in the ventricle26. Third, due to the vascular uptake of 
the drug, the penetration into the brain parenchyma is poor27, 31. A potentially 
lower risk of leakage as well as an improvement of the distribution of the 
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drug to the ventricles can be obtained if the patient is kept in a prone or 
supine position for at least 30 min after the lumbar puncture, a procedure 
which is nowadays common practice9.  
The lumbar puncture is a painful procedure which is another disadvantage 
especially in the treatment of children or if frequent intrathecal 
administration is necessary. 
Ommaya reservoir 
In order to overcome the problems associated with the lumbar injection a 
direct intraventricular administration of the drug was introduced with the use 
of an Ommaya reservoir. The access to the CSF is provided through a surgical 
placement of a catheter into the lateral ventricle. The other end of the 
catheter is attached to a subcutaneously implanted reservoir32 (see Fig. 1.4). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.4: Diagram of an Ommaya reservoir attached to a catheter9. 
 
The advantage of an intraventricular administration consists in a better 
delivery into the CSF as well as a better distribution of the drug throughout 
the CSF compartment26. It was also shown that children with recurrent CNS 
ALL who received intraventricular MTX had a reduced CNS relapse rate33 and 
an prolonged duration of CNS remissions compared to intralumbar 
administration34. Moreover, higher CSF MTX concentrations were reported 
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and a higher inter-patient consistency was achieved after intraventricular 
administration compared to an equivalent intralumbar dose11,26. 
Nevertheless, Strother et al.35 reported a considerable variability in the CSF 
MTX concentration both interindividually and intraindividually (in patients 
receiving several courses) after intraventricular drug administration. A 
possible explanation for this observation is the presence of CNS disease 
which may affect the CSF flow36 and induce sustained CSF MTX 
concentrations37-39. 
Since the administration of a drug via Ommaya is less painful for the patient 
this approach is suitable for frequent CNS-directed therapy. Bleyer et al.40 
showed that more frequent administration of lower doses 
(6x1 mg every 12 h ) induced a longer exposure to cytotoxic concentrations 
of MTX in the CSF. The total drug dose could be reduced. This so called C x T 
(concentration x time) approach was shown to be as effective in the 
treatment of meningeal ALL but less neurotoxic than a single-dose 
administration (12 mg/m2). 
The disadvantage of an Ommaya reservoir implantation is the need for a 
surgical treatment. Also high infection rates and a displacement of the 
catheter were observed. 
 
1.2 Neurotoxicity of methotrexate 
With the recognition that high-dose and intrathecal MTX play essential roles 
in the treatment of ALL, protocols have been developed in which the dose 
and frequency of the administration of MTX were more and more intensified. 
This further led to an increase of incidence of neurological complications in 
childhood ALL survivors. The severity of neurotoxicity varied from a transient 
and reversible form up to lasting damage leading to coma or even death. 
Similar observations were made in other patient populations who received 
intensified MTX regimens for the treatment of osteosarcoma or PCNSL.  
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The common classification of MTX-related neurotoxicity is related to the time 
of manifestation after therapy. Three forms are distinguished: acute, 
subacute and chronic neurotoxicity41-45. 
 
1.2.1 Acute neurotoxicity 
High-dose MTX is associated with acute neurotoxicity which may occur 
during or within hours after the infusion. It is characterised by acute 
somnolence, confusion, fatigue, disorientation or seizures41. Elevated 
intracranial pressure has also been observed41. Acute episodes of cerebral 
oedema have been reported in patients with CNS disease. However, it is 
possible that this toxicity is at least partly mediated by the lysis of tumour 
cells in the CNS since it does not occur in patients without overt disease41. 
Another form of neurological morbidity, the so called acute arachnoiditis 
(chemical arachnoiditis, acute toxic syndrome), was described after the 
intralumbar or intraventricular administration of MTX41. This syndrome 
occurs in 5-40% of patients41 usually within 2-4 h of the injection and lasts 
for 12-72 h46. The most common symptoms are headache, nausea, vomiting, 
fever, back pain, meningismus (pseudomeningitis) and dizziness41. 
Pathologically, pleocytosis (increased number of cells) and increased protein 
levels in the CSF, arachnoiditis and high intracranial pressure were 
observed41, 47, 48. Rarely this syndrome can present in a more dramatic form 
with massive polymorphonuclear pleocytosis in the CSF and high fever 
resembling bacterial meningitis47-49. The acute toxic syndrome is thought to 
be related to the dose and frequency of MTX administered as well as to the 
peak MTX levels in the CSF25, 37, 50.  
Although the acute form of MTX-related toxicity is usually reversible a fatal 
acute encephalomyelitis (inflammation of the brain and spinal cord) after a 
single intrathecal administration of MTX was reported51. 
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1.2.2 Subacute neurotoxicity  
After the administration of high-dose MTX a stroke-like syndrome was 
described which occured about one to two weeks after the infusion45, 52-54. 
Allen and Rosen53 observed this toxicity in a total of eight patients after the 
first, second or third course of high-dose MTX. All patients developed 
hemiparesis (partial paralysis of one body-half). Seizures, speech disorders, 
cranial nerve and gaze palsies and decreased conciousness were also 
reported. In two patients hemiparesis migrated from one side to the other. All 
patients recovered spontaneously after 48-72 h and after subsequent MTX 
courses this syndrome did not reoccur. Similar neurological complications 
occurred in 4% of patients who received 8-9  g/m2 of MTX for a variety of 
malignancies45 and in 15% of patients who received 12.5 g/m2 of MTX in the 
treatment of osteosarcoma43. 
Transient hemiparesis and speech disorder were also reported as a 
complication after intrathecal administration of MTX in one patient. 
Furthermore, this patient had focal cortical injuries which resembled an 
ischemic or stroke-like insult54. 
Intrathecal administration of MTX was also associated with a severe 
myelopathy followed by symptoms like pain in the legs, sensory changes, 
paraplegia (paralysis of both legs) and bladder dysfunction. The onset of 
symptoms occurred 30 min to 1-2 weeks after drug administration. Although 
partial or complete recovery was observed the disorder may have       
sequelae42, 47, 55, 56. Highly intensive short treatment sequences41, 56, a 
prolonged CSF exposure of MTX43 or long-term cumulative treatment56 were 
considered to be risk factors for this form of neurotoxicity. 
 
1.2.3 Chronic neurotoxicity 
Chronic neurotoxicity may develop months to years following MTX therapy.  
A transient leukoencephalopathy (pathologic alteration of the cerebral white 
matter) characterised by multifocal cerebral disturbances without signs of 
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dementia followed by a regained normal neurological status was reported 
after high-dose and intrathecal MTX57, 58. 
A severe form of leukoencephalopathy has also been associated with 
intensified high-dose MTX regimens57, 59. Allen et al.57 observed this 
syndrome in seven patients several months after the initiation of therapy 
with 8-15 g/m2 MTX. Patients presented first with subtle personality changes 
followed by progressive dementia, focal seizures, spastic quadriparesis and 
stupor. Only a partial recovery was seen in all patients after cessation of MTX 
therapy. Leukoencephalopathy was also seen in the computed tomographic 
scan (CT) of these patients as a hypodensity of the white matter. 
Demyelination (damage or destruction of the myelin sheath of neurons) and 
loss of cerebral parenchyma was manifested but no intracerebral 
calcifications were observed which are common after the combination of MTX 
therapy and cranial irradiation47, 60-63. High levels of MTX in the CSF were 
associated with this syndrome with an incidence of about 2%57.  
Severe leukoencephalopathy has been observed after intrathecal 
administration of MTX as well64-66. Symptoms varying from disorientation, 
lethargy, weakness to more severe such as personality changes, speech and 
movement disorders, hemiparesis, seizures and coma were described. In 
some cases the disease was progredient and fatal whereas other patients 
recovered partially or fully64, 66, 67. This severe form of leukoencephalopathy 
occurs rarely when only intrathecal MTX is used in the CNS disease 
prophylaxis41. However, when cranial irradiation is added to a high-dose and 
intrathecal MTX therapy the incidence is estimated up to 45%41, 47, 65. An 
overview of the symptoms of MTX-induced neurotoxicity is presented in 
Table 1.1. 
Besides leukoencephalopathy, chronic toxicity after CNS prophylaxis may be 
associated with significant neuropsychological dysfunctions such as learning 
disability, cognitive disturbances and decrease in intelligence. Although such 
sequelae were observed especially in the combined MTX and cranial 
irradiation treatment68-71, various authors showed that patients treated with  
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Table 1.1: Forms and symptoms of MTX-related neurotoxicity.  
Neurotoxicity Symptoms 
Acute 
High-dose MTX: Somnolence, confusion, fatigue, 
disorientation, seizures 
Intrathecal MTX: Chemical arachnoiditis: headache, nausea, 
vomiting, fever, back pain, dizziness 
Subacute 
High-dose and/or intrathecal MTX: Encephalopathy 
characterised by hemiparesis, speech and movement 
disorders, seizures, confusion, affective disturbances 
Intrathecal MTX: Myelopathy characterised by pain in the 
legs, sensory changes, paraplegia, bladder dysfunction 
Chronic 
High-dose and/or intrathecal MTX: Leukoencephalopathy 
characterised by confusion, somnolence or irritability, 
seizures, dementia, quadriparesis, visual disturbances, 
speech and movement disorders, coma, death 
Learning disability, cognitive disturbances, decrease in 
intelligence  
 
 
MTX without radiation therapy may also develop learning disability and a 
decrease in intelligence quotient72-74. 
 
1.2.4 Possible mechanisms of neurotoxicity  
Several hypotheses for the mechanism of induction of MTX-related 
neurotoxicity have been postulated. Some authors suggest a direct toxic 
effect of MTX on the CNS since experiments in animals or cell cultures 
showed that the drug may cause a direct axonal injury and affect the 
astrocytes75-78. 
Other investigators proposed that MTX-induced biochemical alterations may 
be responsible for the development of neurological complications44. Since 
MTX as a folate analogue impairs the folate cycle which is further related to 
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several other metabolic pathways there is a potential for possible indirect 
mediation of neurotoxicity. A detailed overview of the biochemical alterations 
induced by MTX is presented in this chapter. 
Adenosine metabolism 
Polyglutamated MTX and DHF inhibit the enzymes of the purine synthesis 
leading to an accumulation of glycineamide ribonucleotide (GAR) and 
5-aminoimidazole-4-carboxamide ribonucleotide (AICAR). Selected steps in 
the purine synthesis and degradation are depicted in Fig. 1.5.  
AICAR can inhibit 5’-adenylate deaminase and adenosine deaminase, 
enzymes mediating the catabolism of adenine ribotide and adenine riboside 
leading to elevated levels of adenosine monophosphate (AMP) and 
adenosine79.  
Elevated CSF concentrations of adenosine have been associated with clinical 
manifestation of acute neurotoxicity after high-dose MTX with or without 
intrathecal MTX80, 81. However, patients who received systemic MTX without 
developing signs of neurotoxicity had increased adenosine levels as well81.  
In two reports there was a partial or complete resolution of clinical symptoms 
after the administration of the adenosine receptor antagonist    
theophylline80, 81. These reports indicate that increased levels of adenosine 
may cause neurotoxicity, which is reversed by adenosine receptor 
antagonists.  
Biopterin metabolism 
MTX affects the biopterin pathway by inhibiting the regeneration of 
tetrahydrobiopterin (THB) from 7,8-dihydrobiopterin (DHB). The reduced 
biopterin is required for the hydroxylation of tyrosine, phenylalanine and 
tryptophan. The biosynthesis of bioamines and the metabolism of biopterins 
is shown in Fig. 1.6. 
Tetrahydrobiopterin can be either synthetised de novo from guanosine 
triphosphate (GTP), a pathway not affected by MTX, or it can be recycled from 
dihydrobiopterin in three ways all of which are affected directly or indirectly 
by MTX. The drug directly inhibits the enzyme dihydropteridine reductase 
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Fig. 1.5: Selected steps in purine synthesis and degradation.  
Abbreviations: AICAR: 5-aminoimidazole-4-carboxamide ribonucleotide; 
AICART: 5-aminoimidazole-4-carboxamide ribonucleotide transformylase; 
AMP: adenosine monophosphate; FGAR: formyl-glycineamide ribonucleotide; 
FICAR: 5-formamidoimidazole-4-carboxamide ribonucleotide; GAR: 
glycineamide ribonucleotide; GART: glycineamide ribonucleotide 
transformylase; IMP: inosine monophosphate; P
i
: inorganic phosphate; PRPP: 
5-phosphoribosyl-1-pyrophosphate; THF: tetrahydrofolate.  
Interrupted arrows indicate indirect conversion. 
 
 (DHPR)82 which is necessary for the reduction of quinoide dihydrobiopterin 
(qDHB) into the reduced form of biopterins, representing probably the main 
source of salvage. Moreover, quinoide dihydrobiopterin can be 
nonenzymatically converted into dihydrobiopterin which is reduced to
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tetrahydrobiopterin by DHFR. Furthermore, tetrahydrobiopterin may be 
regenerated from quinoide dihydrobiopterin in the presence of the enzyme 
5,10-methylenetetrahydrofolate reductase (MTHFR), whereby 5-methyl-THF is 
converted in 5,10-methylene-THF. This salvage process can be affected by 
MTX due to depletion of 5-methyl-THF.  
Since tetrahydrobiopterin is necessary for the synthesis of neurotransmitters 
such as serotonin and dopamine, a MTX-induced alteration of the biopterin 
pathway could result in a diminished synthesis of the necessary 
neurotransmitters83. An impairment of the catecholamine and biopterin 
metabolism has been associated with clinical signs of subacute neurotoxicity 
reported in several cases of children who received high-dose MTX alone or in 
combination with intrathecal MTX84,85. Decreased concentrations of 
homovanillic acid and 5-hydroxyindoleacetic acid, the major metabolites of 
dopamine and serotonin, respectively were determined in the CSF of one 
patient directly after the infusion of MTX. Both metabolites returned into the 
normal range after the spontaneous resolution of symptoms84. Another 
patient who was comatose had a decreased level of tetrahydrobiopterin in 
the CSF. The child did not respond to calcium folinate and 
methylprednisolone therapy but an improvement of the clinical condition was 
achieved after the administration of L-dopa, carbidopa and 
5-hydroxytryptophan (substitutive therapy for biopterin deficiency)86.  
In contrast to these case reports, some studies85, 87-89 revealed different 
results suggesting that after the administration of MTX the biosynthesis of 
serotonin and dopamine remains unaffected. Furthermore, experiments in 
rats and neuroblastoma cell cultures, performed to induce a deficiency of 
tetrahydrobiopterin with MTX, revealed no significant decrease in the 
reduced biopterin87,88 suggesting that MTX is unlikely to impair the 
hydroxylation of tyrosine and tryptophan88.  
Due to the contradictory literature data it still remains unclear whether or to 
which extent MTX is capable of altering the neurotransmitter biosynthesis by 
affecting the biopterin metabolic pathway.  
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Fig. 1.6: Biosynthesis of bioamines and metabolism of biopterins. 
Abbreviations: DHFR: dihydrofolate reductase; 7,8-DHB: 7,8-dihydrobiopterin; 
DHPR: dihydropteridine reductase; GTP: guanosine triphosphate; HIAA: 
5-hydroxyindoleacetic acid; HVA: homovanillic acid; MTHFR: 
5,10-methylenetetrahydrofolate reductase; Phe: phenylalanine; PheH: 
phenylalanine hydroxylase; qDHB: quinoide dihydrobiopterin; THB: 
tetrahydrobiopterin; Trp: tryptophan; 5-OH-Trp: 5-hydroxytryptophan; TrpH: 
tryptophan hydroxylase; Tyr: tyrosine; TyrH: tyrosine hydroxylase.  
Intermediate conversion is depicted with interrupted arrows. 
 
Homocysteine metabolism 
The homocysteine pathway is linked to the folate cycle via the coenzyme 
5-methyl-THF which serves as the methyl group donor for the methylation of 
homocysteine to methionine. This reaction is catalysed by the enzyme 
methionine synthase and requires vitamin B
12
 as a cofactor. In the kidneys 
and the liver homocysteine can be metabolised to methionine via 
betaine-homocysteine methyltransferase (BHMT), but this enzyme has not 
been found in the brain of animals or man90. The reaction of methionine and 
adenosine triphosphate in the presence of the enzyme methionine 
adenosyltransferase yields S-adenosylmethionine (SAM), the most important 
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methyl donor in the metabolism of the cell. SAM can be further metabolised 
to S-adenosylhomocysteine (SAH). The hydrolysis of SAH results in adenosine 
and homocysteine (see Fig. 1.7). 
The main route of catabolism of homocysteine is by entering the 
transsulphuration pathway starting with the conversion to cystathionine, 
catalysed by cystathionine-ß-synthase (CBS). Cystathionine is converted to 
cysteine which can subsequently be oxidised to cysteine sulphinic acid (CSA) 
and cysteic acid (CA). In analogy to the cysteine oxidation pathway 
homocysteine can be oxidised to homocysteine sulphinic acid (HCSA) and 
homocysteic acid (HCA). Enzymes catalysing this metabolic route of 
homocysteine have not been described, therefore a non-enzymatic 
conversion has been suggested91. Due to the high structural resemblance of 
CSA, CA, HCSA and HCA to aspartate and glutamate, known as excitants in 
the mammalian brain, these sulphur-containing amino acids exhibit strong 
excitatory effects as well92.  
By reducing the level of 5-methyl-THF and thereby disabling the 
remethylation of homocysteine MTX strongly interferes with the metabolism 
of this amino acid. By affecting the homocysteine pathway indirectly MTX 
could induce an elevation of the concentration of the amino acid as well as a 
decrease of SAM and increase of SAH in the CSF. All three compounds could 
be involved in the pathogenesis of neurotoxicity. The potential consequences 
of the alteration of homocysteine and its metabolites are presented below 
while those of SAM and SAH will be shown in chapter 1.4. 
During the oxidation of homocysteine, reactive oxygen species are produced 
which could further oxidise neuronal unsaturated fatty acids resulting in 
nerve damage93-95. Furthermore, sulphur-containing excitatory amino acids 
have a high affinity to the N-methyl-D-aspartate (NMDA) receptor96-99 a 
subtype of the glutamate receptor present in the CNS. The stimulation of the 
NMDA receptor induces an intracellular release of calcium ions leading 
further to an activation of cytotoxic enzymes and resulting in cell death100-102. 
NMDA receptor antagonists are effective anticonvulsive agents and it was  
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Fig. 1.7: Homocysteine metabolism.  
Abbreviations: ATP: adenosine triphosphate; SAM: S-adenosylmethionine; 
SAH: S-adenosylhomocysteine; THF: tetrahydrofolate. Enzymes: (1): 
methionine synthase; (2): betaine-homocysteine methyltransferase; (3): 
methionine adenosyltransferase; (4): methyltransferase; (5): 
S-adenosylhomocysteine hydrolase; (6): cystathionine-ß-synthase; (7): 
cystathionase; (8): cysteine dioxygenase; (9): cysteine sulphinic acid 
dehydrogenase. 
The conversion of cysteine to gluthatione requires steps which are not 
presented (interrupted arrow). 
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suggested that sulphur-containing excitatory amino acids are likely to play a 
role in the pathogenesis of seizures. Elevated concentrations of 
homocysteine in the CSF were reported in patients who received high-dose 
MTX103-105. Quinn et al.106 observed elevated concentrations of homocysteine 
in a patient after intraventricular administration of MTX. Drachtman et al.103 
reported elevated homocysteine levels in patients with signs of subacute 
neurotoxicity compared to asymptomatic patients. These authors also 
observed a resolution of symptoms in patients after administration of the 
NMDA receptor antagonist dextromethorphan. This fact suggests that the 
observed neurotoxicity was at least partly mediated by the 
sulphur-containing excitatory amino acids. 
Very high concentrations of HCSA and CA but especially CSA and HCA were 
found in the CSF of patients who received high-dose MTX104, 105. Patients with 
clinical signs of toxicity also had the most elevated concentrations of the 
metabolites. On the contrary, in a control group of healthy adults the 
sulphur-containing excitatory amino acids were not detected104.  
 
1.3 Folates 
The folate metabolism is the main target of MTX and its polyglutamates and 
therefore special attention should be paid to the assessment of the potential 
role of the folate pathway impairment in the pathogenesis of the drug-related 
neurotoxicity. Since 5-methyl-THF (N5-methyltetrahydrofolic acid) is the main 
transport form of reduced folates its concentration in serum and CSF has 
been used to assess the cellular folate status. The evaluation of the 
concentration of 5,10-methylene-THF (N5,N10-methylenetetrahydrofolic acid) 
could be important in determining the proliferative potential since it is a 
substrate for the thymidilate synthesis. The chemical structure of the two 
reduced folates is presented in Fig. 1.8.  
Depletion of reduced folates has been observed in some metabolic disorders 
such as DHFR deficiency, hereditary folate malabsorption and nutritional 
folate deficiency107. Moreover, serum folate deficiency has also been
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Fig. 1.8: The chemical structure of A: N5,N10-methylenetetrahydrofolic acid 
and B: N5-methyltetrahydrofolic acid. 
 
associated with psychiatric disorders such as depression and schizoid 
psychosis and symptoms such as insomnia, forgetfulness, irritability and 
mental retardation have been reported108-114.  
Clinical signs such as deceleration of head growth, behavioural changes, 
psychomotor retardation, cerebellar ataxia, dyskinesia, pyramidal signs and 
occasional seizures have been associated with decreased concentration of 
5-methyl-THF in the CSF115. Depletion of the methyl donor was also observed 
in patients treated with MTX104, 105. Quinn et al.106 reported a decrease of the 
CSF 5-methyl-THF concentration in one patient who received MTX 
intraventricularly without calcium folinate rescue. The authors also showed 
that the lower concentration persisted in the CSF for at least a week after the 
last intra-Ommaya MTX administration. 
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However, it is unclear if there is a direct relationship between the decreased 
concentration of reduced folates and MTX-induced neurotoxicity. On the 
other hand, it has been shown that the folate metabolism is closely related to 
other metabolic pathways. Moreover, patients with MTHFR deficiency were 
shown to have significantly decreased levels of SAM116, 117 and significantly 
elevated levels of homocysteine118. This could be an indication that the 
reduced folates participate indirectly in the development of the MTX-related 
neurotoxicity by altering other metabolic pathways. Nevertheless, it is 
important to elucidate the relationship between the concentration of the 
reduced folates which are primarily affected by MTX and metabolite levels 
which are thought to be involved in the pathogenesis of MTX-associated 
neurotoxicity. 
 
1.4 S-adenosylmethionine/S-adenosylhomocysteine 
It has been postulated that the MTX-induced depletion of reduced folates 
possibly induces an impairment of the homocysteine pathway which could 
further lead to a decrease of the SAM and an increase of the SAH 
concentration. Because of the importance of the cellular role of SAM and SAH 
(also referred to as the methyl-transfer pathway), their CSF determination was 
an aim of this work and the consequences of their alteration are therefore 
presented in detail in this chapter. 
Since SAM arises through the reaction between adenosine and methionine 
(see Fig. 1.7) it contains a methylated sulphur which is positively charged. 
Because of such chemical structure SAM is an instable compound which 
easily donates the methyl group converting to SAH (see Fig. 1.9). 
SAM is thought to be the sole methyl donor in a variety of transmethylation 
reactions119 involving at least 130 methyltransferase enzymes120. The 
biological activity of many compounds such as proteins, nucleic acids, fatty 
acids, phospholipids and polysaccharides is altered by methylation121, 122. 
Moreover, SAM is necessary for the inactivation of catecholamines and other
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Fig. 1.9: Chemical stucture of A: S-adenosylmethionine and B: 
S-adenosylhomocysteine. 
 
biogenic amines and it is indirectly involved in the polyamine, purine and 
pyrimidine synthesis123-126. SAH on the other hand is a powerful competitive 
inhibitor of methyltransferase enzymes127, 128. Therefore, a decrease of the 
SAM concentration and/or an increase of the SAH concentration could induce 
hypomethylation leading further to a variety of disorders in the cell.  
It is known that SAM takes part as a methyl donor in the synthesis of choline 
which is a part of the structure of neuronal myelin sheath. The role of the 
myelin sheath is to protect axons and enable a rapid and efficient 
transmission of impulses along the nerve cell (see Fig. 1.10). It was 
postulated that hypomethylation could induce demyelination leading to 
neuronal damage. In effect, low CSF SAM concentrations were associated with 
demyelination of the cerebral white matter117, 129.  
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Fig. 1.10: Diagram of an axon with normal and damaged myelin sheath. 
 
Demyelination has been observed in various diseases such as depression, 
Alzheimer’s dementia, HIV infection, subacute combined degeneration of the 
spinal cord and multiple sclerosis117, 129-135 all of which are assocciated with 
neurological disorders. Moreover, demyelination is a common feature 
observed in MTX-associated subclinical and clinical     
leukoencephalopathy136-142 and it has therefore been postulated that the 
alteration of the CSF concentration of SAM and SAH may play a role in its 
pathogenesis. 
Surtees et al.136 reported a significant decrease of CSF SAM concentration in 
children with ALL who were intrathecally treated with MTX. They associated 
these findings with a subclinical demyelination which was observed in these 
patients. Similar findings regarding the CSF SAM concentration were reported 
in one patient who received MTX intraventricularly106. 
Kishi et al.137 investigated both SAM and SAH in two ALL patients with 
clinically manifest leukoencephalopathy, a group of ALL patients without 
clinical symptoms of leukoencephalopathy and a control group. ALL patients 
had a significantly lower concentration of SAM compared to the reference 
group whereas the concentration of SAH was similar in both groups. The two 
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patients with severe neurotoxicity had a slightly lower CSF SAM concentration 
and a markedly higher SAH concentration compared to the ALL patients 
without manifest leukoencephalopathy, suggesting that a SAM/SAH ratio may 
be a marker for leukoencephalopathy rather than the concentration of SAM 
solely. However, the two neurotoxic patients received a combination of 
high-dose and intrathecal MTX as well as cranial irradiation whereas other ALL 
patients received no cranial irradiation. Since the influence of cranial 
irradiation on the development of leukoencephalopathy in these patients 
could not be assessed it remains unclear whether such severe neurotoxicity 
can be induced by high-dose and intrathecal MTX through an alteration of the 
SAM/SAH ratio. 
If neurotoxicity associated with MTX is partly mediated by an alteration of the 
concentration of SAM and SAH it may be possible to prevent or at least 
reduce it by normalising the levels of these metabolites without thereby 
compromising the efficacy of MTX. It was shown in severely depressed 
patients that after oral or intravenous SAM administration its CSF 
concentration increased indicating the capacity of the metabolite to pass the 
blood-brain barrier130. Also betaine has shown to be effective in elevating the 
concentration of SAM in the CSF129.  
Surtees et al.117 showed that the normalisation of SAM levels in the CSF was 
associated with remyelination. Furthermore, after substitution with SAM an 
antidepressant effect in patients with Parkinson’s disease138 and an 
improvement in cognitive dysfunction as well as mood and speed of mental 
processing in patients with Alzheimer’s dementia was reported139. All these 
data indicate that a supplementation with SAM may be beneficial also for 
patients treated with MTX who develop a transient or lasting alteration of the 
methyl-transfer pathway. 
In summary, it has been shown that the folate metabolism, which is impaired 
after MTX therapy, interferes with several other metabolic pathways. 
Therefore, it is probable that the pathogenesis of MTX-associated 
neurotoxicity is complex and multifactorial. Nevertheless, elucidating the 
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mechanisms of this type of toxicity could provide possibilites for its 
circumvention thus increasing the safety of the MTX therapy.  
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2 AIM AND OBJECTIVES 
MTX administered as a high-dose infusion and/or intrathecally is gaining 
more and more importance in modern therapy regimens for ALL, PCNSL, 
osteosarcoma and medulloblastoma since it is associated with higher and 
prolonged remission rates. Patients seem to benefit from an intensified 
therapy regimen which comprises both a higher dose of the antifolate as well 
as a more frequent administration. Since such therapy intensification is also 
associated with a higher incidence of neurotoxicity it is essential to elucidate 
the pathogenetic mechanism of this undesired side effect in order to prevent 
it. It has been suggested that MTX-associated neurotoxicity is a consequence 
of the alteration of biochemical pathways related to the folate cycle.  
Since clinical signs of neurotoxicity are thought to be a consequence of the 
MTX-induced damage to the brain tissue it is necessary to reveal MTX-related 
biochemical changes in the neuronal cells. However, this would require 
sampling of neuronal tissue which is not possible in humans. CSF (of all body 
fluids) reflects most closely the biochemical status in the brain tissue and 
was therefore regarded as the matrix in which such biochemical analysis 
could be performed. 
The aim of this study was to assess the effect of systemic high-dose and/or 
intrathecal administration of MTX on the folate and homocysteine pathway in 
the CSF. The CSF analysis involved the determination of the concentration of 
• Methotrexate 
• 5-methyl-THF 
• 5,10-methylene-THF 
• Calcium folinate 
• S-adenosylmethionine and S-adenosylhomocysteine  
• Homocysteine 
• Homocysteic acid and homocysteine sulphinic acid 
• Cysteine 
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• Cysteic acid and cysteine sulphinic acid 
• Glutathione 
The analysis of homocysteine and sulphur-containing excitatory amino acids 
in the CSF was performed by Achim Becker140.  
CSF samples were obtained from patients who received high-dose and/or 
intrathecal MTX therapy for PCNSL or childhood ALL. PCNSL patients had an 
implanted Ommaya reservoir and an intensive protocol regarding 
administration of MTX which enabled frequent CSF sampling. From ALL 
patients samples were obtained by lumbar puncture throughout the therapy 
regimen.  
In order to achieve the aim of the study the following objectives were defined: 
• Development and validation of an high-performance liquid 
chromatography (HPLC) method for the analysis of 5,10-methylene-THF, 
5-methyl-THF, calcium folinate and MTX in the CSF 
• Development and validation of an HPLC method for the analysis of SAM   
and SAH in the CSF 
• Development and validation of an HPLC method for the analysis of 
homocysteine and cysteine in the CSF (A. Becker) 
• Development and validation of an analytical method using capillary 
electrophoresis for the analysis of sulphur-containing excitatory amino 
acids (A. Becker)  
• Sampling and evaluation of the possible neurotoxic symptoms using 
common toxicity criteria (CTC) in cooperation with medical doctors  
• Determination of the concentration of the above listed substances in 
the CSF    
• The quantitative assessment of the effect of systemically and/or 
intrathecally administered MTX on the folate pathway and SAM/SAH. 
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3 MATERIALS AND METHODS 
3.1 Materials 
A brandname may be trademarked even when it is not noticed.  
 
3.1.1 Reference substances 
• Folinic acid, calcium salt (Sigma Aldrich, Steinheim, Germany) 
• Methotrexate (Sigma Aldrich, Steinheim, Germany) 
• N5,N10-methylenetetrahydrofolate (Dr. Schircks Laboratories, Jona, 
Switzerland) 
• N5-methyltetrahydrofolate (Sigma Aldrich, Steinheim, Germany) 
• S-adenosyl-L-homocysteine (Sigma Aldrich, Steinheim, Germany) 
• S-adenosyl-L-methionine, iodide salt (Sigma Aldrich, Steinheim, 
Germany) 
3.1.2 Chemicals for the analysis of MTX and reduced folates 
• Ascorbic acid (Merck, Darmstadt, Germany) 
• Methanol LiChrosolv® HPLC grade (Merck, Darmstadt, Germany) 
• Phosphoric acid 85% (V/V) (Fluka Chemie GmbH, Neu-Ulm, Germany) 
• Potassium dihydrogen phosphate (Merck, Darmstadt, Germany) 
• Sodium hydroxide (Merck, Darmstadt, Germany) 
• Tris(hydroxymethyl)-aminomethane (Merck, Darmstadt, Germany)  
• Water Ampuwa® (Fresenius Kabi AG, Bad Homburg, Germany) 
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3.1.3 Chemicals for the analysis of SAM and SAH 
• Acetonitrile (Fisher Scientific, Longborough, UK) 
• Chloroacetaldehyde 45% (Merck, Darmstadt, Germany) 
• 1-Heptanesulphonic acid, sodium salt 98% (ACROS Organics, New 
Jersey, USA) 
• Perchloric acid 70% (Sigma-Aldrich, Steinheim, Germany)  
• Phosphoric acid 85% (V/V) (Fluka Chemie GmbH, Neu-Ulm, Germany) 
• Potassium dihydrogen phosphate (Fluka Chemie GmbH, Neu-Ulm, 
Germany) 
• Sodium acetate (Fluka Chemie GmbH, Neu-Ulm, Germany) 
• Sodium chloride (Fluka Chemie GmbH, Neu-Ulm, Germany) 
• Water PurelabTM Plus (USF, Ransbach-Baumbach, Germany) 
 
3.1.4 Consumables and devices 
• Analytical balance Kern 770 (Gottlieb Kern & Sohn, Albstadt, Germany) 
• Centrifuge Microfuge® Lite (Beckman-Coulter, Fullerton, USA) 
• Magnetic stirrer RMH71 (Gerhardt GmbH & Co. KG, Königswinter, 
Germany)  
• One-channel pipets 1-1000 µL (Fischer Scientific, Schwerte, Germany) 
• Pipet tips (Brand GmbH & Co, Wertheim, Germany) 
• pH meter inoLab pH level 2 (WTW, Weilheim, Germany) 
• Reaction tubes 1 mL (Eppendorf AG, Hamburg, Germany)  
• Sample mixer (Gesellschaft für Laborbedarf, Würzburg, Germany) 
• Ultrasonic bath Sonorex Super RK 103 H (Bandelin, Berlin, Germany) 
• Vials 2 mL (Sarstedt, Nümbrecht, Germany) 
• Waterbath MGW Lauda RM 6 (Werk Lauda, Lauda-Königshofen, 
Germany) 
• Waterdestiller PurelabTM Plus (USF, Ransbach-Baumbach, Germany) 
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3.2 Instruments  
3.2.1 HPLC system for the analysis of MTX and reduced 
folates  
• Vacuum membrane degaser: SCM 1000 
                                        (Thermo Separation Products, Inc.,   
                   Egelsbach, Germany) 
• System contoller:   SN4000 
(Thermo Separation Products, Inc, 
Egelsbach, Germany) 
• Pumps:    SpectraSYSTEM® P4000                                               
          (Thermo Separation Products, Inc,     
         Egelsbach, Germany) 
• Autosampler:   SpectraSYSTEM® AS3000 
(Thermo Separation Products, Inc,  
Egelsbach, Germany) 
• Precolumn:    Supelguard™ LC-18-DB; 
2 x 0.46 cm, 5 µm 
(Supelco, Bellefonte, USA) 
• Column:    Supelcosil™ LC-18-DB;  
                                                        15 x 0.46 cm, 3 µm 
      (Supelco, Bellefonte, USA)  
• Detectors:    UV Detector: UV6000LP 
Fluorescence Detector: FL3000 
(Thermo Separation Products, Inc,      
Egelsbach, Germany) 
• Software:    ChromQuest®, Version 2.51 
(ThermoQuest Corporation, Egelsbach 
Germany)  
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3.2.2 HPLC system for the analysis of SAM and SAH 
• Interface:    D-6000 
(Merck-Hitachi, Darmstadt, Germany) 
• Pumps:    L-6200 Intelligent Pump 
                                            L-6000 Pump                                                              
          (Merck-Hitachi, Darmstadt, Germany) 
• Autosampler:   AS-2000A 
(Merck-Hitachi, Darmstadt, Germany) 
• Precolumn:    Nucleosil™ LC-18-DB; 
2 x 0.46 cm, 5 µm 
(Supelco, Bellefonte, USA) 
• Column:    Eclipse AAA LC-18-DB;  
                                                        15 x 0.46 cm, 5 µm 
(Agilent Technologies Inc., Palo Alto,   
USA)  
• Detector:    Fluorescence Detector: L-7480 
(Merck-Hitachi, Darmstadt, Germany) 
• Software:    Model D-7000 Chromatography        
Station Software 
(Merck-Hitachi, Darmstadt, Germany) 
 
 
3.3 HPLC analysis for the determination of reduced 
folates and MTX in the CSF 
3.3.1 Chromatographic conditions 
In order to determine the CSF concentrations of 5,10-methylene-THF, 
5-methyl-THF, calcium folinate and MTX an assay from Belz et al141 was 
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adapted based on reversed-phase chromatography with fluorescence and 
ultraviolet (UV) detection*.  
Since the three reduced folates have natural fluorescence at excitation and 
emission wavelengths of λ=294 nm and λ=356 nm respectively, the use of 
fluorescence detection without prior sample derivatisation was enabled. The 
signal intensity of calcium folinate was similar with both fluorescence and UV 
detector and the latter was used for its quantification at λ=310 nm. MTX does 
not show fluorescence at the above-specified conditions and was therefore 
quantified by using UV detection together with calcium folinate.  
Sample preparation consisted in thawing the frozen sample at room 
temperature and pippeting 100 µL into a vial which was then put into the 
autosampler. 50 µL of the sample was injected into the system. The flow rate 
was kept constant at 1 mL/min. The analytes were eluted using a mobile 
phase which consisted of methanol (eluent A) and 10 mM phosphate buffer, 
pH 2.1 (eluent B). The buffer was prepared by dissolving 1.36 g of potassium 
dihydrogen phosphate in 1000 mL water and phosphoric acid was used to 
adjust the pH. Elution was performed by the use of the gradient presented in 
Table 3.1. The retention times of each of the analysed substances are 
presented in Table 3.2. 
 
3.3.2 Sample collection 
In order to avoid oxidation of the instabile tetrahydrofolates 
5,10-methylene-THF and 5-methyl-THF, CSF samples were collected into vials 
containing ascorbic acid. A solution of ascorbic acid (25 mg/mL) was 
prepared by dissolving 250 mg in 10 mL water. This solution was aliquoted 
into vials each containing 100 µL and frozen at -20 ºC. Immediately before 
sampling, vials were thawed at room temperature. 500 µL CSF was added and  
                                       
* In tables 5,10-methylene-THF will be abbreviated as 5,10-MeTHF, 5-methyl-THF as 5-MTHF 
and calcium folinate as Ca-folinate in order to obtain a better survey of data in the available 
space. 
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Table 3.1: Gradient for HPLC elution of 5,10-methylene-THF, 5-methyl-THF, 
calcium folinate and MTX  
Time 
(min) 
Methanol  
(%) 
Phosphate buffer  
(10 mM, pH 2.1) 
(%) 
0 87 13 
12 87 13 
20 60 40 
22 87 13 
23 87 13 
 
 
Table 3.2: Retention times of 5,10-methylene-THF, 5-methyl-THF, calcium 
folinate and MTX during HPLC analysis. 
Analyte Retention time 
(min) 
5,10-MeTHF 6.5 
5-MTHF 8.8 
Ca-folinate 18.0 
MTX 21.0 
 
 
samples were centrifuged at 15 500 x g for 10 min. The supernatant was 
frozen directly afterwards at -20 ºC. 
 
3.3.3 Validation 
The method was validated according to the Guideline of the Food and Drug 
Administration (FDA Guidance for Industry, Bioanalytical Method 
Validation)142. Selectivity, stability of the compounds, recovery, limit of 
quantification, limit of detection, precision, accuracy and linearity were 
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assessed. The results were evaluated with the Software “Method Validation in 
Analytics” (MVA®), Version 2.0 (Novia GmbH Saarbrücken, Germany). 
3.3.3.1 Selectivity 
Selectivity of the method assures that the desired analytes are identified and 
quantified without interference of related compounds (degradants, 
metabolites, impurities etc.) or components of the matrix (endogenous 
substances etc.).  
The selectivity of the method for each compound was assessed by 
comparison of chromatogrammes of buffer or CSF samples to which 
standard solutions of each compound were added and samples which 
contained buffer or CSF without the addition of analytes.  
 
3.3.3.2 Stability 
Some information refering to the stability of the analysed substances was 
found in the literature, such as the stability of stock solutions when stored 
at -20 ºC141. The stability of the analytes in CSF at room temperature and the 
stability when stored at 4 ºC was investigated. 
To determine the stability at room temperature a frozen sample which served 
as reference was thawed and analyzed. Immediately after that a freshly 
prepared solution containing equal concentrations of the analytes as the 
reference sample was placed in the autosampler and analysed repeatedly for 
10 h. This procedure was performed on the following two days as well. 
To determine the stability at 4 ºC three samples were prepared analyzed and 
stored in the refrigerator. These samples were analysed on three subsequent 
days and compared to reference samples (containing equal analyte 
concentrations) which were stored at –20 ºC and thawed immediately before 
analysis. Thus, it was possible to distinguish between the instability of the 
analytes and the variation in the chromatographic system due to changes of 
temperature and air pressure. 
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Moreover, stability of the analytes in CSF was determined after two freeze 
and thaw cycles. Thereby it was possible to determine whether patient CSF 
samples could be analysed twice or three times if necessary without analyte 
loss. CSF samples were spiked with all four analytes in three different 
concentrations. An aliquot of each of the three CSF samples was analysed, 
the rest was frozen. The frozen aliquots were thawed after few days, 
analysed and the remaining content was frozen again. This was referred to as 
the first freeze and thaw cycle. The frozen samples were thawed once more 
and analysed. This was the second freeze and thaw cycle. 
The stability was calculated in different time intervals with the following 
equation (Eq. 3.1): 
 
  
 
 
 
3.3.3.3 Recovery 
Recovery experiments were performed in order to determine if there was any 
difference in response between a buffer solution and the CSF matrix when 
equivalent concentrations of analytes were measured. No difference or a 
constant ratio enable calibration of the analytes in the buffer solution.  
The CSF used in the experiment was obtained from six patients and pooled. 
The response in the pooled CSF was determined for each analyte at three 
different concentrations which corresponded to the lower, middle and upper 
range of the calibration curve. The determination of each concentration was 
repeated three times. Since 5,10-methylene-THF and 5-methyl-THF are 
endogenous in the CSF it was necessary to determine the response of these 
analytes in the unspiked CSF as well. The unspiked CSF was also analysed 
three times and the mean value of the response (peak area) was then 
substracted from the response of the spiked CSF samples. These results were 
Eq. 3.1 100
CPA
CPA
(%)Stability
REF
x ⋅=
sample reference CSF the of area peak corrected CPA REF = 
x at sample CSF the of area peak corrected CPA x = temperature 
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compared to the results of buffer solutions containing equal concentrations 
of analytes as the CSF samples and recovery was calculated according to the 
following equation (Eq. 3.2): 
 
 
 
 
 
 
3.3.3.4 Limit of detection 
The limit of the detection (LOD) is the minimal amount of a compound which 
can be detected with certainty. For the described HPLC method the limit of 
detection was estimated as signal-to–noise ratio 3:1. 
 
3.3.3.5 Lower limit of quantification 
The lower limit of quantification (LLOQ) is the lowest concentration of the 
analyte which can be precisely and accurately quantified. For the described 
HPLC method the limit of quantification was defined as the lowest 
concentration of the analyte which had a between-day coefficient of variation 
and relative error lower than 20%. 
 
3.3.3.6 Precision 
Precision experiments study the effect of random variations in the 
performance of a method. Precision is assessed through multiple analysis of 
a homogenous sample and standard deviation is the statistical parameter 
used for its description. The standard deviation (synonym coefficient of 
variation, CV) is calculated with the following formula (Eq. 3.3): 
 
Eq. 3.2 
veryecoRR =
100 
x 
x 
(%) R 
Buffer 
CSF ⋅ = 
sample the of area peak the of value Mean x Buffer = buffer 
CSF the of area peak the of value Mean x CSF = sample 
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The precision of the method within a day (within-day precision, repeatability) 
and between days (between-day precision, reproducibility) was assessed. 
Within-day precision was obtained by preparing and analysing six CSF 
samples with equivalent concentrations of analytes. The unspiked CSF was 
analysed as well and the correction of the results was performed as 
described in chapter 3.3.3.3. Three different concentrations were selected 
corresponding to the lower, middle and upper span of the calibration curve.  
Between-day precision was obtained by the analysis of quality controls (see 
chapter 3.3.5.) on six subsequent days.  
 
3.3.3.7 Accuracy 
Accuracy shows how close the experimental value is to the value accepted as 
true or reference value. To determine the accuracy of the HPLC method CSF 
samples containing known nominal concentrations were analysed and their 
experimental value was calculated using the calibration curve. The statistical 
parameter which describes accuracy is the relative error (RE) which is 
calculated as following (Eq. 3.4): 
 
 
 
 
 
Eq. 3.3 
Eq. 3.4 
errorrelativeRE =
analysisthefromobtainedvalueC =
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nom
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C
100)CC(
(%)RE
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Accuracy is then calculated with the following equation (Eq. 3.5): 
 
 
3.3.3.8 Linearity 
In order to validate a method it is important to establish the mathematical 
relationship between the measured response and the concentration of the 
analyte. If the measured response has a linear relationship with the 
concentration it can be described with the following mathematical equation 
(Eq. 3.6): 
 
 
 
 
 
 
Linearity of the method was tested by analysing seven CSF samples 
containing different concentrations of the analytes. Such calibration samples 
were freshly prepared and analysed on six subsequent days. To show the 
linearity of the method the coefficient of correlation (r) and the residuals 
were calculated.  
The coefficient of correlation is a measure of the degree of correlation and is 
in the range of -1≤ r ≤1. A value of 0 indicates no correlation between the 
measured response and the analyte concentrations and values -1 or 1 
indicate a perfect correlation with negative and positive slopes, respectively. 
The calculation of r is presented in Eq. 3.7:  
 
 
 
 
Eq. 3.6 
100RE(%)Accuracy += Eq. 3.5 
abxy ii +=
analytetheofionconcentratxi =
tcoefficienerceptinta =
tcoefficienslopeb =
response measured y i = 
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Furthermore, it was investigated whether a better fit of the calibration curve 
can be obtained by a weighted linear regression (1/x or 1/x2).  
Residuals are the difference between the measured and nominal 
concentrations. When the residuals are plotted versus the respective 
concentrations they should be randomly distributed around the value of 
zero. If this is not the case a linear relationship may not exist between 
response and concentration. 
 
3.3.4 Calibration 
3.3.4.1 Preparation of stock solutions 
Since 5,10-methylene-THF and 5-methyl-THF are oxidable compounds stock 
solutions where prepared by dissolving the reference substances in a tris 
buffer (pH 7.6) containing ascorbic acid as antioxidant. The buffer was 
prepared by dissolving 15.8 g tris(hydroxymethyl)-aminomethane and 10 g 
ascorbic acid into almost 1000 mL water. The pH was adjusted with sodium 
hydroxide and the volume of the solution completed to 1000 mL. Stock 
solutions were prepared for each analyte separately in the following manner: 
Each reference substance was weighed and dissolved in 10 mL of the tris 
Eq. 3.7 
ncorrelatiooftcoefficienr =
analytetheofionconcentratxi =
ionsconcentratanalysedtheofmeanx =
responsesmeasuredtheofmeany =
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= 
= 
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Materials and Methods  
 41
buffer. This procedure was repeated three times so that at the end there 
were three vials for each reference substance which should contain the same 
concentration of the analyte. The concentration in each of the three vials was 
analysed by HPLC and if the variation coefficient was not greater than 3% they 
were accepted as stock solutions, aliquoted and kept at -20 ºC. 
 
3.3.4.2 Preparation of calibrator solutions 
The range for the calibration of each analyte was chosen so that the lowest 
concentration for each analyte was the lower limit of quantification and the 
highest concentration (upper limit of quantification, ULOQ) was above the 
expected concentrations in the CSF after metabolic changes. To obtain such a 
calibration curve 7 calibrator solutions (one for each calibration point) 
containing all four reference substances were prepared from stock solutions 
by dilution with tris buffer. 40 µL of a calibration solution was then added to 
960 µL of pooled CSF. Another CSF sample was spiked with 40 µL of tris 
buffer and served as reference for substracting the endogenous CSF 
concentration of 5,10-methylene-THF and 5-methyl-THF. The final 
concentrations of the calibrator solutions are presented in Table 3.3. 
 
3.3.4.3 Calculation of concentrations 
The calibration curves were generated by analysing the 7 calibration points 
and the reference CSF in a random order. Peak area was determined with the 
ChromQuest® software. A substraction of the reference value was performed 
for each calibration point for 5,10-methylene-THF and 5-methyl-THF. Peak 
area was plotted against the concentration of the analytes and a linear 
regression analysis was performed using the MVA® software. The unknown 
concentrations were calculated from the regression equation. 
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Table 3.3: Calibrator concentrations for HPLC analysis of reduced folates and 
MTX in CSF. 
 Final concentration (nM) 
Calibration 
point 
5,10-MeTHF 5-MTHF Ca-folinate MTX 
1 10.0 10.0 100.0 20.0 
2 20.0 20.0 200.0 50.0 
3 30.0 30.0 400.0 200.0 
4 50.0 50.0 1000.0 1000.0 
5 100.0 100.0 2000.0 2000.0 
6 200.0 200.0 4000.0 6000.0 
7 300.0 300.0 6000.0 10000.0 
 
 
3.3.5 Quality control  
A calibration curve was generated always prior to the analysis of patient 
samples. The calibration curve was accepted when the following criteria were 
fulfilled: 
• Accuracy of LLOQ ≤ 20% 
• Correlation coefficient r ≥ 0,99 (linear regression, weighted 1/x); 
deviation of residuals ≤ 15% 
• At least 5 calibration points had to meet the requirement for the 
residuals including LLOQ and ULOQ 
The CSF samples were thawed and left for no longer than 3 h at room 
temperature before analysis. The concentrations of the analytes were 
calculated from the calibration curve (weighted 1/x2). 
To assure the quality of measurement quality control (QC) samples in two 
different concentrations were prepared before sample analysis was initiated. 
At least 5% of all analysed samples were QC samples The concentrations of 
the QC samples were in the lower and upper range of the calibration curve 
for each analyte. QC samples were prepared using the same procedure as for 
Materials and Methods  
 43
the calibration points except that QC samples were prepared in a larger 
volume, aliquoted and frozen at -20 ºC. The QC samples were analysed 
between the analysis of the CSF samples. It was demanded that at least 67% 
of the calculated concentrations of QC samples are within ± 15% of the 
nominal value. 
Some samples contained amounts of MTX which were above the ULOQ. Such 
samples were diluted with pooled CSF (1:5). Prior to the dilution the pooled 
CSF was analysed by HPLC and did not contain any traces of MTX.  
 
 
3.4 HPLC-analysis for the determination of SAM and 
SAH in CSF 
3.4.1 Chromatographic conditions 
A method based on reversed phase chromatography was developed and 
validated for the analysis of SAM and SAH in CSF samples. 
The fluorescence detection of both substances was enabled by their 
derivatisation with chloroacetaldehyde (the derivatisation process is 
described in chapter 3.4.3). The formed 1,N6-etheno derivatives are highly 
fluorescent and were eluted on a reversed-phase column especially designed 
for the separation of amino acids. The analytes were eluted using a mobile 
phase which consisted of acetonitrile (eluent A) and an aqueous solution 
(pH 4.5) containing 40 mM of potassium dihydrogen phosphate and 8 mM of 
the ion-pair reagent 1-heptanesulphonic acid (eluent B). Eluent B was 
prepared by dissolving 5.44 g potassium dihydrogen phosphate and 1.6 g 
1-heptanesulphonic acid in 1000 mL water. The pH of the solution was 
measured and adjusted to pH 4.5 when necessary using phosphoric acid. A 
gradient (presented in Table 3.4) was used for the elution of the analytes.  
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Table 3.4: Gradient for the elution of SAM and SAH by HPLC.  
Time 
 (min) 
Acetonitrile 
 (%) 
Phosphate buffer (40 mM, pH 4.5) 
with 1-heptanesulphonic acid (8 mM)
(%) 
0 2 98 
10 2 98 
31 17 83 
32 17 83 
34 2 98 
 
 
The injection volume was 100 µL. The flow rate was kept constant at 
1 mL/min and SAM and SAH were detected using fluorescence detection at 
an excitation wavelength of 270 nm and an emission wavelength of 410 nm. 
The retention times were 23.5 min and 19.7 min for SAM and SAH, 
respectively. 
 
3.4.2 Sample collection 
Perchloric acid was used for the precipitation of proteins in the CSF. A 1.2 M 
solution was prepared by diluting 720 µL of perchloric acid (70%) with water 
up to 10 mL. This solution was aliquoted into vials, each containing 100 µL. 
The vials were marked and frozen at –20 ºC. Immediately before collecting a 
patient sample a vial was thawed. 500 µL of CSF were added and the content 
was centrifuged for 10 min at 15 500 x g. The supernatant was frozen 
at -20 ºC immediately after centrifugation. 
 
3.4.3 Derivatisation of SAM and SAH 
The derivatisation of SAM and SAH with chloroacetaldehyde and the 
formation of their fluorescent 1,N6-etheno derivatives was well studied, 
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optimised and reported in several publications143-146. It has been shown that 
the incubation time and temperature as well as the pH of the reaction and 
the concentration of chloroacetaldehyde have a considerable impact on the 
derivatisation. 
In accordance with the work of Wagner et al.143 SAM and SAH were 
derivatised with 5.5 M chloroacetaldehyde at pH 3.5-4.0, 39 ºC for 16 h.  
Chloroacetaldehyde (5.5 M) was prepared each day by diluting 1 mL of a 50% 
solution with 430 µL water. A 3 M sodium acetate solution was used for the 
adjustment of pH. This solution was prepared by disolving 24.6 g of sodium 
acetate in 100 mL water and was stored at room temperature. The 
derivatisation of each sample was performed as following: 25 µL of the 5.5 M 
solution of chloroacetaldehyde and 14 µL of the 3 M sodium acetate solution 
were added to 250 µL of each CSF sample.  
All samples were stored for 16 h overnight in the waterbath at 39 ºC. The 
derivatisation reaction was stopped by freezing. The samples were thawed 
and analysed within 24 h after derivatisation. The derivatisation reaction is 
presented on the example of SAM in Fig. 3.1.  
 
3.4.4 Development and optimisation of the method 
In the developmental phase of the assay various columns were tested in 
order to achieve a good separation and selectivity.  
Because of the polar properties of SAH and especially SAM which is ionised 
an attempt of separation of the two compounds was made on a amine 
column (Luna NH
2
®, 150 x 4.6 mm, 5µm, Phenomenex, Torrance, USA) and 
two reversed-phase columns (Kromasil® C18, 125 x 4.0 mm, 3.5 µm, Agilent 
technologies, Palo Alto, USA and Eclipse AAA® LC-18-DB, 150 x 4.6 mm, 
5 µm, Agilent technologies, Palo Alto, USA). Phosphate buffer (40 mM, 
pH 4.5) and isopropanol or acetonitrile were used as eluents and 
optimisation of separation was attempted with the use of gradients. In 
addition, 1-heptanesulphonic acid (8 mM) was added to the phosphate buffer  
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Fig. 3.1: Derivatisation of SAM with chloroacetaldehyde.  
 
and separation with the respective eluent was attempted on the reversed 
phase columns. 
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3.4.5 Validation of the assay 
The validation of the assay was performed according to the guideline of the 
Food and Drug Administration (Guidance for Industry, Bioanalytical Method 
Validation)142.  
 
3.4.5.1 Selectivity 
For the assessment of selectivity chromatogrammes of pooled CSF were 
compared to chromatogrammes of the same pooled CSF spiked with 
standard solutions of SAM and SAH. 
 
3.4.5.2 Stability  
pH-dependent stability 
Prior to preparing stock solutions of SAM and SAH their pH-dependent 
stability was investigated. The analytes were incubated for 48 h at 37 ºC in 
aqueous solutions with different pH (1-10). The incubation was followed by 
the derivatisation and measurement of the analytes.  
 
Stability in acidic CSF samples 
Moreover, the stability of the analytes in CSF samples to which perchloric 
acid (pH 1) was added and which were frozen at -20 ºC, was compared to the 
stability of the same CSF samples frozen without prior acidification (pH 7.4). 
This experiment was performed since some CSF samples for SAM and SAH 
analysis obtained from cooperation partners were frozen without prior 
deproteinisation with perchloric acid. 
 
Room temperture stability in CSF samples 
In addition the 1 h room temperature stability of SAM and SAH in the CSF 
with and without the addition of perchloric acid was investigated in order to 
determine if there is any loss of the analytes when samples are not frozen or 
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deproteinised immediately after collection, a situation which may occur in 
routine hospital practice.  
 
Stability of 1,N6-etheno derivatives of SAM and SAH in CSF 
Furthermore, stability studies were performed in order to assess if the 
analytes were stable for 24 h and could be left in the autosampler after 
derivatisation and analysed during the night. CSF samples were spiked with 
three different concentrations of SAM and SAH. The concentrations 
corresponded to the lower, middle and upper range of the calibration curve. 
After derivatisation an aliquot of each sample was analysed and the rest was 
left on room temperature and the analysis was repeated after 24 h. Such 
procedure was repeated at two subsequent days. 
 
Freeze and thaw stability 
Moreover, the stability of SAM and SAH after two freeze and thaw cycles were 
analysed. CSF samples were spiked with SAM and SAH in three different 
concentrations. An aliquot of each of the three CSF samples was derivatised 
and analysed, the rest was frozen. The frozen aliquots were thawed after two 
days, analytes were derivatised and the rest was frozen one more time. This 
was referred to as the first freeze and thaw cycle. The frozen samples were 
thawed once more, derivatised and analysed. This was the second freeze and 
thaw cycle. 
 
3.4.5.3 Recovery 
The recovery experiment was performed in order to establish if the 
calibration curves could be obtained from calibrator solutions diluted with 
isotonic sodium chloride solution. The experiment was performed as 
described in chapter 3.3.3.3. 
 
3.4.5.4 Limit of detection and lower limit of quantification 
LOD and LLOQ were determined as described in chapter 3.3.3.4 and 3.3.3.5. 
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3.4.5.5 Precision and accuracy 
Within-day and between-day precision and accuracy of the method were 
assessed as described in chapter 3.3.3.6 and 3.3.3.7. Since SAM and SAH are 
present in the CSF the peak areas had to be corrected by substraction of the 
value which was measured in the unspiked CSF.  
 
 
3.4.6 Calibration 
3.4.6.1 Preparation of stock solutions 
Stock solutions were prepared by dissolving the analytes in water to which 
perchloric acid was added. Each analyte was weighed three times and the 
same procedure was used to exclude any imprecision in this step as 
described in chapter 3.3.4.1. After aliquotation stock solutions were frozen 
at –20 ºC. 
 
3.4.6.2 Preparation of calibrator solutions 
Seven calibration points were used to obtain regression curves for SAM and 
SAH, respectively. Calibration was performed using pooled CSF as matrix. 
The calibration range included the LLOQ as the lowest calibration point. The 
ULOQ was higher than the expected values after possible metabolic changes 
following MTX administration. The calibrator solutions were obtained by 
diluting stock solutions of the analytes and each calibrator solution 
contained both SAM and SAH. Into each of the 7 vials containing 240 µL of 
pooled CSF 10 µL of the respective calibrator solution was added. 240 µL of 
the CSF spiked with 10 µL of water and this sample served as reference to 
determine the endogenous concentrations of SAM and SAH. The final 
concentrations of the calibration curve for SAM and SAH, respectively, are 
presented in Table 3.5. 
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Table 3.5: Final concentration of SAM and SAH in CSF samples used for 
calibration  
                                           Final concentration (nM) 
Calibration point SAM SAH 
1 25.0 5.0 
2 50.0 7.5 
3 75.0 10.0 
4 125.0 20.0 
5 250.0 50.0 
6 500.0 75.0 
7 1000.0 100.0 
 
 
3.4.6.3 Calculation of concentration 
The calibration points and the reference CSF were analysed in a random 
order and the response in the reference sample was substracted from the 
calibration points response. Such corrected peak areas were plotted against 
the concentration of the analyte and the coefficient of regression and 
residuals were determined (see also chapter 3.3.4.3). 
 
3.4.7 Quality control 
Samples were derivatised as described in chapter 3.4.3.  
The concentrations of SAM and SAH in the CSF samples of patients were 
obtained from calibration curves which were obtained every day prior to the 
analysis of patient samples. Calibration curves were weighted (1/x2 for SAM 
and 1/x for SAH) and they were accepted if the criteria described in chapter 
3.3.5 were met. QC samples were used to assure the quality of sample 
measurement. Two types of quality control samples were used. The first type 
consisted of QC samples which served to test the HPLC system. Solutions of 
three different concentrations corresponding to the lower, middle and upper 
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part of the calibration curve were prepared by diluting stock solutions of SAM 
and SAH with pooled CSF (as described in chapter 3.4.6.2). The samples were 
derivatised, aliquoted and frozen at –20 ºC. One aliquot of each 
concentration was analysed every day to assure the quality of the system.  
The second type of QC samples served to assure the quality of the 
derivatisation. Three solutions of SAM and SAH were prepared in the same 
manner as for the system check. The solutions were then aliquoted and 
frozen at –20 ºC. One aliquot of each concentration was derivatised together 
with the CSF samples of patients and determined on the subsequent day. All 
together six QC samples each day were analysed inbetween the CSF samples 
of patients. The quality of the measurement was assured if at least 4 of 6 QC 
samples were within ± 15% of the nominal value. 
 
 
3.5 Clinical studies  
3.5.1 Adult patients with primary central nervous system 
lymphoma (PCNSL) 
In cooperation with Prof. Dr. Schlegel (Department of Neurology, University 
Hospital, Rheinische Friedrich-Wilhelms-Universität, Bonn) CSF samples were 
obtained from five patients suffering from PCNSL. All of them received 
chemotherapy according to the Bonn protocol for PCNSL.  
 
Patients characteristics 
The characteristics of the five patients are shown in Table 3.6.  
Patient 5 showed clinical signs of MTX-related chronic neurotoxicity in form 
of leukoencephalopathy during therapy confirmed by a radiology finding 
(MRI, T2-weighted). 
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Table 3.6: Characteristics of patients with PCNSL 
Patient 
Age 
(years) 
Gender 
BSA 
(m2) 
Morbidity 
1 62 F n.k. Relapse of PCNSL of the B-cell line 
2 40 F 1.62 PCNSL of the B-cell line 
3 66 F 1.63 PCNSL of the B-cell line 
4 73 F 1.94 Relapse of PCNSL of the B-cell line 
5 64 F 1.79 PCNSL of the B-cell line 
BSA: body surface area; n.k: not known  
 
Bonn protocol for PCNSL  
The Bonn protocol for PCNSL consisted of two cycles (1 and 2). Each cycle 
consisted of three chemotherapy blocks (A, B and C). The protocol is 
presented in Table 3.7. 
Block A and B were identical regarding MTX therapy. MTX was administered 
in both blocks as high-dose infusion (5 g/m2 over 24 h) followed by 
intraventricular courses (3 mg/day) via an Ommaya reservoir on three 
subsequent days. If the creatinine clearance which was determined before 
each block was low (decreased renal function) the dose of MTX was reduced. 
Patients older than 65 years received 3 g/m2. 
After high-dose MTX patients were rescued with calcium folinate 
(30 mg/m2, i.v.). The rescue was given 34, 42, 48 and 54 h after the start of 
infusion. The MTX concentrations were monitored in the serum at 24, 42, 48 
and 54 h after the initiation of infusion. If they were elevated (> 150 µM at 
24 h; >1 µM at 42 h; >0.4 µM at 48 h or >0.2 µM at 54 h) rescue was 
intensified. In that case patients received calcium folinate (30 mg/m2, i.v) 
every four hours until the concentration of MTX in serum was below 0.2 µM. 
In contrast to block A and B, patients did not receive high-dose MTX in block 
C. They received four intraventricular courses of MTX through the Ommaya 
reservoir (day 3-6). Calcium folinate was not administered during this block. 
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Table 3.7: Bonn protocol for PCNSL  
*or 3 g/m2 for patients older than 65 years 
 
 
 
Day Drug Dose 
1 2 3 4 5 6 7 
Block A 
MTX* 005 g/m2 i.v. +       
Vincristine 002 mg/m2 i.v. +       
Ifosfamide 800 mg/m2 i.v.  + + + +   
Dexamethasone 10 mg/m2 p.o.  + + + +   
MTX 03 mg i.cv.  + + +    
Prednisolone 2.5 mg i.cv.  + + +    
Cytarabine 30 mg i.cv.     +   
Block B 
MTX* 5 g/m2 i.v. +       
Vincristine 002 mg/m2 i.v. +       
Cyclophosphamide 200 mg/m2 i.v.  + + + +   
Dexamethasone 10 mg/m2 p.o.  + + + +   
MTX 03 mg i.cv.  + + +    
Prednisolone 2.5 mg i.cv.  + + +    
Block C 
Cytarabine 3 g/m2 i.v. + +      
Vindesine 5 mg/m2 i.v. +       
Dexamethasone 10 mg/m2 p.o.   + + + + + 
MTX 03 mg i.cv.   + + + +  
Prednisolone 2,5 mg i.cv.   + + + +  
Cytarabine 30 mg i.cv.       + 
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Between each two blocks patients had two weeks time to recover. Patients 
with a relapse (patient 1 and 4) were treated according to a modified version 
of the Bonn protocol which included two cycles (1 and 2) consisting of blocks 
A and C each. For patient 1 the Bonn protocol for PCNSL was additionally 
adjusted. The adjustment consisted in the reduction of the dose of MTX 
(3 g/m2) and the earlier start of rescue 60 mg, i.v. which occured one hour 
after the end of high-dose MTX infusion and was repeated every six hours. A 
total of five calcium folinate infusions was administered to this patient. 
 
CSF sampling 
Samples from patient 1 who received an intensified calcium folinate rescue 
after the high-dose infusion were obtained only at the end of a high-dose MTX 
infusion (0 h) and 1, 3.5, 7 and 24 h later. This patient received no intrathecal 
MTX. The five obtained samples were collected with ascorbic acid and used 
for the analysis of 5,10-methylene-THF, 5-methyl-THF, calcium folinate and 
MTX. After collecting samples were stored at -20 ºC. An overview of the 
sample collection times of patient 1 is shown in Fig. 3.2.  
Samples from patients 2-5 were collected always shortly before the 
administration of intraventricular MTX therapy. An overview of the sampling 
time for block A and B is given in Table 3.8. In block C MTX was administered 
only intraventricularly and samples were obtained from day 3 to 7. Problems 
such as late inclusion in the study, complications during therapy and therapy 
break-up occured and it was not possible to obtain samples from all therapy 
blocks from each patient. An overview of the obtained samples is presented 
in Table 3.9. 
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 Fig. 3.2: Diagram of the sampling time and calcium folinate rescue of patient 
1. 
Table 3.8: Sample collection during the Bonn protocol for PCNSL 
Block A/B High-dose 
MTX 
i.cv. 
MTX 
Rescue Sampling time 
Day 1 +   No samples obtained 
Day 2  + + 
1h after the end of the infusion 
and before i.cv. administration 
Day 3  + + + + 
Just before i.cv. administration 
Patient has received two 
infusions of calcium folinate 
prior to sampling 
Day 4  +  
Just before i.cv. administration 
Calcium folinate rescue 
completed prior to sampling 
Day 5  +  Just before i.cv. administration 
0 1 7 13 19 25 (h) 
End of high-dose 
MTX infusion 
Calcium 
folinate  
Sample 
collection 
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Table 3.9: Overview of collected CSF samples from patient 2-5. 
Block Day Sample collection 
  Patient 2 Patient 3 Patient 4 Patient 5 
A1 2 - - + - 
 3 + - + - 
 4 + - + - 
 5 + - + - 
B1 2 + - + 
 3 + + + 
 4 + + + 
 5 + + 
Patient did 
not receive 
block B1 
+ 
C1 3 + + + + 
 4 + + + + 
 5 + + + + 
 6 + + + + 
 7 + + + + 
A2 2 - - + - 
 3 - + + + 
 4 - + + + 
 5 - + + + 
B2 2 + + 
 3 + + 
 4 + + 
 5 + - 
Patient did 
not receive 
block B2 
C2 3 + + - 
 4 + + - 
 5 + + - 
 6 - + - 
 7 + + - 
Patient did 
not receive 
block B2 and 
C2 
+: sample obtained; -: sample not obtained 
 
 
3.5.2 Pediatric patients with acute lymphoblastic leukaemia 
(ALL) treated according to ALL BFM 2000 
In cooperation with Prof. U. Bode (University Children’s Hospital, Bonn, 
Germany) CSF samples were obtained from a population of pediatric patients 
with ALL who received high-dose MTX according to the therapy protocol ALL 
BFM 2000. In the collected CSF samples 5,10-methylene-THF, 5-methyl-THF, 
calcium folinate, MTX, SAM and SAH were determined. 
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Patients characteristics  
A total of 27 patients suffering from ALL classified into standard-risk or 
middle-risk were included in this study. Since the therapy protocol is very 
similar for the two groups they were assessed together. Median age of the 
patients was 4 years ranging from 2-17 years. 74 CSF samples from 22 
patients were obtained for the determination of reduced folates and MTX. 
SAM and SAH were analysed in 84 CSF samples obtained from 22 patients 
(see also Appendix B).  
Protocol ALL BFM 2000 
This protocol consisted of several components which differed between the 
risk groups but all patients started the therapy with protocol I which 
consisted of two phases (1 and 2).  
Protocol I 
During the first seven days of protocol I/phase 1 (also called prednisone 
prephase) all patients received prednisone which was started on day 1 with 
25% of the calculated dose. The dose was then increased rapidly during the 
next few days to the final-dose of 60 mg/m2/d p.o. or i.v. which was applied 
three times in equal daily doses (EDD). The end-dose was achieved at latest 
on day 5.  
After the prednisone prephase, patients were randomised into two groups, 
one continued the therapy with prednisone (60 mg/m2/d p.o in 3 EDD) while 
the other received dexamethasone (10 mg/m2/d p.o. or i.v. in 3 EDD) 
instead. All patients received intrathecal MTX on day 1, 12 and 33 of 
phase 1, the dose was age-dependent (as presented in Table 3.10).  
Table 3.10: Age-related dosage of intrathecal MTX in protocol ALL BFM 2000. 
Age  
(years) 
MTX 
(mg) 
≥ 1 8 
≥ 2 10 
≥ 3 12 
Materials and Methods  
 58 
If the patient had an initial CNS disease or there was a suspicion of it or if 
lymphoblasts or hyperleucocytosis (≥ 50 000/µL) were identified in an initial 
lumbar puncture then intrathecal MTX was applied also on day 18 and 27. 
After the intrathecal administration of MTX patients had to rest with their 
head down for at least four hours (supine position). 
No rescue therapy was applied during this part of treatment. Patients 
younger than 1 year were treated according to another protocol and 
therefore not included in the analysis.  
During phase 1 patients were treated with vincristine (1.5 mg/m2), 
daunorubicine (30 mg/m2) and asparaginase (5000 IU/m2). After completing 
phase 1 patients went into phase 2 in which they received cyclophosphamide 
(1 g/m2), mercaptopurine (60 mg/m2), cytarabine (75 mg/m2) and intrathecal 
MTX. The complete therapy during protocol I is presented in Table 3.11. 
After completing protocol I patients were categorised into risk groups and 
received further therapy according to the risk group they belonged. Three 
groups were defined: standard-risk (SR), middle-risk (MR) and high-risk (HR) 
according to patients’ immunophenotype, immunogenotype, clinical picture 
and the response in the early phase of therapy. The characteristics of the 
patients are presented in Table 3.12. 
SR and MR patients received similar therapy which consisted of protocol M 
and protocol II or III while HR patients received HR blocks which is not further 
described since CSF samples of HR patients were not included in the analysis. 
Protocol M 
About two weeks after the end of protocol I therapy was continued in SR and 
MR patients with protocol M. During this treatment phase patients received 
high-dose MTX (5 g/m2 p.i. over 24 h), intrathecal MTX (dosage 
age-dependent see Table 3.10) and 6-mercaptopurine (25 mg/m2 p.o.). 
High-dose MTX infusions were administered in two-week intervals. 10% of the 
high-dose MTX was administered in the first 30 min while the rest of the 
dose was infused over 23.5 h. The concentration of MTX in serum was 
monitored at: 24, 36, 42 and 48 h after the beginning of the MTX infusion.  
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Table 3.11: Protocol I of ALL BFM 2000. 
Drug Dosage Day 
Total no 
of admin. 
Phase 1 
Prednisone/ 
Prednisolone* 
Beginning with 25%, 
dose escalation completed 
until day 5 
60 mg/m2/d p.o. in 3 EDD 
half of the dosage in 3 EDD 
1-7 
 
 
8-28 
29 -31 
7 
 
 
63 
9 
Vincristine 1.5 mg/m2 (max. dose 2 mg) 8, 15, 22, 29 4 
Daunorubicine 30 mg/m2 p.i. 1 h 8, 15, 22, 29 4 
Asparaginase 5000 IU/m2 p.i. 1 h 
12, 15, 18, 21
24, 27, 30, 33
8 
MTX i.th. (see Table 3.10) 
1, 12, 33 
(18, 27)# 
3 
(5) 
Phase 2 
Cyclophosphamide 1 g/m2 p.i. over 1h 36, 64 2 
Mercaptopurine 60 mg/m2 p.o. 36 –63 28 
Cytarabine 75 mg/m2 i.v. 
38-41; 45-48 
52-55; 59-62 
16 
MTX i.th. (see Table 3.10) 45, 59 2 
*or Dexamethasone (10 mg/m2/d p.o. or i.v. in 3 EDD) from day 8-28. From day 29-31  
the dosage of dexamethasone was reduced to 50%. # only patients with CNS disease  
 
 
Calcium folinate rescue (15 mg/m2 i.v.) was started 42 h after the initiation of 
the MTX infusion if the serum MTX concentrations were as expected (see 
Table 3.13). If serum MTX level was higher than expected rescue was 
intensified and started at 36 h.  
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Table 3.12: Categorisation of ALL patients according to their characteristics. 
Category Characteristics of patients 
Standard-risk 
(SR) 
• Adequate response to a 7-day prednisone prephase and 
i.th. MTX on day 1: < 1000 WBC/µL blood on day 8 
• Cytomorphological complete remission on day 33  
• No presence of translocation t(9; 22) or t(4; 22) or fusion 
gene Bcr/Abl or MLL/AF4  
• MRD-negative on day 33 and before protocol M, 
measured with at least two markers with a sensitivity of 
≤ 10-4   
Patients are categorised as SR only when all four criteria are 
fulfilled 
Middle-risk 
(MR) 
• Adequate response to a 7-day prednisone prephase and 
i.th. MTX on day 1: < 1000 WBC/ µL blood on day 8 
• Cytomorphological complete remission on day 33 
• No presence of translocation t(9; 22) or t(4; 22) or fusion 
gene Bcr/Abl or MLL/AF4 
• Patient does not fulfill neither the MRD criterion for SR nor 
for HR  
Patients are categorised as MR only when all the above 
mentioned criteria are met 
High-risk 
(HR) 
• Inadequate response to a 7-day prednisone prephase and 
i.th. MTX on day 1: > 1000 WBC/µL blood on day 8 
• Cytomorphologically no complete remission on day 33 
which means non-response on that day 
• Presence of translocation t(9; 22) or fusion gene Bcr/Abl  
• Presence of translocation t(4; 11) or fusion gene MLL/AF4  
• MRD ≥ 10 -3 (high level of residual disease) prior to 
protocol M 
Patients are categorised as HR if only one of the criteria is 
fulfilled 
MRD: minimal residual disease; WBC: white blood cell count  
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Table 3.13: Expected concentration in serum and rescue regimen after the 
high-dose MTX infusion. 
Time after beginning 
of the MTX-infusion 
(h) 
Expected concentration 
of MTX in serum 
(µmol/L) 
Dose of calcium 
folinate 
(mg/m2 i.v.) 
24 ≤ 150.0 - 
36 ≤ 3.0 - 
42 ≤ 1.0 15 
48 ≤ 0.4 15 
54 ≤ 0.4 15 
 
 
Intrathecal MTX was administered 1 h after beginning of the high-dose MTX 
infusion. An overview of protocol M is given in Table 3.14. After completing 
protocol M, SR and MR patients were randomised into SR-1, SR-2, MR-1 and 
MR-2. SR-2 and MR-2 received protocol II while SR-1 and MR-1 received 
protocol III. 
Table 3.14: Protocol M of ALL BFM 2000 
Drug Dosage Day 
Total no 
of admin. 
6-mercaptopurine 25 mg/m2 p.o. 1-56 56 
MTX 5 g/m2 i.v. 8, 22, 36, 50 4 
MTX i.th. (see Table 3.10) 8, 22, 36, 50 4 
 
 
Protocol II 
This protocol consisted of two phases (1 and 2) and was initiated about two 
weeks after the end of protocol M.  
In phase 1 patients received dexamethasone (10 mg/m2/d p.o. or i.v. in 
3 EDD), vincristine (1.5 mg/m2 i.v., max. dose 2 mg), doxorubicine 
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(30 mg/m2 p.i. over 1 h), asparaginase (10000 IU/m2 p.i. 1 h) and if they had 
CNS disease intrathecal MTX (age–dependent dosage see Table 3.10). Phase 
1 was followed by phase 2 in which patients received cyclophosphamide 
(1 g/m2 p.i. over 1 h), thioguanine (60 mg/m2 p.o.), cytarabine (75 mg/m2 
i.v.) and intrathecal MTX. An overview of protocol II is presented in Table 
3.15. Calcium folinate rescue after intrathecal MTX was not administered in 
protocol II. 
 
Table 3.15: Protocol II of ALL BFM 2000. 
Drug Dosage Day  
Total no 
of admin. 
Phase 1 
Dexamethasone 
10 mg/m2 p.o./i.v. 3 EDD 
Dosage reduced to 50% 
1-21 
22-24 
63 
9 
Vincristine 
1.5 mg/m2 i.v. 
(max. dose 2 mg) 
8, 15, 22, 29 4 
Doxorubicine 30 mg/m2 p.i. 1h 8, 15, 22, 29 4 
Asparaginase 10000 IU/m2 p.i. 1 h 8, 11, 15, 18 4 
MTX* i.th. (see Table 3.10) 1, 18 2 
Phase 2 
Cyclophosphamide 1 g/m2 p.i. 1 h 36 1 
Thioguanine 60 mg/m2 p.o. 36-49 14 
Cytarabine 75 mg/m2 i.v. 38-41, 45-48 8 
MTX i.th. (see Table 3.10) 38, 45 2 
*MTX was administered in phase 1 only to patients with overt disease; EDD: equal daily 
dose 
 
 
Protocol III 
This protocol was applied to SR-1 patients once and MR-1 patients twice. 
Protocol III was started approximately two weeks after the end of protocol M.  
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This protocol was also divided into two phases. In both of them patients 
received the same medication in the same dosage (except cyclophosphamide 
in phase 2 0.5 g/m2 p.i. over 1 h instead of 1 g/m2) as in the respective 
phases of protocol II but the number of administrations and time intervals 
between them were different. An overview of protocol III is presented in 
Table 3.16. 
 
Table 3.16: Protocol III of ALL BFM 2000. 
Drug Dosage Day  
Total no 
of admin. 
Phase 1 
Dexamethasone 
10 mg/m2 p.o/i.v. 3 EDD 
Dosage reduced to 50% 
1-15 
16-18 
45 
9 
Vincristine 
1.5 mg/m2 i.v. 
(max dose 2 mg ) 
1, 8 2 
Doxorubicine 30 mg/m2 p.i. 1h 1, 8 2 
Asparaginase 10000 IU/m2 p.i. 1 h 1, 4, 8, 11 4 
MTX* i. th (see Table 3.10) 1 1 
Phase 2 
Cyclophosphamide 0.5 g/m2 p.i. 1 h 15 1 
Thioguanine 60 mg/m2 p.o. 15-28 14 
Cytarabine 75 mg/m2 i.v. 17-20, 24-27 8 
MTX i.th. (see Table 3.10) 17, 24 2 
*MTX was administered in phase 1 only to patients with overt disease 
 
One week after completing protocol III patients who were classified into MR-1 
received a so called ‘interval therapy’ over 10 weeks. This therapy consisted 
of 6-mercaptopurine (50 mg/m2 p.o. daily) and MTX (20 mg/m2 p.o. once a 
week). About a week after the end of the interval therapy patients received 
protocol III for the second time. 
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Two weeks after completing the last protocol patients started receiving a 
maintenance therapy which was the same as the above mentioned interval 
therapy and was administered until 24 months after diagnosis. 
CSF sampling 
CSF samples were obtained by lumbar puncture during the protocols I, M, II 
and III as presented in Table 3.17. 
The samples were obtained as described in chapter 3.3.2 and 3.4.2. 
5,10-methylene-THF, 5-methyl-THF, calcium folinate, MTX, SAM and SAH were 
measured. 
 
Table 3.17: Sample collection during ALL BFM 2000. 
ALL BFM 2000 Day 
Protocol I 1, 12, 33, 45, 59 
Protocol M 8, 22, 36, 50 
Protocol II 38, 45 
Protocol III 17, 24 
 
 
Patients with manifest signs of neurotoxicity 
In addition, samples were obtained from three patients with clinical signs of 
MTX-associated neurotoxicity. Their characteristics and sample schedule are 
presented in this chapter. 
Case 1 
A 15-year old boy, was diagnosed for the first time with ALL and classified as 
MR-1. Chemotherapy was initiated according to ALL BFM 2000. During 
protocol I the patient received a cumulative dose of 60 mg MTX intrathecally 
which was not accompanied by calcium folinate rescue. After completing 
protocol I without complications therapy was continued with protocol M in 
which the patient received high-dose MTX (5 g/m2) combined with intrathecal 
MTX (12 mg) and calcium folinate rescue. Ten days after receiving the third 
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high dose of MTX the patient presented with signs of neurotoxicity. He 
complained of headache and dizziness, was agitated and irritable. The right 
arm and leg were paralysed (hemiparesis) as well as the left facial side. 
Seizures did not occur. Symptoms resolved completely within a few days and 
the therapy was continued according to the protocol. Ten days after the next 
(fourth) high-dose MTX infusion neurotoxicity reoccured. This time 
hemiparesis presented in the left body half and the right facial side. At this 
time-point an evaluation of neurological symptoms was performed by 
pediatric oncologists using common toxicity criteria (CTC). 
MRI of the brain was performed revealing ischemic lesions in the white 
matter characterised as supraventricular infarctions. Signs of neurotoxicity 
persisted for about 24 h and resolved again abruptly and completely. Three 
days after the second toxicity episode CSF was collected by lumbar puncture. 
Furthermore, one patient sample was obtained during protocol I (day 45) and 
another one was obtained one month after neurotoxicity (protocol III day 17).  
Case 2 
A 13-year old boy was diagnosed for the first time with ALL. After being 
classified and randomised into the MR-1 arm he started receiving 
chemotherapy according to ALL BFM 2000. Similar to case one, this patient 
received a cumulative dose of 60 mg MTX intrathecally during protocol I 
without signs of neurological complications. One week after receiving his 
first high-dose (5 g/m2) and intrathecal (12 mg) MTX administration followed 
by calcium folinate rescue the patient presented with paresis in the right 
hand which lasted about 36 h. After the second therapy course the same 
symptoms occured in the left hand and leg. Patient also developed a 
transient speech disorder. Within 72 h the clinical symptoms resolved but 
intention tremor and an altered reflex activity were observed. 
Neurotoxicity evaluation was performed according to the CTC after the 
second toxicity episode by pediatric oncologists. MRT revealed changes in 
the white matter (demyelination) but neither ischemic lesions nor overt 
disease were present. 
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Four CSF samples were obtained one of them prior to neurotoxicity 
(Protocol I, day 33). One sample was obtained one day after resolution of 
symptoms following the second toxicity episode. One week later, MTX 
therapy was continued and a sample was obtained during the second 
high-dose infusion and just before intrathecal administration. Ten days later 
patient presented with nausea and emesis and a sample was obtained in 
conjunction with diagnostic lumbar puncture.  
Case 3 
The third patient with signs of neurotoxicity was a 35-year old female who 
received chemotherapy after her second ALL relapse. The patient had 
received MTX after the diagnosis of ALL as well as after the first relapse. The 
disease was firstly diagnosed at the age of 17 and the patient received MTX 
therapy accompanied by cranial irradiation. She was not treated in Bonn and 
it was not possible to obtain documentation from that period in order to 
assess possible neurological complications. Ten years later she developed 
her first relapse and was treated with high-dose (1 g/m2) and intrathecal 
(12 mg) MTX without cranial irradiation. A total of nine high-dose infusions 
and 60 mg intrathecal MTX were administered. MTX-related neurological 
complications were not observed at that time. Six years later she started 
receiving therapy for the second relapse which did not include MTX. 
However, the patient had evident signs of MTX-related chronic neurotoxicity. 
Cognitive decline, memory loss, confusion, depressed level of conciousness, 
personality change, speech impairment and tremor were documented. The 
evaluation of neurotoxicity was performed according to CTC as in the former 
two cases. MRI revealed severe leukoencephalopathy in both brain 
hemispheres. Also circular lesions were present which were associated with 
an overt infection. 
CSF was obtained at time of second relapse diagnosis. The second sample 
was obtained three months later. Ten days after collecting the second sample 
the patient presented with signs of toxicity probably due to a CNS infection. 
She had severe headache and pain followed by high fever. A lumbar puncture 
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was performed for diagnostic purposes. The CSF had an intensive yellow 
colour indicating hyperbilirubinemia which was later confirmed. 
 
3.5.3 Pediatric patients with acute lymphoblastic leukaemia 
(ALL) treated according to TOTAL XV 
CSF samples from a group of pediatric patients with ALL who were treated 
with high-dose MTX according to the protocol TOTAL XV were obtained in 
cooperation with Prof. M. Relling (St. Jude Children’s Research Hospital, 
Memphis, USA). These children were part of a prospective clinical study in 
which the aim was primarily to analyse the homocysteine metabolism after 
high-dose MTX.  
Patients characteristics 
CSF samples for the determination of 5,10-methylene-THF, 5-methyl-THF, 
calcium folinate and MTX were obtained from 27 patients. The median age 
was 4 years, ranging from 1-14 years. A total of 53 samples was analysed. 
Because of the small number of samples all patients were assessed together 
regardless of their risk classification.  
Protocol TOTAL XV 
This protocol consisted basically of three therapy blocks: 
Remission/Induction, consolidation and maintenance therapy.  
Remission/Induction (6-7 weeks) 
Remission/Induction therapy was initiated by intrathecal administration of 
cytarabine (20-40 mg, age-dependent) and high-dose MTX-infusion (1 g/m2 
over 4 or 24 h). The latter is also referred to as Upfront-high-dose MTX. 
Calcium folinate rescue was started 42 h after beginning of the MTX infusion. 
The initial dose was 50 mg/m2  i.v. and 15 mg/m2 i.v. were administered 
every six hours later-on. All together 7 administrations of calcium folinate 
were foreseen and the concentration of MTX in serum was monitored 
throughout the rescue. If the level of MTX was higher than 1 µM at 42 h after 
the beginning of the infusion calcium folinate rescue was intensified.  
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Treatment was continued with prednisone (40 mg/m2), vincristine 
(1.5 mg/m2), daunorubicine (25 mg/m2) and asparaginase (10000 IU/m2) four 
days after high-dose MTX infusion. These drugs were administered for the 
subsequent 24 days. The second part of the Remission/Induction therapy 
consisted of high-dose cyclophosphamide (1 g/m2), cytarabine (75 mg/m2) 
and 6-mercaptopurine (60 mg/m2). An overview of the exact dosage regimen 
of the Remission/Induction therapy is presented in Table 3.18. 
 
Table 3.18: Remission/Induction therapy 
Drug Dosage Day  
Total No of 
admin. 
Cytarabine 20-40 mg 1 1 
MTX 1 g/m2 i.v. 1 1 
Prednisone 40 mg/m2 i.v. 5-32, 3 EDD 84 
Vincristine 1.5 mg/m2 i.v. 5, 12, 19, 26 4 
Daunorubicine 25 mg/m2 i.v. 5, 12 2 
L-Asparaginase 10.000 IU/m2 i.m. 
6, 8, 10, 12, 14, 
16 (19, 21, 23)* 
6 
(9) 
Cyclophosphamide 1 g/m2 i.v. 26 1 
Cytarabine 75 mg/m2 i.v. 27-30, 34-37 8 
6-Mercaptopurine 60 mg/m2 p.o. 26-39 14 
TIT i.th. see Table 3.19 19 (8, 26)# 1 (3) 
*Administration of drug only if there were ≥ 5% blasts on day 19 of Remission/Induction 
# Only patients with CNS status 2 or 3 or Philadelphia chromosome. EDD: equal daily dose 
 
 
Triple intrathecal therapy (TIT) consisting of MTX, hydrocortisone and 
cytarabine was given on day 19 of the Remission/Induction block (patients 
with CNS status 2 or 3 as well as patients with Philadelphia chromosome 
received this therapy additionally on day 8 and 26). Drug dosage was 
age-dependent (see Table 3.19). Rescue with calcium folinate (5 mg/m2 p.o.) 
was administered 24 h and 30 h after the TIT. 
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Table 3.19: Dosage of the triple intrathecal therapy (TIT) according to age. 
Age 
(months) 
MTX 
(mg) 
Hydrocortisone 
(mg) 
Cytarabine 
(mg) 
13-23 8 16 24 
24-35 10 20 30 
≥ 36 12 24 36 
 
 
Similar to ALL BFM 2000 patients were categorised into three groups: 
Low-risk (LR), standard-risk (SR) and high-risk (HR). Risk was defined by 
patients’ immunophenotype, immunogenotype, clinical picture and response 
in the early phase of therapy. The characteristics of the patients are 
presented in Table 3.20. 
Consolidation (8 weeks) 
During consolidation therapy patients received high-dose MTX infusion which 
was followed by the TIT on day 1, 15, 29 and 42. High-dose MTX was given 
as 24 h-infusion, where 10% of the whole dose was administered within the 
first hour (loading dose). The dosage of MTX depended on the risk 
classification of the patient and the MTX clearance which was determined 
after the first high-dose infusion of MTX (Upfront-high-dose MTX, see 
Remission/Induction). Furthermore, mercaptopurine (50 mg/m2) was given 
every day. The chemotherapy regimen during the consolidation therapy is 
presented in Table 3.21. 
Calcium folinate rescue was started 42 h after the beginning of high-dose 
MTX. A total of 5 doses of calcium folinate was administered (standard or 
high-risk, 15 mg/m2  i.v. or p.o.; low-risk 10 mg/m2  i.v. or p.o. every six 
hours). The rescue was intensified if the concentration of MTX in serum was 
> 1 µM 42 h after the beginning of the infusion.  
 
 
 
Materials and Methods  
 70 
Table 3.20: Categorisation of patients treated with TOTAL XV according to 
their characteristics. 
Category Characteristics of patients 
Low-risk 
(LR) 
• Age: 1-10 years 
• pre-B ALL 
• Leukocyte count < 50 x 109/L 
 
Standard-risk 
(SR) 
• Age: 1-16 years 
• pre-B ALL (with translocation t(1; 19) of the 
E2A-PBXI-fusion gene or MLL-rearrangement), T-ALL, 
testicular leukaemia, 
• hypoploidic  chromosomes (< 45 chromosomes) 
• CNS 3 status ( ≥ 5 Leucocytes/µL CSF, blasts in CSF) 
• ≥ 5% blasts in the bone marrow on day 19 or 26 of R/I 
• minimal residual disease (≥ 0.01%) on day 46 of R/I 
 
High-risk 
(HR) 
• Age: 1-16 years 
• Patients with Philadelphia chromosome (Bcr-Abl) 
• ≥ 1% blasts in the bone marrow on day 46 of the R/I 
• ≥ 0.1% blasts in the bone marrow 16 weeks after R/I 
 
R/I: Remission/Induction; MLL: mixed lineage leukaemia 
 
Table 3.21: Consolidation therapy 
Drug Dose Day  
Total no of 
admin. 
MTX 
ca. 2.5 g/m2 i.v (LR)* 
ca. 5.0 g/m2 i.v. (SR, HR)# 
1, 15, 29, 43 4 
6-Mercaptopurine 50 mg/m2 p.o. 1-56 56 
*Desired steady-state concentration in plasma for low-risk patients: 33 µM 
#Desired steady-state concentration in plasma for standard/high-risk patients: 65 µM 
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Maintenance therapy (120–146 weeks) 
Maintenance therapy was started 7 days after the last high-dose MTX infusion 
of the consolidation block. The chemotherapy in this block depended 
strongly upon the risk categorisation of the patient. Patients received a 
treatment schedule during week 1-6 which was repeated during week 11-16 
(seeTable 3.22). During week 7-9 and 17-19 Reinduction I and II therapy was 
given (presented in Table 3.23).  
 
Table 3.22: Maintenance therapy during week 1-6 and 11-16 
LR SR, HR 
Drug 
Dosage 
Day 
of 
week 
Total 
no of 
admin. 
Dosage 
Day 
of 
week 
Total 
no of 
admin. 
MTX 
40 mg/m2 
i.v. 
1# 4 --- --- --- 
6-
Mercaptopurine 
75 mg/m2 
p.o. 
1-7 42 
50 mg/m2 
p.o. 
1-7 42 
Doxorubicine --- --- --- 
30 mg/m2 
i.v. 
1* 2 
Vincristine 
2 mg/m2 
i.v. 
1* 2 
2 mg/m2 
i.v. 
1* 2 
L-Asparaginase --- --- --- 
2500 IU/m2 
i.m. 
1 6 
Dexamethasone 
8 mg/m2 
p.o. 
1-5* 
3EDD 
30 
12 mg/m2 
p.o. 
1-5* 
3EDD 
30 
*only in the 1st and 4th week; # only in the 2nd, 3rd, 5th and 6th week  
 
From week 21-28 patients received a regimen presented in Table 3.24 which 
was repeated five times. Subsequently (from week 68-100) patients received 
6-mercaptopurine (daily 75 mg/m2, p.o.), MTX (once a week 40 mg/m2, i.v.) 
and dexamethasone (every four weeks, 8 or 12 mg/m2, p.o.) in combination 
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Table 3.23: Reinduction therapy I (week 7-9) and II (week 17-19) 
 LR SR, HR 
Drug Dosage 
Day of 
week 
Total 
no of 
admin.
Dosage 
Day of 
week 
Total 
no of 
admin. 
Reinduction I 
Doxorubicine 
30 mg/m2 
i.v. 
1 1 
30 mg/m2 
i.v. 
1, 8 2 
Vincristine 
1.5 mg/m2 
i.v. 
1, 8, 15 3 
1.5 mg/m2 
i.v. 
1, 8, 
15 
3 
L-Asparaginase 
10000 
IU/m2 i.m. 
3 days 
per 
week 
9 
25000 
IU/m2 i.m. 
1, 8, 
15 
3 
Dexamethasone
8 mg/m2 
p.o.  
1-8,  
15-21 
48 
8 mg/m2 
p.o.  
1-8,  
15-21 
48 
TIT 
see Table 
3.19 
1 1 
see Table 
3.19 
1 1 
Reinduction II 
Doxorubicine 
30 mg/m2 
i.v. 
1 1 --- --- --- 
Vincristine 
1.5 mg/m2 
i.v. 
1, 8, 15 3 
1.5 mg/m2 
i.v. 
1, 8, 15 3 
L-Asparaginase 
10000 
IU/m2 i.m. 
3 days 
per 
week 
9 
25000 
IU/m2 i.m. 
1, 8, 17 3 
Dexamethasone
8 mg/m2 
p.o. 
1-8; 
15-21 
48 
8 mg/m2 
p.o. 
1-8, 
15-21 
48 
Cytarabine --- --- --- 
2 g/m2 i.v.  
2 EDD 
15, 16 4 
TIT 
See Table 
3.19 
1 1 
See Table 
3.19 
1 1 
TIT: triple intrathecal therapy; EDD: equal daily doses 
Materials and Methods  
 73
Table 3.24: Maintenance therapy during week 21-28. 
LR SR, HR 
Drug 
Dosage 
Day of 
week 
Total 
no of 
admin. 
Dosage 
Day of 
week 
Total 
no of 
admin. 
MTX 
40 mg/m2 
i.v. 
1ª 6 
40 mg/m2 
i.v. 
1b 4 
Vincristine 
2 mg/m2 
i.v. 
1* 2 
2 mg/m2 
i.v. 
1* 2 
Cyclophosphamide --- --- --- 
300 mg/m2 
i.v. 
1# 2 
Dexamethasone 
8 mg/m2 
p.o. 
1-5* 10 
12 mg/m2 
p.o. 
1-5* 10 
Cytarabine --- --- --- 
300 mg/m2 
i.v. 
1# 2 
6-Mercaptopurine 
75 mg/m2 
p.o. 
1-7 56 
75 mg/m2 
p.o. 
1-7 56 
* only in the 24th and 28th week; # only in the 23rd and 27th week; a only in the 21st -23rd week 
and 25th -27th week; b only in the 21st, 22nd, 25th and 26th week 
 
with vincristine (2 mg/m2, i.v.). Girls completed the therapy after 100 weeks, 
boys received 6-mercaptopurine and MTX for another 46 weeks. Triple 
intrathecal therapy was applied at least seven times but not more than 
sixteen times which depended on the risk profile of the patient. 
CSF sampling 
Not more than three CSF samples were obtained from each patient by lumbar 
puncture. Samples were collected before the Remission/Induction therapy 
and on day 1 and day 15 of the consolidation block. CSF was obtained 
immediately before the intrathecal administration of MTX.  
For the analysis of 5,10-methylene-THF, 5-methyl-THF, calcium folinate and 
MTX, samples were collected into vials containing ascorbic acid as described 
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in chapter 3.3.2. SAM and SAH were not determined since CSF samples 
stabilised with perchloric acid were not obtained (see also chapter 3.4.2). 
 
 
3.6 Statistical data analysis  
Statistical analysis of data was performed by the use of Excel® 2002 
(Microsoft, Redmond, USA) and SPSS 12.0 for Windows® (SPSS Inc., Chicago, 
USA). 
3.6.1 Descriptive statistics 
In order to describe the obtained data measures of central tendency were 
used. Central tendency considers two important aspects of a continuous 
variable which are: the center of the distribution and how the observations 
are dispersed within the distribution.  
To describe the center of distribution sample median and sample mean (see 
Eq. 3.8) were considered  
 
Sample median (x~ ): The sample median is the middle of a distribution: 
half of the scores are above the median and half 
are below. If there is an even number of 
observations the median is the average of the two 
central scores 
 
Sample mean ( )x :  
n
x
x
n
1i
i∑
==  
      valuesindividualxi =  
      
nsobservatio
sampleofnumbertotaln =
 
 
Eq. 3.8 
Materials and Methods  
 75
The following measures were used for the description of how the 
observations were dispersed within a distribution: 
 
Standard deviation (SD):   
( )
1n
xx
SD
n
1i
2
i
−
−
=
∑
=  
      valuemeanx =  
      valueindividualxi =  
      
nsobservatio
sampleofnumbertotaln =
 
 
Relative standard deviation (RSD):  see Eq. 3.3 
 
Range:  The range represents the difference 
between the largest (maximum) and the 
smallest (minimum) value. 
 
The data were graphically presented with the use of box-and-whisker plots. 
The box plot is a rectangular box in which the upper line represents the third 
quartile (75% of observations are below) and the lower line the first quartile 
(25% of observations are below). The horizontal line in the box represents the 
second quartile (median). The vertical lines (whiskers) extend from the top or 
bottom of the box to the maximum and minimum value, respectively. Values 
that are above or below one and a half box length (calculated from top or 
bottom of the box) are defined as outliers and marked with a circle. Values 
that are above or below the range of three box lengths are defined as 
extreme values and marked with a starsign (see Fig. 3.3).  
 
 
 
 
 
Eq. 3.9 
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Fig. 3.3: Box-and-whisker plot 
 
3.6.2 Inferential statistics 
Inferential statistics was used to infer (make predictions) about a population 
based on the data obtained from a sample of the population. By convention 
the null hypothesis is stated as no real difference between two or more 
populations. The alternative hypothesis (research hypothesis) is stated as the 
opposite to the null hypothesis. The null hypothesis is tested using inferential 
statistics. In this work the null hypothesis was rejected at an error probability 
(p) of ≤ 0.05 which means that there was a probability of no more than 5% of 
rejecting a true null hypothesis.  
In order to assess whether data were normally distributed the Shapiro-Wilk-
Test was used for samples with no more than 50 observations and the 
Kolmogorov-Smirnov-Test for samples with more than 50 observations. The 
null hypothesis in both tests was rejected at a significance level p < 0.05 
meaning that the distribution was significantly different from normal 
distribution. Small samples (less than 10 values) were treated as if they were 
not normally distributed. 
Outlier Extreme value 
Median 
Maximal value  
Minimal value 
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Various statistical tests were used to investigate if there was any difference in 
the measured parameter between two or more samples. The selection of an 
appropriate test depended upon the type of variables (continuous or 
discrete), their distribution and number. Moreover, it was considered whether 
the variables were dependent or independent from each other. An overview of 
the tests used is presented in Fig. 3.4.  
 
3.6.3 Correlation analysis 
Correlation was used to determine the degree to which two variables showed 
a possible interrelationship. The correlation coefficient (r) was used to 
measure the strength of the relationship between two variables as well as the 
direction of the relationship. This is a well-defined mathematical index which 
can take values from -1.00 to +1.00. If r = 1.00 there is a perfect positive 
correlation, r = -1.00 indicates a perfect negative (inverse) correlation and r=0 
means that there is no linear correlation between the two variables. If the 
variables were normally distributed the correlation coefficient was calculated 
according to Pearson. For variables measured on an ordinal scale or not 
normally distributed Kendall rank correlation was used to quantify the 
possible relationship between two variables. 
In Table 3.25 the interpretation of correlation coefficients is summarised. The 
statistical significance of a given correlation was also tested and the level of 
significance was set to p < 0.05.  
 
3.6.4 Regression analysis 
Regression analysis was used to evaluate the relationship between an 
independent (predictor) and a dependent (response) variable. A least-squares 
regression line was computed to describe a linear relationship (see Eq. 3.6) 
between the predictor variable (x) and the response variable (y). 
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 Fig. 3.4: Decision algorithm for the selection of the appropriate statistical test. 
 
Table 3.25: Interpretation of correlation coefficients 
Coefficient of correlation (r) Degree of correlation 
< 0.2 Slight, negligible 
0.2 – 0.4 Weak 
0.4 – 0.7 Moderate 
0.7 – 0.9 High, strong  
> 0.9 Very high, very strong 
 
 
 
yes 
no 
> two 
Two-way 
ANOVA 
One-way  
ANOVA 
Kruskal-Wallis 
test 
 Mann-Whitney 
U-test 
Number of compared 
samples 
Variables independent 
from each other 
 
no yes 
Variables independent 
from each other 
no yes 
two 
Variables independent 
from each other 
> two 
no 
yes 
two 
yes 
no 
Normal distribution 
Number of compared
samples 
Variables independent 
from each other 
Wilcoxon 
test 
Paired 
t-test 
Two-sample
t-test 
Friedman 
test 
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4 RESULTS 
4.1 Analysis and validation 
HPLC analysis was used for the determination of reduced folates and MTX as 
well as SAM and SAH. The results of method development and validation are 
presented in this chapter. 
4.1.1 HPLC analysis for the determination of reduced folates 
and MTX in CSF 
Belz et al.141 developed a method for the determination of 5-methyl-THF, 
calcium folinate and MTX using HPLC with UV and fluorescence detection. 
This method was used as a basis and was further modified to enable the 
quantification of 5,10-methylene-THF. 
Fluorescence detection was used for the determination of 5-methyl-THF and 
5,10-methylene-THF, whereas calcium folinate and MTX were quantified with 
the use of UV detection. 
 
4.1.1.1 Method development 
The mobile phase from Belz et al.141 was modified. Methanol was used for 
elution instead of acetonitrile since it has a higher polarity index (6.6) and a 
lower eluotrope equivalent (5.5) in comparison to acetonitrile (6.2 and 7.3, 
respectively)147. Therefore, retention times of the analytes were prolonged 
when an equivalent concentration of methanol was used compared to 
acetonitrile. This further enabled a better separation of peaks in the 
chromatogramme. Such change in mobile phase required an optimisation of 
the gradient. The resulting gradient is presented in Table 3.1. 
In order to define the optimal excitation and emission wavelength for the 
endogenous reduced folates a scan was performed with the fluorescence 
detector. The results revealed an optimal excitation (λ = 294 nm) and 
emission wavelength (λ = 356 nm) which was in accordance with literature 
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data141. The UV detector was used in parallel with the fluorescence detector. 
In that way MTX which has no natural fluorescence could be analysed 
simultaneously with the reduced folates. A scan was performed to find the 
optimum wavelength (λ = 310 nm). Calcium folinate was also detected by UV 
absorption whereas the peaks of 5,10-methylene-THF and 5-methyl-THF were 
seen only at higher concentrations indicating that UV detection is not 
sensitive enough for determining lower concentrations of these compounds. 
 
4.1.1.2 Selectivity 
Chromatogrammes presented in Fig. 4.1 show CSF samples before and after 
spiking with 5-methyl-THF, 5,10-methylene-THF, calcium folinate and MTX. 
5-methyl-THF and 5,10-methylene-THF are endogenous substances in the CSF 
and were identified by the enlargement of the respective peaks after spiking.  
 
4.1.1.3 Stability 
In order to investigate the stability of the analytes in CSF in presence of 
ascorbic acid, samples were kept at room temperature or 4 ºC and analysed. 
Two freeze and thaw cycles were performed as well. The stability 
investigation is described in chapter 3.3.3.2.  
Stability of the analytes at room temperature 
Table 4.1 shows the stability of the analytes at room temperature. The range 
is obtained from three different concentrations of each analyte which 
corresponded to the lower, middle and upper range of the calibration curve. 
Stability was calculated with the use of Eq. 3.1. If there was no tendency 
during the stability observation period and if the results were within the 
range of instrument precision then the analytes were considered to be stable. 
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Fig. 4.1: Characteristic chromatogrammes of pooled CSF (A: UV detection, C: 
fluorescence detection) and pooled CSF spiked with 25 nM 
5,10-methylene-THF, 25 nM 5-methyl-THF, 500 nM calcium folinate and 
500 nM MTX (B: UV detection, D: fluorescence detection). 
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Table 4.1: Room temperature stability of 5,10-methylene-THF, 5-methyl-THF, 
calcium folinate and MTX in CSF (n=3).  
Stability at room temperature (%) Time (h) 
 5,10-MeTHF 5-MTHF Ca-folinate MTX 
1 98.5-101.2 97.7-100.9 98.8-102.4 99.9-100.3 
2 95.7-98.2 97.1-99.7 99.0-101.5 99.3-99.8 
3 95.6-96.7 95.6-99.8 99.8-100.4 99.7-102.6 
4 91.8-93.8 95.5-98.4 97.1-99.9 95.8-100.1 
5 89.6-91.1 95.4-97.5 98.2-99.5 99.6-100.2 
6 88.5-90.3 95.9-96.8 98.0-99.1 97.6-100.1 
7 86.7-88.4 95.6-96.3 98.4-100.3 100.0-103.4 
8 83.6-85.7 95.9-96.5 97.7-100.0 99.4-100.1 
9 83.4-84.8 94.6-96.1 99.6-101.3 100.1-102.5 
10 80.5-82.9 95.1-95.9 95.6-100.8 97.5-99.7 
 
As expected calcium folinate and MTX were stable throughout the 10 h 
period at room temperature (97.1-103.4%). 5-methyl-THF had an acceptable 
stability throughout the observation period (94.6-100.9%) but a slight loss 
tendency was observed. 5,10-methylene-THF was instable over 10 h but a 
loss of less than 5% was observed within 3 h. Therefore, all patient CSF 
samples were kept for no more than 3 h at room temperature prior to 
analysis. Since one sample was analysed for 30 min a maximum of six 
samples was placed in the autosampler. 
Stability of analytes at 4 ºC 
The results of the stability investigation at 4 ºC are presented in Table 4.2. 
Since a loss tendency was observed for 5,10-methylene-THF at 4 ºC as well, 
patient samples were not kept for longer than 24 h in the refrigerator. All CSF 
samples in which reduced folates and MTX were analysed were kept for not 
longer than 3 h at room temperature or 24 h at 4 ºC. 
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Table 4.2: Stability of 5,10-methylene-THF, 5-methyl-THF, calcium folinate 
and MTX at 4 ºC in CSF (n=3). 
Stability at 4 ºC (%) Time (h) 
 5,10-MeTHF 5-MTHF Ca-folinate MTX 
24 95.0-97.4 99.1-104.1 99.6-102.3 98.5-101.0 
48 92.8-95.7 98.2-99.9 98.6-101.4 99.5-101.6 
72 91.1-93.2 95.6-97.9 99.8-105.2 94.1-103.5 
 
Freeze-and-thaw stability  
The freeze-and-thaw stability of the analytes is presented in Table 4.3. The 
results indicate acceptable stability (95.8-105.4%) of all four analytes in the 
CSF after two cycles of thawing and freezing. Therefore, it was possible to 
analyse patient samples up to three times if necessary. Because of the 
instability at room temperature it was important that the samples were 
refrozen as soon as possible after thawing. 
Table 4.3: Stability of 5,10-methylene-THF, 5-methyl-THF, calcium folinate 
and MTX in the CSF after freezing and thawing of CSF samples (n=3). 
Freeze and thaw stability (%) Cycle 
 5,10-MeTHF 5-MTHF Ca-folinate MTX 
1 97.1-99.1 98.6-101.7 99.4-103.5 99.6-100.9 
2 95.8-97.4 96.4-98.3 100.1-105.4 100.2-101.5 
 
4.1.1.4 Recovery 
Recovery was determined as described in chapter 3.3.3.3. The results are 
presented in Table 4.4. 
The results of the recovery experiments reveale that the response (specified 
as peak area) of calcium folinate and MTX in CSF is constant in the range of 
95.0-112.5% compared to the response of the equivalent concentration of the 
analytes in tris-buffer. On the other hand, the recovery of 5,10-methylene-THF 
(60.0-78.8%) and 5-methyl-THF (85.4-94.8%) decreased with the lower analyte 
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Table 4.4: Recovery of 5,10-methylene-THF, 5-methyl-THF, calcium folinate 
and MTX in CSF (n=3). 
5,10-MeTHF  5-MTHF  Ca-folinate  MTX 
Conc. 
(nM) 
Recovery 
(%) 
 
Conc. 
(nM) 
Recovery 
(%) 
 Conc. 
(nM) 
Recovery 
(%) 
 
Conc. 
(nM) 
Recovery 
(%) 
20.0 60.0  20.0 85.4  200.0 112.5  50.0 95.0 
100.0 71.6  100.0 89.2  1000.0 98.7  2500.0 102.7 
250.0 78.8  250.0 94.8  5000.0 100.1  7500.0 100.1 
 
 
concentrations. Due to the results of the recovery experiments it was 
neccessary to calibrate 5,10-methylene-THF and 5-methyl-THF in CSF in order 
to determine their concentration in patient samples. Since all four compounds 
were determined simultaneously the calibration curves were prepared using 
pooled CSF as matrix. 
 
4.1.1.5 LOD and LLOQ  
The criteria for establishing LOD and LLOQ are presented in chapter 3.3.3.4 
and 3.3.3.5, respectively.The limits of detection and the lower limits of 
quantification for the reduced folates and MTX are presented in Table 4.5. 
The precision of the determination of LLOQ defined as coefficient of variation 
was in the range 12.7-19.8% for all four compounds whereas accuracy was 
85.0-90.1%. The method met the requirements of the FDA guideline 
(CV ≤ ± 20% and accuracy ≤ ± 15%). 
 
4.1.1.6 Precision 
Precision was investigated as described in chapter 3.3.3.6. Coefficients of 
variation were calculated with the use of Eq. 3.3. 
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Table 4.5: LOD and LLOQ (with precision and accuracy data) of the reduced 
folates and MTX in CSF (n=6). 
 5,10-MeTHF 5-MTHF Ca-folinate MTX 
LOD (nM) 2.0 2.0 20.0 5.0 
LLOQ (nM) 10.0 10.0 100.0 20.0 
Precision, CV (%)  19.8 17.5 17.7 12.7 
Accuracy (%)  85.0 86.6 87.8 90.1 
 
Within-day precision 
The results of the within-day precision investigation of reduced folates and 
MTX are presented in Table 4.6. The coefficients of variation for the injection 
precision were < 5% for the middle and upper concentrations of all four 
analytes. The lowest concentration of all substances had a variation 
coefficient < 10%. 
Table 4.6: Within-day precision of reduced folates and MTX in CSF (n=6). 
5,10-MeTHF  5-MTHF  Ca-folinate  MTX 
Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
20.0 9.7  20.0 6.6  200.0 4.4  50.0 4.6 
100.0 4.9  100.0 3.3  1000.0 1.8  2500.0 1.8 
250.0 3.1  250.0 2.8  5000.0 0.9  7500.0 0.4 
 
Between-day precision 
The results of the between-day precision are presented in Table 4.7. The 
between-day precision was analysed in order to assess the reproducibility of 
the method. Since all calculated coefficients of variation were in the range 
1.3-14.7% the method met the requirements of the FDA guideline according 
to which the CV should not be higher than 15% 142. 
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Table 4.7: Between-day precision of reduced folates and MTX in CSF (n=6). 
5,10-MeTHF  5-MTHF  Ca-folinate  MTX 
Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
 Conc. 
(nM) 
CV 
(%) 
20.0 14.7  20.0 10.5  200.0 8.8  50.0 6.7 
100.0 9.8  100.0 6.3  1000.0 3.5  2500.0 2.8 
250.0 6.9  250.0 3.9  5000.0 1.3  7500.0 1.3 
 
4.1.1.7 Accuracy 
Accuracy was obtained by analysing three different CSF concentrations of the 
analytes on six subsequent days (see also chapter 3.3.3.7). The mean values 
of obtained coefficients of variation are presented in Table 4.8. Accuracy was 
in the range 88.6-103.4% which is within the range of the FDA guideline 
(85.0-115.0%). 
Table 4.8: Accuracy of the HPLC method for the determination of reduced 
folates and MTX in CSF (n=6). 
5,10-MeTHF  5-MTHF  Ca-folinate  MTX 
Conc. 
(nM) 
Accur. 
(%) 
 Conc. 
(nM) 
Accur. 
(%) 
 Conc. 
(nM) 
Accur. 
(%) 
 Conc. 
(nM) 
Accur.
(%) 
25.0 88.6  25.0 102.5  250.0 89.5  60.0 102.6 
75.0 103.4  75.0 89.6  2000.0 93.7  3000.0 97.4 
200.0 99.4  200.0 100.5  4000.0 100.8  8000.0 99.5 
 
4.1.1.8 Linearity 
The linear relationship between concentrations and the response of the 
analytes was investigated in the CSF on six subsequent days. Calibration 
curves were obtained as described in chapter 3.3.4. The results are presented 
in Table 4.9. 
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Since the calibrator concentrations of analytes were in a wide range the 
curves were fitted using weighting148. In that way low concentrations had a 
higher impact on the calibration curve compared to unweighted regression. 
The best fitting was found with 1/x2 since the residuals were in the range       
-14.9–12.1 (< 15%) and the means (n=42) between 2.1-4.9%. 
A characteristic calibration curve for 5-methyl-THF obtained with linear 
regression (weighting 1/x2) is shown in Fig. 4.2. 
 
Table 4.9: Coefficients of correlation and residuals of calibration curves for 
different regression models (n=6). 
Analyte 
Concentration 
range (nM) 
Coefficient of 
correlation (r) 
Residuals 
Range (%)     Mean (%) 
linear, not weighted 
5,10-MeTHF 10-300 0.9989-0.9994 -35.4-28.8 15.7 
5-MTHF 10-300 0.9991-0.9999 -22.3-9.8 13.7 
Ca-folinate 100-6000 0.9994-0.9999 -15.6-21.7 10.1 
MTX 20-10000 0.9994-0.9999 -9.1-17.1 12.7 
linear, weighted 1/x 
5,10-MeTHF 10-300 0.9981-0.9990 -27.6-26.8 8.7 
5-MTHF 10-300 0.9989-0.9992 -19.6-4.2 7.5 
Ca-folinate 100-6000 0.9991-0.9995 -10.3-16.1 5.1 
MTX 20-10000 0.9992-0.9999 -7.9-10.2 3.7 
linear, weighted 1/x2 
5,10-MeTHF 10-300 0.9965-0.9986 -14.9-12.1 4.9 
5-MTHF 10-300 0.9971-0.9989 -14.7-7.4 4.2 
Ca-folinate 100-6000 0.9980-0.9992 -8.6- 9.3 3.8 
MTX 20-10000 0.9983-0.9989 -5.2-7.4 2.1 
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Fig. 4.2: Characteristic calibration curve for 5-methyl-THF (linear regression 
modell, weighted 1/x2). 
 
4.1.2 HPLC analysis for the determination of SAM and SAH in 
CSF 
4.1.2.1 Method development 
The determination of SAM and SAH as their 1,N6-etheno derivatives has been 
described in several literature reports132, 137, 143, 149. However, in most of them 
the concentrations of the analytes were assessed after separate runs. The 
goal in the developmental phase of this work was to achieve a simultaneous 
determination of both analytes. Therefore, columns were tested in order to 
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obtain an optimal separation of the 1,N6-etheno derivatives of SAM and SAH 
in the CSF (see also 3.4.4).  
Due to the polarity of the compounds an attempt was made to separate the 
two analytes using the Luna NH
2
® column. Phosphate buffer (40 mM, pH 4.5) 
and isopropanol or acetonitrile served as mobile phase. The composition of 
the mobile phase was varied and several gradient systems were run. However, 
no satisfactory separation of the substances was obtained. 
Further, a reversed-phase column was tested using the same mobile phase as 
for the amine column. A separation of the peaks was possible but the peaks 
were neither symmetric nor sharp and it was not possible to obtain the 
needed sensitivity for the quantification of SAH.  
A much better peak symmetry and higher sensitivity for both analytes was 
observed with the use of a reversed-phase column especially designed for the 
separation of amino acids (Eclipse AAA®). The mobile phase consisted initially 
of a phosphate buffer (40 mM, pH 4.5) and acetonitrile but despite the use of 
different gradients SAM eluted always within 5 minutes and it was impossible 
to obtain an adequate selectivity for this analyte. Since the positive charge of 
SAM was thought to be responsible for the quick elution of this analyte the 
ion-pairing agent 1-heptanesulphonic acid (8 mM) was added to the 
phosphate buffer. The elution time of SAM was prolonged for more than 30 
minutes using heptanesulphonic acid. Moreover, SAM eluted later than SAH. 
The mobile phase gradient was optimised and the final gradient presented in 
Table 3.4 resulted in a selective, reproducible separation of SAM and SAH 
with an acceptable run time (1,N6-etheno-SAH had a retention time of 
19.7 min while 1,N6-etheno-SAM was detected after 23.5 min). 
Fig. 4.3 shows a characteristic chromatograme of SAM and SAH in the CSF in 
form of their 1,N6-etheno derivatives on the Eclipse AAA® column. 
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Fig. 4.3: Characteristic chromatogrammes of SAM and SAH in: pooled CSF (A), 
pooled CSF spiked with 15 nM SAH and 125 nM SAM (B). C and D depict the 
marked areas of A and B, respectively, in which the peaks of interest are 
shown more precisely. 
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4.1.2.2 Selectivity 
Selectivity was shown by comparison of the CSF samples of five patients with 
the same CSF samples which were spiked with SAM and SAH (see Fig. 4.3).  
In chromatogramme B it is shown that the peaks identified as SAM and SAH 
have a higher peak area in comparison to the peaks in chromatogramme A. 
No interfering compounds were detected which could interfere with the 
identification or quantification of SAM and SAH. 
 
4.1.2.3 Stability 
pH-dependent stability 
In order to prepare stable stock solutions the influence of pH on the stability 
of SAM and SAH was investigated. Five aqueous solutions containing 15 nM 
SAH and 125 nM SAM were prepared. The pH of the solutions was adjusted 
to 1, 3, 5, 7 and 10, respectively, with the use of perchloric acid or sodium 
hydroxide. They were kept at 37 ºC for 48 h to accelerate any possible 
degradation of the analytes. The experiment was repeated three times. 
There was a strong influence of pH on the stability of SAM. In the solution 
with pH 1 the highest response defined as peak area was observed (stability 
100%) which decreased rapidly with increasing pH. In the alkaline solution no 
SAM was detected (stability 0%). In contrary to SAM, the stability of SAH was 
in the range of 91.2-132.1%. A somewhat higher response was obtained at 
pH 3 but because of the instability of SAM pH 1 was chosen for both 
analytes. The results are presented in Table 4.10.  
As a consequence of these results perchloric acid was added to each CSF 
sample drawn for SAM and SAH analysis prior to freezing. In that way 
samples were deproteinised and pH 1 was obtained in which SAM is stable. 
Since some samples obtained from cooperation partners were not collected 
with perchloric acid, it was investigated whether the pH-dependent instability 
noticed at 37 ºC also occured at -20 ºC. For that reason, CSF samples 
collected from one patient with PCNSL at different time-points were analysed. 
Each sample was divided into several vials after collection. In one vial Table 
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4.10: pH-dependent stability of SAM and SAH after 48 h at 37 ºC in aqueous 
solutions (n=3). 
pH-dependent stability (%) pH 
SAM SAH 
1.0 100.0 100.0 
3.0 48.5 132.1 
5.0 30.8 107.5 
7.0 2.5 95.4 
10.0 0.0 91.2 
 
 
perchloric acid was added while another one was frozen without acidification. 
Samples were kept frozen approximately one year. After thawing, perchloric 
acid was added into the previously non-acidified aliquot as well in order to 
deproteinise the CSF sample and equalise the pH in both CSF samples prior to 
derivatisation. The matched-pair samples were analysed: in the samples kept 
at pH 1 the SAM concentration was 153.1-966.6 nM (median 843.6 nM) while 
a SAM concentration of 105.5-618.2 nM (median 407.5 nM) was determined 
in samples kept at physiological pH. The SAH concentration in the samples 
kept at pH 1 was in one sample below 5 nM (LLOQ) and 6.2-11.0 nM (median 
8.0 nM) in all others while the samples kept at physiological pH exhibited a 
SAH concentration of 11.2-43.7 nM (median 24.7 nM). The results are 
presented in Table 4.11. Furthermore, CSF samples of six other patients 
suffering from ALL which were stored over a year at -20 ºC were analysed. 
Similarly, the decrease of the SAM and increase of the SAH concentration was 
observed in the CSF samples which were not acidified prior to freezing. The 
SAM concentration in samples kept at pH 1 was 51.5-222.7 nM (median 
145.4 nM) and 31.7-85.2 nM (median 66.0 nM) in samples kept at pH 7.4. 
The concentration of SAH was below LLOQ in three and 5.0-7.2 nM in the 
other three samples kept at pH 1 whereas samples kept at pH 7.4 had the 
SAH concentration 5.2-16.2 nM (median 8.5 nM). The results are presented in 
Table 4.12.  
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Table 4.11: CSF SAM and SAH concentrations in samples stored at -20 ºC at 
least one year (all samples obtained from one patient).  
Concentration (nM) 
SAM                                           SAH 
Sample 
pH 1 pH 7.4  pH 1 pH 7.4 
1 153.1 105.6  Below LLOQ 12.1 
2 290.7 198.7  7.0 11.2 
3 381.0 237.4  6.2 24.1 
4 641.2 417.1  6.6 16.6 
5 856.7 539.1  8.0 32.7 
6 856.8 356.5  10.2 18.7 
7 903.0 618.2  7.8 27.9 
8 966.6 482.8  8.0 17.5 
9 899.1 372.1  8.3 43.7 
10 854.3 418.3  8.2 26.4 
11 866.8 321.4  9.1 17.2 
12 831.7 515.7  9.5 25.3 
13 645.4 512.5  6.3 26.2 
14 672.7 398.7  11.0 38.2 
 
 
An investigation of the stability of SAM and SAH in the CSF at room 
temperature for 1 h was performed in order to exclude any possible change 
of the concentration of analytes due to enzymatic conversion. CSF samples 
were collected from six patients. In one vial with CSF, perchloric acid was 
added immediately and the sample was frozen at -20 ºC while another vial 
with the same CSF sample was kept at room temperature for 1 h and then 
frozen. The samples were thawed at latest six weeks after freezing and 
perchloric acid was added into CSF samples kept at physiological pH. The 
analysis of the samples revealed no significant difference between the groups 
(Wilcoxon test, p=0.917 and p=0.345 for SAM and SAH respectively).
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Table 4.12: CSF SAM and SAH concentrations in samples from six patients 
stored at -20 ºC, at least one year. 
Patient SAM (nM)  SAH (nM) 
 pH 1 pH 7.4  pH 1 pH 7.4 
1 192.5 75.5  6.0 16.2 
2 222.7 85.2  7.2 11.9 
3 110.7 71.9  Below LLOQ 5.2 
4 180.0 53.5  5.0 9.0 
5 99.4 60.1  Below LLOQ 7.2 
6 51.5 31.7  Below LLOQ 7.9 
 
 
The concentration of SAM was 81.4-253.6 nM (median 133.9 nM) in the 
deproteinised and 88.0-221.5 nM (median 141.3 nM) in the samples kept 1 h 
at room temperature. The concentration of SAH was 5.0-8.2 nM (median 
6.1 nM) in the acidified samples and 5.0-8.4 nM (median 6.3 nM) in the 
samples kept for 1 h at room temperature. The results are presented in Table 
4.13.  
 
Stability of 1,N6-etheno derivatives of SAM and SAH at room temperature 
The stability of derivatised SAM and SAH in the CSF was investigated at room 
temperature for a period of 24 h in order to establish if the derivatised 
samples were stable enough to be kept in the autosampler and analysed over 
night. Stability was investigated at three different concentrations which 
corresponded to the lower, middle and upper range of the calibration curve. 
Each experiment was repeated three times and the results (shown as mean 
values, n=3) are presented in Table 4.14. The 24 h stability of SAM and SAH 
in form of their 1,N6-etheno derivatives at room temperature ranged from 
98.6 to 104.1% and from 97.2 to 100.3%, respectively. Since no loss 
tendency was observed it was concluded that the analytes could be kept in 
the autosampler and analysed within the investigated time period. 
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Table 4.13: CSF SAM and SAH concentration in six samples immediately 
frozen at pH 1 or kept for 1 h at room temperature and frozen at pH 7.4 for a 
period of maximal six weeks. 
Patient 
Concentration (nM) 
SAM                                           SAH 
 
Frozen 
immediately 
pH 1 
1 h at room 
temper.  
pH 7.4 
 
Frozen 
immediately 
pH 1 
1 h at room 
temper. 
pH 7.4 
1 81.4 88.0  6.0 5.0 
2 205.8 202.6  6.1 6.9 
3 84.8 77.7  8.2 8.4 
4 253.6 221.5  5.0 5.7 
5 95.6 104.4  6.4 6.8 
6 172.2 178.1  5.0 5.1 
 
 
Table 4.14: Stability of the 1,N6-etheno derivatives of SAM and SAH in CSF at 
room temperature (n=3). 
Time (h) Stability  of 1,N6-etheno derivatives (%)  
SAM                                            SAH  
3 95.0-102.9  96.0-101.2 
8 95.5-97.0  93.7-103.4 
24 97.2-100.3  98.6-104.1 
 
 
Freeze-and-thaw stability of SAM and SAH 
The stability of SAM and SAH in CSF after two freeze and thaw cycles was 
investigated as well (see also chapter 3.4.5.2). The results are presented in 
Table 4.15. 
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Table 4.15: Stability of SAM and SAH after freeze and thaw (-20 ºC) cycles 
(n=3). 
Freeze-and-thaw stability (%) Cycle 
SAM  SAH 
1 97.2-101.1  95.1-108.5 
2 99.0-105.2  97.3-104.0 
 
 
SAM and SAH remained stable (99.0-105.2% and 97.3-104.0%, respectively) in 
the CSF after the second freeze-and-thaw cycle, thus enabling a repeated 
analysis of SAM and SAH in patient samples when necessary.  
 
4.1.2.4 Recovery 
The response (peak area) of SAM and SAH in CSF was compared to the 
response when 0.9% NaCl was used as matrix in order to determine if the 
latter could be used as calibration matrix (see also chapter 3.4.5.3). The 
results of the investigation are presented in Table 4.16. The recovery of SAM 
and SAH in the CSF increased with higher concentrations of the analytes 
(60.0-78.2% and 67.2-80%, respectively). Since the recovery was not constant 
pooled CSF was used as matrix for all further investigations. 
Table 4.16: Recovery of SAM and SAH in the CSF compared to 0.9% NaCl 
(n=3). 
SAM  SAH 
Concentration 
(nM) 
Recovery 
(%)  
 
Concentration 
(nM) 
Recovery  
(%) 
50.0 60.0  11.0 67.2 
120.0 61.3  55.0 71.6 
500.0 78.2  110.0 80.0 
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4.1.2.5 Limit of detection and lower limit of quantification 
LOD and LLOQ which were determined as described in chapter 3.3.3.4 and 
3.3.3.5 are presented in Table 4.17. 
Table 4.17: LOD and LLOQ (with precision and accuracy data) of the HPLC 
method for analysis of SAM and SAH (n=6). 
 SAM SAH 
LOD (nM) 5.0 1.0 
LLOQ (nM) 25.0 5.0 
Precision CV (%) 19.0 10.5 
Accuracy (%) 82.0 88.0 
 
4.1.2.6 Precision 
Within-day precision 
The within-day precision in the CSF was investigated by using of quality 
controls as described in chapter 3.4.5.5. The results are presented in Table 
4.18. 
Table 4.18: Within-day precision of SAM and SAH in CSF (n=6). 
SAM                                                          SAH 
Concentration 
(nM) 
CV 
(%) 
 
Concentration 
(nM) 
CV 
(%) 
60.0 14.0  15.0 9.1 
200.0 9.4  35.0 8.7 
650.0 3.8  85.0 6.1 
 
 
The within-day precision was 3.8-14.0% for SAM and 6.1-9.1% for SAH which 
was acceptable according to the criteria of the FDA guideline (≤ 15%). 
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Between-day precision 
The results of the between-day precision are shown in Table 4.19.  
The coefficients of variation presented in Table 4.19 indicated that SAH could 
be determined precisely using this method whereas the determination of 
SAM in lower concentrations was less precise compared to SAH but still 
acceptable according to the FDA guideline (≤ 20% at LLOQ).  
Table 4.19: Between-day precision of SAH and SAM in CSF (n=6). 
SAM                                                        SAH 
Concentration 
(nM) 
CV 
(%) 
 
Concentration 
(nM) 
CV 
(%) 
25.0 19.0  5.0 10.5 
50.0 11.3  8.0 6.6 
125.0 13.5  20.0 10.0 
500.0 7.9  70.0 5.6 
750.0 7.9  100.0 3.3 
 
 
4.1.2.7 Accuracy 
The accuracy of the method was determined using quality controls. The 
results are presented in Table 4.20. The calculated concentrations of SAM 
were 98.3-111.0% of the nominal concentration, wheras 88.6-92.5% were 
found for SAH. Since the calculated concentrations were always within the 
range of ±15% of the nominal concentrations, the method was qualified as 
accurate for the determination of both analytes. 
 
4.1.2.8 Linearity 
Six calibration curves were analysed in order to determine the appropriate 
regression model for the calculation of concentrations of SAM and SAH (see 
also chapter 3.4.6.3). The results are presented in Table 4.21. 
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Table 4.20: Accuracy of the HPLC method for the determination of SAM and 
SAH (n=6). 
SAM  SAH 
Concentration 
(nM) 
Accuracy 
(%)  
 Concentration 
(nM) 
Accuracy 
(%) 
60.0 111.0  15.0 90.0 
200.0 108.5  35.0 88.6 
250.0 98.3  85.0 92.5 
 
 
Table 4.21: Coefficients of correlation and residuals of the calibration curves 
of SAM and SAH. 
Residuals Analyte Concentration 
range (nM)  
Coefficient of 
correlation (r) Range (%) Mean (%) 
linear, not weighted 
SAH 5-100 0.9990-0.9999 -14.5-20.4 8.3 
SAM 25-750 0.9989-0.9999 -42.0-12.7 19.5 
linear, weighted 1/x 
SAH 5-100 0.9983-0.9995 -14.0-7.4 7.2 
SAM 25-750 0.9981-0.9993 -32.6-19.6 13.8 
linear, weighted 1/x2 
SAH 5-100 0.9981-0.9993 -14.7-7.3 6.8 
SAM 25-750 0.9978-0.9990 -14.5-7.0 6.5 
 
 
The results showed better coefficients of correlation using the non-weighted 
model but the range and mean of residuals were lower in both weighted 
models. The range of residuals for SAH was < ±15% when fitted with the 1/x 
or 1/x2 weighted model and the means of residuals were comparable for 
both models (6.8 and 7.2%, respectively). Thus, all concentrations of CSF SAH 
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were calculated using 1/x weighting. For SAM the best fit of data (range of 
residuals < ±15%; mean 6.5%) was achieved using the 1/x2 weighted model. 
A characteristic calibration curve obtained for SAH by linear regression 
(weighted 1/x) and SAM (1/x2) is shown in Fig. 4.4 and 4.5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.4: Characteristic calibration curve of SAH (linear regression model, 
weighted 1/x). 
Results 
 101
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.5: Characteristic calibration curve of SAM (linear regression model, 
weighted 1/x2). 
 
 
4.2 Adult patients with PCNSL 
In order to obtain an insight into the biochemical alterations of the folate and 
methyl-transfer pathway after administration of high-dose and/or 
intraventricular MTX CSF samples were obtained from patients with PCNSL. 
Since these patients received frequent intraventricular therapy prior to which 
CSF could be obtained, it was possible to become several samples during 
MTX therapy blocks. This enabled monitoring of the analytes closely after 
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therapy. Because of the low incidence of PCNSL only five patients were 
recruited in this study in the period from June 2001 to October 2003. All 
patients had an implanted Ommaya reservoir from which CSF samples were 
obtained. One patient (no 1) did not receive intraventricular therapy and 
samples were obtained only within 24 h after the end of one high-dose MTX 
infusion. Another patient (no 5) had manifest neurotoxicity in form of 
leukoencephalopathy and will therefore be assessed separately.  
 
4.2.1 CSF concentrations of reduced folates and MTX 
Block A/B 
Blocks A and B of the Bonn protocol for PCNSL were assessed together since 
they did not differ regarding MTX therapy. Treatment commenced with the 
24 h infusion of high-dose MTX (3 or 5 g/m2) on day 1. A CSF sample was 
obtained on day 2 at the end of the infusion and just before the 
intraventricular administration of MTX (3 mg). Calcium folinate rescue was 
administered between sampling on day 2 and 4. On day 3-5 samples were 
obtained prior to intraventricular MTX.  
In patient 1 an exception to the above described schedule was made. This 
patient received the high-dose MTX (3 g/m2) infusion which was followed by 
an intensified calcium folinate rescue initiated one hour after the end of the 
high-dose infusion (see also chapter 3.5.1). Since five samples were obtained 
from this patient within 24 h after the end of the high-dose MTX infusion it 
was possible to monitor closely the effect of high-dose MTX followed by 
calcium folinate on the CSF concentration of 5,10-methylene-THF and 
5-methyl-THF. Within 24 h after the end of the high-dose MTX infusion the 
concentration of MTX decreased from 2.9 µM (end of infusion) to 0.2 µM 
(24 h) as shown in Fig. 4.6 A. The concentrations of all three reduced folates 
increased in the same period of time (Fig. 4.6 B). The concentrations of 
5,10-methylene-THF and 5-methyl-THF were below LLOQ at the end of the 
MTX infusion and increased slowly after rescue administration. Six hours 
after receiving the first infusion of calcium folinate a quantification of the 
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concentrations of 5,10-methylene-THF and 5-methyl-THF was possible and 
they were 22 nM and 28 nM, respectively, whereas no calcium folinate was 
detected in the CSF. The levels of 5,10-methylene-THF, 5-methyl-THF and 
calcium folinate increased to 28 nM, 44 nM and 118 nM, respectively, 23 h 
after the beginning of the rescue. 
The CSF analysis of MTX in three other PCNSL patients revealed drug levels in 
the range 0.7-2.0 µM (median 1.5 µM) at the end of the high-dose infusion 
(see Fig. 4.7 A). The aim of the subsequent frequent low dose intraventricular 
MTX administration was to provide a constant CSF cytotoxic drug 
concentration (1 µM) during the treatment block. Instead the MTX 
concentration ranged from 0.3-20.3 µM (median 2.3 µM) indicating a large 
intra- and interindividual variability both within and between the blocks. Due 
to the sampling schedule it can be assumed that the measured MTX 
concentrations were the lowest in the CSF on day 3, 4 and 5. Nevertheless, in 
some samples extremely high MTX concentrations were determined (15.0, 
18.7 and 20.3 µM). On the other hand, one patient had low MTX levels in all 
samples (0.3-0.8 µM). A cumulation of MTX in the CSF was not observed but 
the variability increased from day to day. 
The analysis of reduced folates in the three PCNSL patients revealed that 
5,10-methylene-THF was below LLOQ (10 nM) and in some cases below LOD 
(2 nM) whereas calcium folinate was below LOD (20 nM) in all samples. 
Decreased levels of 5-methyl-THF (between LOD (2 nM) and LLOQ (10 nM)) 
were determined in all samples collected directly after the end of the 
high-dose MTX infusion (see Fig. 4.7 B). On day 3, after the patients had 
received systemic calcium folinate rescue, the concentration of 5-methyl-THF 
increased to a median of 54.8 nM (32.2-121.8 nM) which is in the 
physiological range according to literature data141, 150, 151. On the following 
two days the CSF 5-methyl-THF concentration remained in a similar range 
(day 4:  median 65.3 nM (22.6-90.5 nM) and day 5: median 67.6 nM 
(26.7-81.9 nM)).                                                                                            .
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Fig. 4.6: CSF concentration of MTX (A) and reduced folates (B) within 24 h 
after the end of high-dose MTX infusion followed by intensified rescue in 
patient 1. 
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Intraindividually, the highest concentration of 5-methyl-THF was observed on 
day 3 or 4 and was followed by a decline tendency observed at latest on day 
5. An exception to this pattern occured in two blocks where the 
concentration of 5-methyl-THF increased throughout the block. Individual 
data are presented in Appendix A.  
Since the concentration of 5-methyl-THF was below LLOQ on day 2 statistical 
evaluation was performed for day 3-5 by using the Friedman test. There was 
no significant difference between the CSF 5-methyl-THF concentration on 
these days (p=0.565, n=7). MTX data were not statistically evaluated since 
only four matched-pair samples were available throughout the blocks.  
Block C 
During block C patients received intraventricular MTX (3 mg/day) from day 
3-7 which was not accompanied by rescue. Samples were obtained on each 
day just before intraventricular drug administration. 
In analogy to block A and B there was a large intra- and interindividual 
variability of the CSF MTX concentration during block C. An overview of the 
drug concentrations throughout block C is presented in Fig. 4.8 A Individual 
data are shown in Appendix A.  
Patients 3 had MTX levels in the range 1.3-9.1 µM. Patient 2 had very 
elevated CSF MTX concentrations (8.3-39.4 µM) during block C of the first 
cycle. Since no signs of toxicity were observed in this patient, the extreme 
levels of MTX were possibly a consequence of a catheter misplacement of the 
Ommaya reservoir. This disorder was the cause of absence of intrathecal 
therapy during the next block after which the Ommaya was reimplanted and 
the patient received further therapy according to the Bonn protocol. Patient 4 
had low CSF MTX concentration (0.2 to 0.7 µM) in all samples similar as in 
block A/B. 
The CSF analysis of reduced folates revealed that 5,10-methylene-THF and 
calcium folinate could not be determined in any sample. The concentrations 
of 5-methyl-THF in the CSF of the three patients on day 3 of block C were in 
the range 59.2-91.5 nM (median 73.8 nM) which was within the normal range 
according to literature data141,150,151. During block C 5-methyl-THF 
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concentration decreased to 15.3-48.5 nM (median 26.0 nM) on day 7 which 
was two to threefold less than at the beginning of the same block (see also 
Fig. 4.8 B and Appendix A).  
The statistical analysis of the concentrations of MTX and 5-methyl-THF during 
block C was not performed due to the small number of matched-pair samples 
(n=3).  
4.2.2 CSF concentrations of SAM and SAH 
The CSF samples of four PCNSL patients obtained during therapy which were 
stabilised with perchloric acid (1.2 M) were used for the analysis of the 
concentration of SAM and SAH. Samples from patient 1 were not acidified 
prior to freezing and SAM and SAH were therefore not determined. The 
sample analysis was performed with the use of HPLC with fluorescence 
detection as described in chapter 3.4. 
Blocks A/B 
In contrast to the alteration of the 5-methyl-THF concentration in block A/B a 
trend in the concentration of SAM was not observed at the same time. The 
CSF concentrations of SAM and SAH during block A/B are depicted in Fig. 4.9. 
Individual data are presented in Appendix A.  
A large intraindividual variability of the CSF SAM concentration among blocks 
was observed in patient 3. During block B of the first cycle the CSF SAM 
concentration was 516.3-697.2 nM. In block A of the second cycle lower 
levels of SAM were measured (148.1-358.7 nM). In the following therapy 
block B the SAM concentration was again higher (641.2-856.8 nM). In patient 
4 a different pattern was observed. In block A of the first cycle the CSF SAM 
concentrations were 279.4-304.4 nM. In block A of the second cycle the 
variability of the CSF SAM concentration was higher (144.3-441.9 nM). Patient 
2 had relatively constant CSF SAM concentrations in blocks A/B of the first 
cycle and block B of the second (183.1-236.2 nM, 170.8-230.4 nM and 
199.7-261.9 nM respectively). Samples were not obtained during block A of 
the second cycle due to the Ommaya reservoir misplacement.  
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Fig. 4.7: Concentration of MTX (A) and 5-methyl-THF (B) in three PCNSL 
patients during blocks A/B. Blue stars and red circles represent the 
concentration of the analytes in the neurotoxic patient (no 5) in block B1 and 
A2, respectively (see also chapter 4.2.3).                .   
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Fig. 4.8: CSF concentration MTX (A) and 5-methyl-THF (B) in three PCNSL 
patients during block C. Green stars represent the concentration of analytes 
in the patient with neurotoxicity (patient 5, see chapter 4.2.3). 
There was no significant change of the concentration of SAM in blocks A/B 
from day 2-5 (Friedman test; p=0.564, n=5).  
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The concentration of SAH was below LLOQ (5 nM) in all samples obtained 
from patient 2 as well as in the sample obtained on day 5 of Block A1 and 
during the complete block A2 from patient 4. In all other samples from block 
A/B SAH concentrations ranged between 5.0 and 12.5 nM (median 7.0 nM). 
Similar to the concentration of SAM no time dependence in the SAH 
concentrations was observed within the block. No statistical evaluation of the 
SAH concentration during block A/B was performed due to the small number 
of samples for a matched-pair comparison (n=3 for Friedman test).  
Block C 
Similar as in block A/B there was no time-dependence in the CSF SAM 
concentration in block C. The concentrations of SAM determined during 
block C in the three patients are presented in Fig. 4.10. The concentrations 
of SAH are not depicted due to the small number of samples. Individual data 
are presented in Appendix A.  
The concentrations of SAM during blocks C were in the range of 182.4 to 
966.6 nM (median 369.4 nM) in patients 2-4. The concentration of SAH was 
5.3-11.0 nM (median 7.1 nM) in patients 3 and 4 and no trend was observed 
within or between blocks. Patient 2 had CSF SAH levels below LLOQ. 
A statistical analysis of the SAM and SAH concentrations during block C was 
not performed due to the small number of matched-pair samples.  
 
4.2.3 CSF analysis of reduced folates, MTX, SAM and SAH in a 
PCNSL patient with neurotoxicity 
Patient 5 developed chronic neurotoxicity in form of leukoencephalopathy 
during therapy. The evaluation of neurotoxicity according to CTC was not 
available, instead radiology findings were obtained. The MRI (T2-weighted) 
performed after block C1 showed a confluent increase of the signal which 
was interpreted as massive demyelination. The manifestation of clinical 
leukoencephalopathy was followed by a discontinuation of chemotherapy 
which occured after block A2. 
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Fig. 4.9: Concentrations of SAM (A) and SAH (B) in patients 2, 3 and 4 in block 
A/B. The blue stars and red circles represent the concentrations in the patient 
with neurotoxicity during block B1 and A2, respectively (see chapter 4.2.3). 
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Fig. 4.10: SAM concentrations in patients 2, 3 and 4 during block C. Green 
stars represent the SAM concentration in the patient with neurotoxity (block 
C1, see chapter 4.2.3). 
 
CSF samples were obtained during block B1, C1 and A2.  
During the three therapy blocks the CSF concentration of MTX in patient 5 
was 1.1-3.8 µM which was similar to the concentrations determined in the 
other three PCNSL patients (see Fig. 4.7 A and Fig. 4.8 A). Low CSF 
5-methyl-THF concentrations were observed throughout therapy. Compared 
to the other PCNSL patients (median 67.6 nM on day 5, block A/B) patient 5 
had a threefold lower 5-methyl-THF concentration at the end of block B1 (see 
Fig. 4.7 B). Approximately two weeks later on day 3 of block C1 the 
concentration of the reduced folate was again low (13.5 nM vs median 73.8 
nM) and persisted in a low range throughout the block (22.7, 17.7, 16.2 and 
14.0 nM on day 4, 5, 6 and 7 respectively, see Fig. 4.8 B). Extremely low 
5-methyl-THF concentrations were observed in block A2 as well. 
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No trend in CSF SAM concentration was observed within any treatment block. 
However, the SAM level decreased from block to block (90.8-127.4 nM in 
block B1, 44.7-54.7 nM in block C1 and 34.1-47.6 nM in block A2, see Fig. 
4.9 A and Fig. 4.10). Compared to the three other PCNSL patients who had a 
median CSF SAM concentration of 261.9 nM in block A/B and 376.2 nM in 
block C the patient with manifest leukoencephalopathy had considerably 
lower SAM levels. 
The concentrations of SAH were 5.0-11.4 nM during all three blocks and 
neither a difference to the other patients nor a time-dependence was 
observed. 
 
 
4.3 Pediatric ALL patients treated according to ALL 
BFM 2000 
In cooperation with Prof. Bode (University Children’s Hospital, Bonn) CSF 
samples were obtained from patients with childhood ALL treated according 
to ALL BFM 2000. In contrast to the PCNSL collective where a monitoring of 
MTX, reduced folates, SAM and SAH within days was possible, CSF samples 
from ALL patients could be obtained only 1 to 3 weeks after MTX 
administration. This group of ALL patients received intrathecal MTX also 
without calcium folinate rescue whereas combined systemic high-dose and 
intrathecal MTX treatment was followed by calcium folinate. Therefore, it was 
possible to compare the effect of the two modalities on the concentration of 
reduced folates, SAM and SAH throughout therapy. 
27 patients categorised as low or medium risk ALL were included in the 
study. All CSF samples were obtained by lumbar puncture. Usually several 
samples were obtained from each patient. However, it was not always 
possible to obtain enough CSF for the analysis of all analytes. Therefore, 74 
samples from 22 patients were obtained for the analysis of reduced folates 
and in 84 samples from 22 patients SAM and SAH concentrations were 
measured (Data shown in Appendix B). In addition, samples were obtained 
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from three patients with manifest neurotoxicity which were evaluated 
separately. 
Patients included in this study were randomised into two arms. Both groups 
chemotherapy started with protocol I which was followed by protocol M. 
After that one study arm received protocol II while the other received 
protocol III. Since protocols I, II and III are similar regarding MTX treatment 
(see chapter 3.5.2) they were evaluated together. In protocol M high-dose 
and intrathecal MTX was followed by calcium folinate rescue. 
 
4.3.1 CSF concentrations of reduced folates and MTX  
Protocol I and II/III 
During protocol I and II/III patients received at least seven intrathecal MTX 
administrations prior to which samples were obtained. The first sample 
(day 1/protocol I) was obtained prior to any MTX therapy. Therefore, the 
concentration of the analytes in these samples served as a reference to which 
all other results were compared.  
Similar as in the PCNSL population, the concentrations of 5,10-methylene-
THF were below LLOQ or even LOD in all analysed samples. MTX was not 
detected in any sample which was not surprising due to the fact that the 
drug was administered at least one week prior to sampling. The 
concentrations of 5-methyl-THF were quantified in all samples. A trend in the 
level of the reduced folate was observed during protocol I. The data are 
graphically depicted in Fig. 4.11. Just prior to the first intrathecal MTX 
administration the concentration of 5-methyl-THF was 35.2–91.9 nM (median 
56.4 nM; n=8). 12 days later the measured levels of the reduced folate were 
approximately twofold lower (12.0–40.7 nM; median 24.2 nM; n=7). Since the 
obtained samples were not obtained from the same patients the 
Mann-Whitney U-test was used for statistical evaluation and revealed a 
significantly decreased 5-methyl-THF concentration 12 days after intrathecal 
MTX administration (p=0.002). Interestingly, an increase in the concentration 
of 5-methyl-THF was observed in protocol I from day 33 onwards resulting in  
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Fig. 4.11: CSF 5-methyl-THF concentrations during ALL BFM 2000. The yellow 
box-and-whisker plot depicts the concentration prior to any MTX therapy, 
white are the boxes in protocols with intrathecal MTX administration while 
the grey boxes represent the protocol with high-dose and intrathecal drug 
administration followed by rescue. 
 
a nonsignificant difference between concentrations during protocol I (day 33, 
45 and 59) and those prior to therapy. 
Unfortunately, only from three patients samples were obtained both on day 1 
and 12 (matched-pair). In two cases the concentration of 5-methyl-THF was 
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decreased almost twofold on day 12 compared to day 1. In the third case it 
was low on both days In four cases an intraindividual comparison of the 
concentrations prior to MTX therapy and at the end of protocol I (day 59) was 
possible and it revealed tendencially higher reduced folate levels at the end 
of therapy. The matched-pair concentrations of 5-methyl-THF on day 1, 12 
and 59 are shown in Table 4.22.  
 
Table 4.22: Concentration of 5-methyl-THF in the CSF of four ALL patients on 
day 1, 12 and 59 of protocol I. 
 
 
In protocol II/III a large interindividual variability was observed and the CSF 
5-methyl-THF concentration was not significantly different compared to day 1 
of protocol I.  
Protocol M 
Patients treated according to ALL BFM 2000 received in protocol M high-dose 
MTX treatment followed by intrathecal MTX administration and calcium 
folinate rescue. Samples were obtained from these patients on day 8, 22, 36 
and 50, approximately 1 h after the beginning of the high-dose infusion and 
before intrathecal MTX administration. Similar as in the CSF samples 
obtained during protocol I and II/III, 5,10-methylene-THF could not be 
quantified during protocol M and was above LOD only in a few samples. 
Calcium folinate was not detected in any sample which was not surprising 
since the last rescue infusion dated at least two weeks prior to sample 
Patient Conc. 5-methyl-THF (nM) 
 Day 1 Day 12 Day 59 
1 35.2 40.8 44.2 
2 65.3 36.8 66.1 
3 59.6 39.2 - 
4 52.2 - 68.9 
5 53.3 - 70.0 
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collection. The concentration of MTX varied from 0.09-1.6 µM (median 0.5 
µM). At the same time the 5-methyl-THF level was 12.0-122.5 nM (median 
37.3 nM) indicating large interindividual variability which was probably due 
to the fact that MTX had already reached the CNS (see Fig. 4.11). Statistical 
analysis revealed no significant difference between the CSF 5-methyl-THF 
concentration on day 8, 22 and 36 of protocol M (Kruskal-Wallis test, 
p=0.285). Furthermore, the concentration of 5-methyl-THF was not 
significantly different at begin of therapy and during protocol M (Kruskal-
Wallis test, p=0.132). Day 50 was excluded from analysis due to the small 
number of samples (n=4). An intraindividual monitoring of the 
concentrations of 5-methyl-THF was not possible since there was no patient 
from whom samples were obtained at all five time-points.  
 
4.3.2 CSF concentrations of SAM and SAH 
Protocol I and II/III 
CSF samples collected with perchloric acid were used for the determination of 
SAM and SAH. The CSF SAH concentration could be quantified only in 19 
samples (5.0-11.4 nM) whereas it was between LOD and LLOQ in the other 65 
samples. The concentration of SAM was quantified in all samples and in 
analogy to the evaluation of 5-methyl-THF, the concentration measured on 
day 1 of protocol I was used as reference since patients had received no MTX 
therapy priorily. An overview of the concentrations of SAM during all 
protocols of ALL BFM 2000 is shown in Fig. 4.12.  
The median SAM concentration in the reference samples was 188.6 nM 
(n=10). In samples obtained on day 12 the SAM concentrations (median 
114.4 nM, n=8) were significantly lower compared to the reference value 
(Mann-Whitney U-test, p=0.012). On day 33 and 45 the difference was 
significant as well (p=0.031 and p=0.033, respectively). In addition, a 
matched-pair comparison was possible in seven patients samples from whom 
samples were obtained both on day 1 and 12 of protocol I (shown in Table 
4.23). The significant difference between the SAM concentrations before and  
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Fig. 4.12: CSF concentrations of SAM during protocol ALL BFM 2000. The 
yellow box-and-whisker plot stands for the concentrations prior to MTX 
therapy, grey box plots represent the concentrations in protocol M and white 
boxes are the concentrations of SAM during protocols with intrathecal MTX 
therapy only. 
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Table 4.23: CSF SAM concentrations in seven ALL patients on day 1 and 12 of 
protocol I. 
Concentration of SAM (nM) Patient 
Day 1 Day 12 
1 194.9 143.4 
2 278.4 136.1 
3 201.9 152.2 
4 224.4 120.6 
5 156.9 86.1 
6 282.8 131.5 
7 103.1 89.5 
 
 
12 days after intrathecal MTX was confirmed in this group as well (Wilcoxon 
test, p=0.018).  
In protocol II/III the median concentration of SAM was 93.7 nM (n=5) on day 
17/38 and 108.1 nM (n=8) on day 45/24. On both days the CSF SAM 
concentrations were significantly lower compared to the beginning of therapy 
(p<0.001 and p=0.012, respectively). This result is interesting in view of the 
fact that the patients had not received intrathecal MTX in protocol II/III prior 
to day 38/17. 
There was no significant difference between the CSF SAM concentrations from 
day 12-59 of protocol I and the concentration in protocol II/III (Kruskal-Wallis 
test, p=0.898). 
Protocol M 
The analysis of CSF samples obtained during protocol M enabled the 
assessment of the SAM concentrations two weeks after high-dose and 
intrathecal MTX therapy followed by calcium folinate rescue. 
The concentrations of SAH were again below LLOQ in the majority of samples 
of the children population. SAM was determined in all analysed samples and 
was in the range 63.3-506.9 nM (median 177.6 nM) in protocol M (see  
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Fig. 4.12). Statistical evaluation was performed to determine whether there 
are significant differences among the CSF SAM concentrations during protocol 
M. The SAM concentrations in block M were also compared to the beginning 
of therapy (day 1, protocol I). While there were only two patients from whom 
samples were obtained on day 1 of protocol I as well as during protocol M it 
was not possible to perform an intraindividual comparation of SAM 
concentrations after MTX treatment followed by rescue. Therefore, the 
analysis was performed by using the Kruskal-Wallis test which revealed no 
significant difference among the concentrations of SAM on day 8, 22, 36, and 
50 of protocol M (p=0.380). Furthermore, the SAM concentrations during 
protocol M did not differ significantly from those at the beginning of therapy 
(p=0.501). 
 
 
4.3.3 CSF concentrations of reduced folates, MTX, SAM and 
SAH in ALL patients with neurotoxicity 
Case 1 
A 15-year old boy developed signs of subacute neurotoxicity during protocol 
M of ALL BFM 2000 (see also chapter 3.5.2). An evaluation of the neurotoxic 
symptoms was perfomed by the pediatric oncologists according to the CTC. 
The results (patient’s symptoms and their severity) are presented in Table 
4.24.  
The CSF analysis of 5-methyl-THF, SAM and SAH was performed in three 
samples obtained from the patient. In the first sample obtained on day 45 of 
protocol I (approximately ten weeks prior to toxicity) the concentration of 
5-methyl-THF (68.5 nM) was comparable to the median (56.4 nM) obtained 
from the ALL population prior to MTX therapy (day 1, protocol I) and 
somewhat higher than the median (49.9 nM) determined in the ALL 
population on the same therapy day. In the second sample obtained three 
days after the second episode of subacute neurotoxicity the concentration of 
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5-methyl-THF was less than one third compared to the first sample (19.1 nM) 
and about twofold lower than the median concentration in protocol M 
Table 4.24: Evaluation of neurotoxicity according to CTC in case 1. 
Symptom 
CTC 
Grading  
Description of severity according to 
CTC 
Headache 2 Moderate pain 
Ataxia (incoordination) 2 
Mild symptoms interfering with 
function, but not interfering with 
activities of daily living 
Dizziness 3 Interfering with activities of daily living 
Irritability 1 Mild, easily consolable 
Mood alteration 
(anxiety, agitation) 
1 Mild mood alteration not interfering 
with function 
Cranial neuropathy 3 Present, interfering with activities of 
daily living 
Motor neuropathy  4 Paralysis 
Pyramidal tract function 4 Bedridden or disabling; paralysis 
CNS cerebrovascular 
ischemia 
2 Not described 
 
 
(37.3 nM) according to which the patient was treated at the time-point of 
toxicity. One month after the resolution of symptoms the concentration of 
5-methyl-THF (49.6 nM) returned into the physiological range. Samples were 
not obtained during or shortly after the first toxicity episode. 
An overview of the MTX treatment and CSF SAM and 5-methyl-THF 
concentration in the three samples from case 1 are presented in Fig. 4.13. 
The concentration of SAM followed a different pattern compared to 
5-methyl-THF. The first sample contained 35.8 nM SAM which was more than 
threefold lower than the median 112.2 nM determined on day 45 of protocol 
I. Shortly after the toxicity the concentration of SAM was higher (79.3 nM) 
compared to the first sample but it was still about twofold lower than the 
median in block M (177.6 nM). No difference of the SAM level was observed 
one month after toxicity on day 17 of protocol II (82.8 nM). However, on the  
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Fig. 4.13: MTX teatment, sample collection and CSF 5-methyl-THF and SAM 
concentrations prior to and after the second neurotoxicity episode in case 1.  
 
same day the median SAM level in the ALL population was 93.7 nM. The 
concentration of SAH was above LLOQ in all three samples (6.7, 8.6 and 
6.4 nM chronologically). A comparison of the SAH concentrations 
betweencase 1 and the pediatric ALL population without toxicity was not 
possible due to the inability of determining the SAH concentrations in most 
samples of the latter group. 
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Case 2 
In analogy to case 1, this patient developed subacute neurotoxicity during 
protocol M (ALL BFM 2000). The results of the evaluation of neurotoxicity 
according to CTC are presented in Table 4.25. 
 
Table 4.25: CTC neurotoxicity evaluation in case 2. 
Symptom CTC Grading 
Description of severity according to 
CTC 
Motor neuropathy 3 Objective weakness, interfering with 
activities of daily living 
Speech impairment 3 Receptive or expressive dysphasia, 
impairing ability to communicate 
 
The first CSF sample was obtained on day 33 of protocol I. The concentration 
of 5-methyl-THF (13.1 nM) was barely above LLOQ, and about twofold lower 
than the median (26.7 nM) on day 33 of protocol I. The concentration of the 
reduced folate (27.5 nM) just after resolution of toxicity was increased 
compared to the first sample but still lower than the median in protocol M 
(37.3 nM) according to which the patient was treated at that time. One week 
later, a further increase of the 5-methyl-THF concentration was observed 
(34.4 nM) but another 10 days later the patient experienced nausea and 
emesis and the CSF concentration of the reduced folate declined to 17.2 nM. 
In contrast to case 1, the concentration of SAM in the first sample (146.9 nM) 
was comparable to the median obtained on day 33 (124.9 nM). In two 
samples obtained shortly after the toxic episode the SAM concentration (74.8 
nM and 79.4 nM) was more than twofold lower than the median during block 
M (177.6 nM). In the fourth sample an increase of the SAM level was 
observed (106.9 nM) but it was still lower compared to the median during the 
protocol. The CSF SAH concentration was above LLOQ in all four obtained 
samples (12.6 nM, 10.4 nM, 5.8 nM and 12.4 nM chronologically). 
An overview of the MTX treatment as well as the alterations observed in the 
5-methyl-THF and SAM concentrations are depicted in Fig. 4.14.  
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 Fig. 4.14: MTX treatment, sample collection and CSF 5-methyl-THF and SAM 
concentrations prior to and after the second neurotoxicity episode in case 2. 
Case 3 
This patient was an adult female who presented with the second ALL recidive 
and was treated according to a protocol which did not contain MTX. She 
received MTX during therapy for the first ALL diagnosis as well as in the 
treatment of the first recidive. At the time of diagnosis of the second 
recidive, the patient had signs of MTX-related chronic neurotoxicity (manifest 
leukoencephalopathy). The evaluation of chronic neurotoxicity according to 
CTC is presented in Table 4.26.  
Three CSF samples were obtained from the patient within a time period of 
four months. CSF analysis of 5-methyl-THF revealed a constant concentration 
(29.3-31.8 nM) in all three samples. Compared to the median concentration  
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Table 4.26: CTC evaluation of chronic neurotoxicity in case 3. 
Symptom CTC Grade Description of severity according to 
CTC 
Ataxia (incoordination) 3 Moderate symptoms interfering with 
activities of daily living 
Cognitive disturbance 3 
Cognitive disability resulting in 
significant impairment of work 
performance; cognitive decline >2 SD* 
Confusion 3 Confusion or delirium interfering with 
activities of daily living  
Depressed level of 
consciousness 
3 
Obtundation or stupor; difficult to 
arouse; interfering with activities of 
daily living 
Irritability 1 Mild; easily consolable 
Leukoencephalopathy- 
associated radiological 
findings 
2 
Moderate ventriculomegaly; and/or 
focal T2 hyperintensities extending 
into centrum ovale; or involving 1/3 
to 2/3 of susceptible areas of 
cerebrum 
Memory loss 2 Interfering with function but not with 
activities of daily living 
Mood alteration 
(anxiety, agitation) 
1 Mild mood alteration not interfering 
with function 
Depression 2 Interfering with function but not with activities or daily living 
Neuropathic pain 3 Severe pain 
Personality change 2 Change but not disruptive to patient 
or family 
Speech impairment 2 
Awareness of receptive or expressive 
dysphasia, not impairing the ability to 
communicate 
Tremor 2 
Moderate tremor, interfering with 
daily function but not interfering with 
activities of daily living 
SD: standard deviation 
 
(56.4 nM) of the reduced folate in ALL patients prior to therapy (chosen as 
reference despite of the age of 35 years but due to the fact that CSF samples 
were obtained by lumbar puncture), the patient had approximately twofold 
lower concentrations of 5-methyl-THF. The SAM concentration was 
considerably lower in the first two samples (below LLOQ and 34.2 nM, 
respectively) compared to the median (188.6 nM) obtained from ALL patients 
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prior to any MTX therapy. In the third sample the SAM concentration was 
higher (184.5 nM). At that time-point the patient had an overt infection and 
signs of hyperbilirubinemia.  
The concentrations of SAH were above LLOQ in all three samples (7.5-14.3 
nM). The results of the CSF analysis are summarised in Table 4.27. 
 
Table 4.27: CSF analysis of 5-methyl-THF, SAM and SAH in case 3. 
Time Concentration (nM) 
 5-methyl-THF SAM SAH 
At time of the second 
recidive diagnosis 
31.8 Below LLOQ 10.1 
Three months later 31.7 34.2 7.5 
Ten days later during 
acute toxicity 
 not MTX-related 
29.3 184.5 14.3 
 
 
4.4 Pediatric ALL patients treated according to TOTAL 
XV 
In cooperation with Prof. Dr. M. Relling (St. Jude Children’s hospital, 
Memphis, USA) CSF samples were obtained from childhood ALL patients 
treated according to protocol TOTAL XV. SAM and SAH were not determined 
in this population since samples collected with perchloric acid were not 
obtained. 
ALL patients received high-dose MTX infusion followed by calcium folinate 
rescue at the beginning of therapy (Remission/Induction phase, see also 
chapter 3.5.3). 19 days later they received intrathecal MTX as a part of the 
triple intrathecal therapy followed by calcium folinate rescue. The first CSF 
sample from these patients was obtained prior to any MTX therapy (day 1 of 
Remission/Induction) while the second was obtained about 8-9 weeks later at 
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the beginning of the consolidation phase (day 1). On day 1 of the 
consolidation block patients received another high-dose infusion of MTX in 
combination with triple intrathecal therapy and calcium folinate rescue. The 
third sample was obtained on day 15 of the consolidation block.  
Alltogether 42 CSF samples were analysed from 18 patients. Complete 
sampling (3 samples per patient) was obtained only from six patients. From 
the remaining twelve patients samples were collected at two time-points. In 
summary, 10 CSF samples were obtained at day 1 of Remission/Induction 
(R/I), and 16 each were analysed from day 1 (C1) and day 15 (C15) of 
consolidation, respectively. 
As in the other two collectives, 5,10-methylene-THF was below LLOQ in all 
analysed CSF samples. Calcium folinate which was administered at least two 
weeks prior to sampling was not detected in any sample. The concentration 
of 5-methyl-THF at the three time-points was highly variable 17.8-103.9 nM 
(mean 59.8 nM). The explorative data analysis revealed a normal distribution 
of the 5-methyl-THF concentration in the ALL population. Therefore, 
statistical analysis was performed by using of the two-way ANOVA. No 
significant difference of the analyte concentration among the three sampling 
time-points (p=0.932) was observed (see also Table 4.28:). A graphical 
presentation of the CSF concentrations of 5-methyl-THF in patients treated 
according to TOTAL XV is shown in Fig. 4.15. 
 
 
4.5 Correlations among the CSF concentrations of MTX, 
5-methyl-THF, SAM and SAH 
In order to get a better insight into the biochemical alterations after MTX 
administration potential correlations between the concentrations of the drug, 
5-methyl-THF, SAM and SAH in the CSF were investigated. The CSF samples 
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Table 4.28: Concentrations of 5-methyl-THF in the CSF of six patients during 
therapy according to TOTAL XV. 
Concentration of 5-methyl-THF (nM) Patient 
R/I C1 C15 
1 67.5 67.1 67.2 
2 62.7 62.0 66.4 
3 86.2 84.6 86.8 
4 59.8 61.8 56.2 
5 68.5 68.1 79.3 
6 43.0 36.1 43.5 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4.15: Concentration of 5-methyl-THF in the CSF of patients treated 
according to TOTAL XV. 
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obtained from PCNSL patients were thought to be appropriate for such 
analysis since a monitoring of MTX, 5-methyl-THF, SAM and SAH 
concentrations was possible due to the sampling schedule. The correlation 
analysis was performed for patient 2, 3 and 4 together. Due to the two 
different MTX treatment modalities in block A/B and C the correlation 
investigation was performed first for all therapy blocks together and 
thereafter for block C alone. The rational for the latter analysis was the fact 
that calcium folinate was not administered in block C and would therefore not 
have interfered with the effects of the drug. All correlation analyses were 
performed by using of the rank correlation according to Kendall (see also 
chapter 3.6.3). All substance combinations were investigated (see Table 
4.29). A significant correlation of concentrations was found only by SAM and 
SAH in block C. However, this correlation was not significant when all therapy 
blocks were assessed together.  
 
Table 4.29: Correlation of concentrations of 5-methyl-THF, MTX, SAM and 
SAH during therapy in all blocks together and in block C. 
Compounds Rank correlation according to Kendall 
 All blocks Block C 
5-methyl-THF/MTX r=-0.155, p=0.167, N=39 r=-0.292, p=0.106, N=17 
5-methyl-THF/SAM r=-0.037, p=0.717, N=45 r=-0.186, p=0.214, N=23 
5-methyl-THF/SAH r=-0.037, p=0.797, N=25 r=-0.375, p=0.053, N=15 
MTX/SAM r=-0.193, p=0.064, N=45 r=-0.239, p=0.181, N=18 
MTX/SAH r=-0.165, p=0.277, N=23 r=0.463, p=0.051, N=15 
SAM/SAH r=0.255, p=0.058, N=28 r=0.394, p=0.042, N=15 
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5 DISCUSSION 
In the following chapter the results presented in chapter four will be 
discussed in the same order.  
 
5.1 HPLC method for the CSF determination of reduced 
folates and MTX 
A method for the determination of MTX, calcium folinate, 5-methyl-THF and 
5,10-methylene-THF was developed and validated. The CSF concentration of 
5-methyl-THF was assessed due to the fact that it is the main transport form 
of reduced folates and it is also linked to other metabolic pathways such as 
homocysteine. The CSF concentration of 5,10-methylene-THF necessary for 
thymidilate synthesis might be another marker for MTX-induced cytotoxicity 
since its reduction directly affects the DNA synthesis. It was therefore 
investigated simultaneously.  
Several methods for the quantification of plasma and CSF 5-methyl-THF 
concentrations based on microbiologic assays and reversed phase HPLC were 
found in the literature141, 152, 153. Due to the poor reproducibility of the 
microbiological assays an HPLC method was considered. Since the 
concentrations of 5-methyl-THF in the CSF are in the nanomolar range 
sensitive reversed phase HPLC methods using electrochemical or 
fluorescence detection are necessary for its determination141, 152, 154. Although 
the use of electrochemical detection provides generally higher sensitivity 
compared to fluorescence it also has disadvantages. The mobile phase has to 
be degased constantly, the water used for the buffer has to be of highest 
purity and it is difficult to obtain a stable baseline when the detector is set at 
elevated potentials. Under such conditions it is difficult to develop a robust 
method. On the other hand, it is known that the CSF concentrations of 
5-methyl-THF exceed the respective plasma concentrations by two to fourfold 
(in healthy adults 30-80 nM141, 150, 155, in children 60-80 nM136, 151). Thus, the 
use of fluorescence detection was supposed to provide enough sensitivity for 
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its quantitation in CSF141. In addition, tetrahydrofolates exhibit natural 
fluorescence. Thus, no derivatisation is necessary for their determination. 
MTX is not a reduced folate and does not exhibit fluorescence at 
294/356 nm. Therefore, it and had to be determined by using an UV 
detector.  
The method for the simultaneous determination of 5,10-methylene-THF, 
5-methyl-THF, calcium folinate and MTX used in this study was based on the 
work of Belz et al141. The modification consisted in adding one more analyte 
(5,10-methylene-THF) and substituting acetonitrile for methanol in the 
mobile phase. A gradient which was optimised during method development 
was used for the elution of the analytes. The method was validated and the 
results presented in chapter 4.1.1 show that it is acceptable according to the 
international criteria for method validation. 
The main problem when developing a method for the determination of 
tetrahydrofolates is the instability of these compounds. It was shown that 
5,10-methylene-THF was the most instable of the analytes at room 
temperature whereas calcium folinate was the most stable one. The stability 
of calcium folinate was not surprising since it is the main reason why this 
compound is administered as rescue. Because of the instability of two 
reduced folates at room temperature samples could not be kept in the 
autosampler overnight. As a consequece the number of samples which could 
be analysed per day was lower.  
The sensitivity of the method was high enough for the quantfication of 
5-methyl-THF and MTX in the CSF. However, the concentration of 
5,10-methylene-THF was rarely quantifiable and in many cases even not 
detectable. Literature data regarding the concentration of this compound in 
the CSF were not found. The fact that 5,10-methylene-THF could be 
determined in one PCNSL patient who received frequent calcium folinate 
rescue within 24 h after the end of the high-dose MTX infusion indicates that 
it is possible to determine 5,10-methylene-THF in the CSF using the 
described method after highly intensive rescue regimens. Possible 
explanations for the low CSF concentration are that 5,10-methylene-THF 
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could be trapped in the cell having a poor affinity for the reduced folate 
carrier and rapid metabolism or consumption for thymidilate synthesis. 
Calcium folinate was also quantified in only one (and the same) patient as 
5,10-methylene-THF. This indicates that also calcium folinate may be 
quantified in the CSF using the described method only after very intensive 
rescue regimens. Such result is plausible since it was estimated that only 
approximately 1% of systemic calcium folinate passes the blood-brain 
barrier156. Peripherally, it is rapidly converted into 5-methyl-THF which then 
passes the blood-brain barrier by means of active transport156-158. The 
method was sensitive enough for the quantification of nanomolar ranges of 
MTX and therefore appropriate for the monitoring of the drug concentration 
in the CSF of patients treated with systemic high doses or intrathecally. 
For the quantification of 5,10-methylene-THF in the CSF a more sensitive 
method is necessary. This could be achieved by using a more sensitive 
fluorescence detector and increasing the volume of injection which was in 
this case kept at 50 µL to provide a longer duration of the precolumn and 
column. Moreover, exctraction procedures could be considered in order to 
obtain concentrated samples.  
The advantage of the described method is its simplicity. Due to natural 
fluorescence samples are directly injected into the autosampler without any 
previous time-consuming derivatisation. Moreover, the sensitivity of the 
method is sufficient for the determination of 5-methyl-THF and MTX so that 
there is no need for a pre-concentration of the analytes in the sample. 
Furthermore, the method revealed to be very robust which is a considerable 
advantage in routine analysis. 
In summary, the described reversed-phase HPLC method is adequate for 
determining the concentration of the main form of tetrahydrofolates 
(5-methyl-THF) and MTX in the CSF of patients after systemic high-dose or 
intrathecal administration of MTX followed by calcium folinate rescue. Due to 
its simplicity and low cost it is suitable for routine use in monitoring the 
above mentioned analytes. 
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5.2 HPLC method for the CSF determination of SAM 
and SAH 
A decreased concentration of SAM or altered SAM/SAH ratio has been 
associated with disorders such as demyelination seen in patients with 
MTX-related leukoencephalopathy, Alzheimer’s dementia, depression and 
Parkinson’s disease117, 129-131, 137-139, 159. Therefore, the determination of SAM 
and SAH in tissue, plasma and CSF has gained more and more interest in the 
past few decades. Various methods for the analysis of SAM alone or together 
with SAH mostly based on reversed phase HPLC were found in the 
literature143-146, 160-163. In brain tissue where the concentrations of these 
compounds are relatively high simple methods using HPLC with UV detection 
are sufficient for their quantification160-163. In CSF and plasma, the 
concentration of SAM and SAH is about 1000-fold lower than in the tissue 
and therefore more sensitive methods are required. An overview of methods 
used for urine, plasma or CSF determination of SAM and SAH are presented 
in Table 5.1. 
The most sensitive published method for the determination of SAM and SAH 
employed HPLC with electrochemical detection (see Table 5.1). Melnyk et 
al.165 analysed SAM and SAH in plasma, lymphocytes and tissue using a 
method which did not require extraction or derivatisation of the compounds. 
Furthermore, both SAM and SAH were separated and quantified in the same 
run. However, the most important disadvantage of the method was the use 
of a relatively high potential (+920 mV) for the oxidation of the compounds. 
Such high potential is often associated with poor selectivity since most 
endogenous CSF compounds are oxidised as well. Moreover, it stresses the 
analytical cell of the electrochemical detector resulting in a short duration of 
live. Further, disadvantages consisted in using the highest quality of water, 
filtering and constant degasing of the mobile phase to achieve the required 
robustness of the method. However, because of the high sensitivity of the 
method its use was initially planned for the analysis of the CSF concentration 
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Table 5.1: Methods for SAM and SAH quantification in urine, plasma and CSF 
Authors Method LOD Matrix Comment 
Wagner et 
al. 
(1987) 143 
HPLC-
FD 
SAM 0.1 pM 
SAH not 
analysed 
Urine 
Derivatisation with CAA at 
40 ºC for 12-16 h. 
Weir et al. 
(1992)164 
HPLC-
FD 
Not stated CSF 
Derivatisation with CAA at  
39 ºC for 8 h 
SAM and SAH were 
determined in separate runs 
Capdevila 
et al. 
(1998)149 
HPLC-
FD 
SAM 5 pM 
SAH not 
stated 
Plasma 
tedious extraction of plasma 
samples prior to derivatis-
ation with NDA for 10 min 
Determination in separate 
runs 
Kishi et al. 
(2000)137 
HPLC-
FD 
SAM 15 nM 
SAH 7 nM 
CSF 
Derivatisation whith CAA for 
60 min at 60 ºC 
Separation of SAM and SAH in 
the same run on a vinyl 
copolymer column 
Castro et al. 
(2002)144 
HPLC-
FD 
SAM 5 nM 
SAH 2.5 nM 
Plasma 
Derivatisation with CAA  
4h/40 ºC 
SAM resulted as impure peak 
and had to be purified and 
measured again.  
Melnyk et 
al.  
(2000) 165 
HPLC-
ECD 
SAM 200 fM 
SAH 40 fM 
Plasma 
Redox potential set at 400 
and 920 mV 
SAM and SAH separation in 
the same run 
Struys et al.  
(2002) 166 
MS-MS 
SAM 7.5 nM 
SAH 2.5 nM 
CSF 
Simultaneous SAM and SAH 
analysis 
CAA: chloroacetaldehyde; ECD: electrochemical detection; FD-fluorescence detection; LOD: 
limit of detection; MS-MS: tandem mass spectrometry NDA: naphtalene dialdehyde; 
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of SAM and SAH in this study. During the method development several 
problems occured. First, the baseline stability was poor requiring a long time 
for equilibration. Second, when standard solutions or CSF samples were 
injected a broad peak appeared in the chromatogramme which disabled the 
detection of the desired analytes. This interfering peak derived from the 
perchloric acid added to the standard solutions and CSF samples. The 
confirmation was obtained by analysing a solution of perchloric acid alone 
and standard solutions containing no perchloric acid. In the study of Melnyk 
et al. samples were collected with the addition of trichloroacetic acid165. Since 
all CSF samples in this study were collected before and during method 
development using perchloric acid it would have been difficult to analyse 
them using this method.  
Therefore, an attempt was made to develop and validate an HPLC method 
using fluorescence detection which would be sensitive enough for 
determining the CSF concentrations of SAM and SAH. Several methods for the 
quantification of adenosine, SAM and SAH based on reversed-phase HPLC 
with fluorescence detection have been described in the literature143-146. Since 
SAM and SAH do not exhibit natural fluorescence derivatisation of the 
analytes is required prior to analysis. The reaction of these compounds with 
chloroacetaldehyde resulting in their fluorescent 1,N6-etheno derivatives has 
been well studied137, 143, 144, 146, 164. However, the sensitivity of these methods 
for CSF SAH analysis was questionable since the determined SAH 
concentration often coincided with the lower limit of detection of the 
method. Moreover, the separation of these compounds seemed to be difficult 
since they were often analysed in separate runs with different mobile phases. 
It was shown in the work of Wagner et al.143 that the derivatisation reaction 
with chloroacetaldehyde depends on the concentration of the derivatising 
agent, the pH as well as time and temperature of derivatisation. The authors 
showed that optimal derivatisation conditions are obtained with a 5.5 M 
solution of chloroacetaldehyde, a pH between 3.5 and 4.0, and a 12-16 h 
incubation at 39 ºC. These conditions were reproduced for the derivatisation 
of SAM and SAH in this work. Although some authors used shorter incubation 
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times such as 4 or 8 h at 39 °C144, 164 or even 1 h at 60 ºC137 this was not 
attempted in this method since according to Wagner et al. a loss of the 
analytes due to incomplete derivatisation occurs.  
The disadvantage of chloroacetaldehyde as derivatising agent is its 
unspecificity since all CSF compounds containing adenosine in their structure 
can build the 1,N6-etheno derivatives. The similar structure of the derivatives 
would further present a difficulty for the separation of the compounds. In 
fact, tedious separation procedures of the 1,N6-etheno derivatives of SAM and 
SAH have been reported in several articles143, 164, 167.  
In order to obtain the separation of 1,N6-etheno SAM and 1,N6-etheno SAH in 
the same run, different columns were tested. An column with an endcapped 
amine phase, a reversed-phase column and a reversed-phase column 
especially designed for the separation of amino acids were tested (see also 
chapter 3.4.4 and 4.1.2). Since both 1,N6-etheno derivatives are polar 
compounds their separation was attempted on a relatively polar column. 
Although different mobile phases and different gradients were examined, no 
successful separation of the compounds on the polar column was achieved. 
Also the reversed-phase column turned out to be inadequate. Although the 
1,N6-etheno derivatives of SAM and SAH were separated from each other poor 
selectivity was observed. Peaks were neither sharp nor symmetric and the 
required sensitivity could not be obtained. In contrast, good results were 
obtained with the use of the reversed-phase column especially designed for 
the separation of amino acids. The selectivity was adequate, the investigated 
peaks were sharp and symmetric and a much higher sensitivity was achieved. 
This is in accordance with other authors who investigated the separation of 
SAM and its metabolites (without prior derivatisation) on different 
reversed-phase columns observing a similar effect168. Furthermore, the 
influence of the column properties was also investigated for 1,N6-etheno 
derivatives of adenosine and adenine. A good separation of the compounds 
was achieved with the use of a vinyl alcohol copolymer column146.  
The mobile phase which was selected for the separation of the compounds 
consisted of acetonitrile and a phosphate buffer containing the ion-pairing 
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reagent heptanesulphonic acid. Since 1,N6-etheno SAM is a cation which 
elutes very quickly disabling a successful separation from other endogenous 
compounds, the role of the heptanesulphonic acid was to neutralise the 
analyte by forming an ion-pair. The ion-pair had a higher affinity towards the 
column compared to 1,N6-etheno SAM resulting in a longer retention time. 
Before the introduction of heptanesulphonic acid into the mobile phase 
1,N6-etheno SAM eluted before 1,N6-etheno SAH whereas in the presence of 
the ion-pairing reagent the peak of the SAM derivative was detected later 
than that of the SAH derivative.  
The method was further optimised regarding the mobile phase gradient in 
order to obtain a good separation of compounds in the shortest possible 
time. Finally, the retention time for 1,N6-etheno SAH was 19.7 min and for 
1,N6-etheno SAM 23.5 min. One run was completed in 35 min which can be 
considered as acceptable run time in routine. The validation of the analytical 
method followed its development.  
It is known that temperature and pH influence the stability of SAM. It was 
shown that the highest stability of SAM was obtained in acidic solution (pH 1) 
whereas in alkaline solution (pH 10) it was completely degraded after 48 h at 
37 ºC. Moreover, a reduced SAM concentration in CSF samples stored 
at -20 ºC for at least one year at physiological pH was measured compared to 
the same samples stored at -20 ºC and pH 1. Such result indicates that SAM 
is instable in the CSF when stored frozen at physiological pH. On the other 
hand, significantly higher CSF SAH concentrations were determined in 
samples kept frozen at pH 7.4 compared to the same samples kept frozen at 
pH 1. Nevertheless, the increase of the SAH concentration was by far not 
equimolar to the loss of SAM. This indicated that the decomposition of SAM 
in the CSF was only partly due to the conversion to SAH.  
An explanation for the pH- and temperature-dependent decomposition of 
SAM was found in the work of Parks et al169. They showed that after heating 
(temperature not stated) at pH 4 or pH 7 for 30 min the hydrolysis to 
methylthioadenosine and homoserine takes place (Fig. 5.1, cleavage at site 
A). A brief heating (100 ºC) in alkaline solutions results in the formation of 
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methionine (Fig. 5.1, cleavage at site B) whereas alkaline hydrolysis at lower 
temperatures (25 ºC) results in the formation of adenine and 
S-ribosylmethionine (Fig. 5.1, cleavage at site C). The formation of SAH (Fig. 
5.1, cleavage at site D) and decarboxylated SAM (Fig. 5.1, cleavage at site E) 
were considered to be due to enzymatic reaction and were not detected in 
vitro169 . Based on the results of Parks et al. it was hypothesized that the 
degradation observed at -20 ºC could be due to enzymatic degradation prior 
to freezing.  
 
 
 
 
 
 
 
 
Fig. 5.1: Degradation of S-adenosylmethionine: hydrolysis sites A, B and C, 
enzymatic cleaving possible at sites D and E. 
 
Such hypothesis was additionally based on the fact that there are over 100 
enzymes belonging to the family of methyltransferases which could have 
been responsible for the demethylation of SAM120. Perchloric acid is used to 
precipitate proteins in biological samples and would therefore have 
inactivated all enzymes in a sample offering an explanation for the different 
results in acidic and neutral samples. If the enzymatic decomposition was 
responsible for the observed alteration of the CSF SAM and SAH 
concentrations a CSF sample which was kept at room temperature for an 
hour should have had altered SAM and SAH levels compared to the same 
sample which was immediately deproteinised with perchloric acid, 
centrifuged and frozen. However, neither decreased SAM nor increased SAH 
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concentrations were measured in the samples kept 1 h at room temperature 
compared to the aliquots which were acidified and frozen. This led to the 
conclusion that it is not the enzyme activity but possibly a chemical 
degradation which induces the decrease of the concentration of SAM and 
increase of the concentration of SAH in the samples which are kept for a 
longer time at -20 ºC without prior addition of perchloric acid.  
However, the mechanism of SAM metabolism in the CSF seems to be complex 
and the reason why a loss of SAM in the CSF at physiological pH was 
observed only after long-time storage (at least one year) remains unclear and 
requires further investigation. Nevertheless, due to the instability of SAM 
special attention had to be paid to the storage of biological samples in which 
SAM and SAH were to be quantified. Using CSF samples without stabilisation 
with perchloric acid for the investigation of the methyl-transfer pathway after 
MTX therapy would lead to the false conclusion that the altered SAM and SAH 
concentrations are a consequence of MTX activity. Therefore, when CSF 
samples are stored at -20 ºC they should be acidified (pH 1) priorily or 
measured within a short time-period after collection. 
Although the HPLC method for determination of CSF SAM and SAH in this 
work fulfills the requirements according to the international criteria for the 
biovalidation of analytical methods it was observed that the coefficient of 
variation of the between-day precision for 1,N6-etheno SAM was relatively 
high (7.9-19%). The somewhat poorer reproducibility of the method for 
1,N6-etheno SAM was probably due to the use of the ion-pairing reagent. 
Similar findings have been described in the literature144.  
The method was shown to be sensitive for the CSF analysis of SAM in 
patients after systemic high-dose and/or intrathecal MTX treatment since 
SAM was quantified in all samples. In contrast, SAH was only detected in 
most samples but not quantified. From four adult patients three had 
quantifiable CSF SAH levels (all three patients were > 60 years) whereas in the 
children ALL population this was the case only in 19 of 84 samples. The limit 
of detection of SAH was 1 nM whereas the limit of quantification was 5 nM 
suggesting that in most of the analysed CSF samples in this population the 
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SAH concentration ranged between 1 and 5 nM. Compared to literature 
data137, 164, 166, the CSF SAH concentration was significantly lower in this study 
(see also Table 5.2).  
 
Table 5.2: CSF SAH concentrations determined in several studies in different 
patient populations. 
Author Method 
Sample 
storage 
Population 
CSF SAH conc. 
(nM) 
Keating 
et al. 
1991132 
HPLC- 
FD 
pH 1, -20 ºC 
29 adult patients 
with supposedly 
normal CSF SAH 
levels 
Range 8.9-41.1 
Mean 19.0 
Kishi et 
al.  
2000137 
HPLC- 
FD 
Physiological 
pH, -70 ºC 
18 reference 
children 
7 children with ALL 
receiving MTX 
therapy 
Mean 17.3 
 
Mean 18.9 
Struys 
et al.  
2000166 
MS-MS 
Physiological 
pH, -20 ºC 
10 children with 
unknown 
neurological 
dysfunction 
Range 8.9-14.1 
Mean 11.3 
This 
work 
HPLC 
FD 
pH 1, -20 ºC 
22 children with ALL 
4 adults with PCNSL 
both groups 
receiving MTX 
Range <1.0-15.2* 
Range <1.0-12.5* 
*median not calculated since most values were below LLOQ, ECD: electrochemical detection; 
FD: fluorescence detection; MS-MS: tandem mass spectrometry 
 
Keating et al.132 and Kishi et al.137 measured higher CSF SAH concentrations 
in a reference population compared to the results in this study. The latter 
group also reported no significant difference in the CSF SAH level between 
the pediatric reference population and patients with ALL. On the other hand, 
Discussion 
 140 
Struys et al.166 measured somewhat lower CSF concentrations of SAH in a 
pediatric reference population. In a personal communication these authors 
reported that also lower SAH levels (5 nM) were observed in other patients170. 
Such observation is in accordance with the results in this study. Moreover, it 
cannot be excluded that the somewhat lower SAH concentrations in this 
study result from the difference in storage conditions.  
In summary, a method for the determination of SAM and SAH as their 
1,N6-etheno-derivatives using reversed phase HPLC with fluorescence 
detection has been developed and validated. The advantage of this method 
was the separation of the analytes within one run of acceptable duration. It 
was shown that the successful separation and the achievement of 
appropriate sensitivity depended primarily on the selection of the column 
and that especially packed columns are necessary for obtaining satisfactory 
results. Such columns are cost-intensive but performing two separate runs 
for analysis of SAM and SAH or tedious clean-up procedures are 
time-consuming and at the end more expensive. 
Since the 1,N6-etheno derivatives are stable at room temperature for at least 
24 h samples can be kept in the autosampler and analysed overnight 
enabling the determination of a larger number of samples (25-30) per day. 
The disadvantage of the method is certain the time-consuming derivatisation 
process. Also it is concluded that this method is not sensitive enough for the 
CSF analysis of SAH in the children population who had received MTX as 
high-dose infusion and/or intrathecally. Therefore, in order to determine the 
low SAH concentrations a more sensitive method is necessary. As the optimal 
derivatisation process has been applied, an adequate column regarding peak 
symmetry and sharpness has been used and a large sample volume (100 µL) 
has been injected the achievement of higher sensitivity could be attempted 
by using a more sensitive fluorescence detector.  
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5.3 CSF concentrations of MTX, reduced folates, SAM 
and SAH in PCNSL patients 
The biochemical alteration of the folate and methyl-transfer pathway in the 
CNS after MTX therapy was studied in patients treated according to the Bonn 
protocol for PCNSL. Due to the frequent intraventricular drug administration 
and the presence of an Ommaya reservoir it was possible to obtain CSF 
samples within 4-5 subsequent days during therapy blocks. Therefore, the 
CSF concentrations of reduced folates and SAM and SAH closely after MTX 
therapy could be monitored. Moreover, patients received a combination of 
high-dose (3-5 g/m2) and intraventricular MTX (3 mg) followed by rescue in 
some therapy blocks (A and B) whereas intraventricular MTX without rescue 
was administered in block C. Therefore, the influence of rescue could be 
assessed. Furthermore, in one patient the effect of an intensified rescue with 
calcium folinate (60 mg/6 h, 5 administrations) on the concentration of 
reduced folates was monitored within 24 h after the end of the high-dose 
(3 g/m2) MTX infusion.  
 
MTX concentration 
At the end of the high-dose infusion the CSF concentrations of MTX were 0.7 
to 2 µM (median 1.5 µM, n=6). Seidel et al.171 reported similar concentrations 
in a pediatric ALL population who received 6-8 g/m2 infusions. They 
determined a CSF concentration of 0.1 to 1.2 µM per 1 g/m2 MTX two hours 
before the end of a 24 h infusion. Millot et al.172 measured also a mean of 
1.5 µM of MTX in the CSF at the end of a 24 h infusion of 5 g/m2 in pediatric 
ALL patients. During block C the CSF drug concentrations were 0.2 to 9.1 µM 
24 h after intra-Ommaya administration. Strother et al.35 reported peak CSF 
MTX levels of 423.6 µM (median) after an intra-Ommaya administration of 2 
to 10 mg (median dose 6 mg) which decreased to 0.4 to 138.2 µM (median 
4.6 µM) 24 h later.  
A large intra- and interindividual variability of the CSF MTX concentration was 
observed in all blocks. In several studies variability of MTX concentrations in 
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the serum and CSF after high-dose MTX infusions alone or in combination 
with intrathecal MTX has been reported171, 173, 174. However, it has been shown 
that intraventricular administration reduces the concentration variability40. 
This was not confirmed in the present study since in block C were only 
intraventricular MTX was administered a large intra- and interindividual 
variability was observed as well (0.2-9.1 µM). Furthermore, in some samples 
in block C extremely high MTX concentrations were determined 
(18.7-39.4 µM). Nevertheless, such results are in accordance with the 
findings of Strother et al.35 who also observed a large intra- and 
interindividual variability after intra-Ommaya MTX administration 
(0.4-138.2 µM 24 h after administration of 2-10 mg).  
 
Concentration of reduced folates 
In six CSF samples obtained at the end of the high-dose MTX infusion the 
concentration of 5-methyl-THF was below LLOQ (10 nM). On day 3 of block C 
the median CSF 5-methyl-THF concentration in the same patients was 
73.8 nM. Since this sample was obtained more than two weeks after the 
high-dose and intraventricular MTX treatment followed by rescue the CSF 
level of the reduced folate was considered physiological for these patients 
and was used as reference. A more than sevenfold decrease of the CSF 
concentration of the main reduced folate was present at the end of the 
high-dose (3-5 g/m2) MTX infusion. Surtees et al.136 also reported a 
significant decrease of 5-methyl-THF in the CSF of children suffering from 
ALL at the end of a high-dose MTX infusion (6-8 g/m2). However, the extent 
to which the reduced folate concentration was depleted was not stated.  
The administration of calcium folinate induced an increase in the 
concentrations of 5-methyl-THF in all patients. In the sample obtained 
approximately 15 h after initiation of rescue (30 mg/m2, see also chapter 
3.5.1) the concentration of 5-methyl-THF was in the physiological range (day 
3 block A/B) but calcium folinate was not detected. It is known that calcium 
folinate is systemically converted to 5-methyl-THF which then passes the 
blood-brain barrier156, 158, 175, 176. The results of the CSF investigation are in 
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accordance with the findings of Mehta et al156 who reported primarily an 
increase of 5-methyl-THF in the CSF after intravenously administered rescue. 
Also Allen et al.177 observed that the CSF concentration of the reduced folate 
increased after oral calcium folinate rescue. An overview of the literature data 
referring to CSF 5-methyl-THF concentrations after calcium folinate rescue is 
presented in Table 5.3.  
An increase in the concentration of 5,10-methylene-THF was observed only in 
PCNSL patient 1 (see 4.3.1) who received intensified rescue. In this patient 
the concentration of 5,10-methylene-THF was 28 nM 23 h after start of 
rescue indicating that the concentration of the metabolite was above the 
physiological range (literature data for CSF concentrations of 
5,10-methylene-THF are not available). It is probable that calcium folinate 
was converted to both 5-methyl-THF and 5,10-methylene-THF resulting in 
their elevation. Such hypothesis was made due to the fact that in the folate 
cycle 5,10-methylene-THF is irreversibly converted into                   
5-methyl-THF157, 178-180. 
Calcium folinate which was always administered as a racemic form was 
detected only after intensified rescue (120 nM, 23 h after rescue start). Thyss 
et al158. could not detect calcium folinate in the CSF within 24 h after an 
infusion of 100 or 250 mg in healthy individuals who were not administered 
MTX. In contrast Mehta et al.156 found low concentrations of calcium folinate 
in the CSF after the administration of 50-100 mg/m2 following 
intraventricular MTX administration and reported that the CSF concentration 
of calcium folinate represented less than 1% of the corresponding serum 
concentration. This offers an explanation for the fact that in this work 
calcium folinate was not detected in the CSF of PCNSL patients who received 
standard rescue.  
During block C in which the patients received intraventricular MTX only a 
constant decrease of the concentration of 5-methyl-THF was observed. At the 
end of block C a two to threefold lower CSF concentration of 5-methyl-THF 
was measured (median 23.2 nM on day 7 vs 73.8 nM on day 3). At that time-  
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Table 5.3: CSF 5-methyl-THF concentrations after high-dose or 
intraventricular MTX treatment followed by calcium folinate rescue. 
Authors MTX therapy 
CSF 
5-methyl-THF 
conc. after 
MTX therapy 
Calcium 
folinate 
rescue 
CSF 
5-methyl-THF 
conc. after 
rescue 
Mehta et 
al.156 
6.25 or 7 
mg/m2 i.cv. 
Not reported 
50 or 100 
mg/m2 i.v. 
200-600 nM 
few hours 
after rescue 
Allen et 
al.177  
8-12 g/m2 i.v. Not reported 
10 mg/6 h 
p.o. Total 11 
doses 
≈ 30 nM 72 h 
after rescue 
start 
Thyss et 
al.158  
2.5 g/m2 i.v. Not reported 
Dose not 
stated 
50 nM two 
weeks after 
third high-
dose MTX 
infusion 
Surtees et 
al.136 
6-8 g/m2 i.v.+ 
7.5-12.5 mg 
i.th.  
Not reported 
Dose not 
stated 
Not 
significantly 
different 
compared to 
prior therapy  
3-5 g/m2 i.v. + 
3 mg i.cv. 
PCNSL patients 
Below 10 nM 
at the end of 
the MTX 
infusion 
30 mg/m2 i.v. 
3x prior to 
sampling 
56 nM 
approx. 15 h 
after rescue 
start  
This work 5 g/m2 i.v. + 
8-12 mg i.th.  
ALL patients 
(see also 
chapter 5.4) 
Not measured 
15 mg/m2 i.v. 
3x 
Not 
significantly 
decreased 
two weeks 
after therapy 
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point (day 7) patients had received a cumulative dosis of 12 mg MTX 
intraventricularly. Also Quinn et al.106 reported low CSF 5-methyl-THF 
concentration in one patient after intra-Ommaya MTX administration 
(2 mg/day, 3 administrations) without rescue. However, in contrast to the 
gradual decrease observed in PCNSL patients they observed a rapid decrease 
from approximately 75 to 20 nM in 24 h. Moreover, they observed low CSF 
concentrations of 5-methyl-THF after nine days as well. 
A decrease of the CSF concentration of reduced folates was expected since 
intraventricular MTX without rescue was administered during block C. It was 
also demonstrated that this decrease was not as striking as after the 24 h 
high-dose MTX infusion. This was surprising since it has been shown that 
higher MTX levels are present in the CSF after intraventricular administration 
of low doses compared to systemic high-dose infusion35, 171, 172. On the other 
hand, it is known that folate enter the CSF from blood through active 
transport181, 182. It has also been shown that high-dose MTX causes folate 
depletion in serum183. Moreover, 1-5% of the high-dose MTX infusion reaches 
the CNS171, 172. Therefore, it is possible that the depletion of CSF reduced 
folates after systemic high-dose treatment is the consequence of both 
systemic (serum) and CNS-directed effects of the drug on the pool of reduced 
folates. In contrast, intraventricular MTX would cause only a depletion of 
folates in the CSF whereas the systemic exposure is much lower compared to 
a high-dose infusion.  
 
SAM and SAH concentrations 
A significant alteration in the CSF concentration of SAM was not observed 
during a treatment block in any of the patients (data graphically depicted in 
Appendix A). The opposite finding is of Quinn et al.106 in a case report of one 
patient receiving intra-Ommaya MTX without rescue. They observed an 
approximately threefold decrease of the CSF SAM concentration one day after 
administration of 2 mg MTX. This was the only report found in the literature 
in which the CSF SAM concentration was determined closely after 
intraventricular MTX therapy.  
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In block A/B all patients received calcium folinate rescue which induced an 
increase in the CSF 5-methyl-THF concentration to the normal range on day 3 
of the therapy block. Since the concentration of the reduced folate was low 
for a relatively short time period, it is imaginable that there was not enough 
time to induce an alteration of the SAM and SAH concentration in the CSF in 
block A/B. In block C the 5-methyl-THF concentration decreased slowly from 
day to day and low levels persisted probably for some time. Therefore it 
cannot be excluded that an alteration of the SAM and SAH concentration 
occured at a later time-point between blocks when samples were not 
obtained. An indication for such hypothesis was the lower CSF SAM 
concentration measured at the beginning of the block A of the second cycle 
in patient 3 (see appendix A). This was interesting in view of the fact that 
block A is the only block following block C in which intraventricular MTX 
therapy was administered without rescue. Assuming that the low CSF 
5-methyl-THF concentration from block C persisted for some time and 
caused further a decrease of the SAM concentration this may explain the low 
CSF SAM concentration at the beginning of block A2. However, in patient 4 
(see appendix A) a decreased SAM concentration in block A2 was not 
observed. Nevertheless, the measured CSF MTX concentrations of patient 4 
were much lower (0.2-0.7 µM) in block C1 compared to patient 3 
(1.3-9.4 µM). Also the CSF 5-methyl-THF concentration of patient 4 on day 7 
of block C1 was 47.8 nM (normal range) whereas only 15.3 nM were 
measured in patient 3. It is possible that the CSF concentration of 
5-methyl-THF concentration in patient 4 after block C1 did not decrease 
enough to cause an alteration of the SAM concentration. Unfortunately, 
patient 2 did not receive intraventricular therapy during block A2 due to an 
Ommaya misplacement and therefore samples could not be obtained during 
this block. 
Similar observations were not made for the CSF SAH concentrations. Kishi et 
al.137 measured CSF SAH concentrations in ALL patients after high-dose and 
intrathecal MTX therapy. These authors reported no significant difference 
between the CSF SAH levels in a pediatric reference population and cancer 
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patients treated with a combination of high-dose MTX infusion (2 g/m2) and 
intrathecal MTX administration (12 mg/m2) followed by rescue. Only this 
report was found in the literature in which CSF SAH concentrations were 
measured after MTX therapy. 
 
PCNSL patient with neurotoxicity 
Since one of the PCNSL patients manifested signs of chronic neurotoxicity 
during therapy it was interesting to compare her CSF concentrations of 
reduced folate, SAM and SAH to the other non-toxic patients. It was observed 
that she (PCNSL patient 5) had very low CSF levels of 5-methyl-THF 
throughout therapy. Morever, in block B1 (first block in which samples were 
obtained) a decrease of the CSF concentration of the reduced folate was 
observed on day 4 and 5 so that the patient finished the treatment block with 
almost threefold lower CSF 5-methyl-THF concentration compared to the 
others. Furthermore, she presented at therapy block C1 two weeks later with 
a more than fourfold lower 5-methyl-THF concentration (compared to other 
PCNSL patients) which persisted throughout the block. Since the CSF 
concentration of the reduced folate could not be monitored during the 
treatment pause it is unknown whether the concentration was low during the 
entire time between blocks. However, this is likely since the patient did not 
receive calcium folinate inbetween. Furthermore, a decrease of the CSF SAM 
concentration was observed from block to block. In block A2 the SAM 
concentration was the lowest (35.1-47.6  nM) which was significantly lower 
compared to the median of 261 nM determined in the non-toxic PCNSL 
patients during block A/B. At that time-point the patient had manifest signs 
of leukoencephalopathy. Kishi et al.137 reported decreased CSF SAM levels in 
two ALL patients with MTX-associated leukoencephalopathy as well. However, 
these authors also observed about twofold higher CSF SAH concentrations in 
the toxic patients compared to the non-toxic ALL patients and the reference 
population. In contrast, the SAH concentration was in the same range during 
all blocks as in the non-toxic PCNSL patients in which it could be quantified. 
In contrast to the PCNSL patient, the neurotoxic ALL patients of Kishi et al. 
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received cranial irradiation. It was shown in animal experiments that total 
body irradiation induced a reduction of folate levels in the liver184. It is 
possible that a similar effect occurs with CNS folates after radiotherapy. 
Therefore, it is imaginable that after a combination of MTX and cranial 
irradiation the folate metabolism is altered to a higher extent inducing 
further metabolic changes such as accumulation of SAH which is not seen in 
the non-irradiated patients. Due to scarce literature data it remains unclear 
whether or under which circumstances MTX could alter the CSF SAH 
concentration, requesting further investigations to elucidate this issue.  
 
5.4 CSF concentrations of reduced folates, SAM and 
SAH in ALL patients 
In analogy to the Bonn protocol for PCNSL there were phases during ALL BFM 
2000 in which patients received intrathecal MTX (8-12 mg, age-dependent) 
without calcium folinate rescue and others in which intravenous high-dose 
(5 g/m2) and intrathecal MTX was followed by calcium folinate (15 mg/m2, 
see chapter 3.5.2). Therefore, the two therapy modalities were assessed 
separately in ALL patients as well. In contrast to the PCNSL collective where 
samples were obtained on subsequent days during treatment blocks with 
MTX, samples from ALL patients were obtained one to three weeks after drug 
administration.  
During protocol M in which patients received calcium folinate rescue samples 
were always obtained two weeks after MTX therapy and no significant 
alteration in the CSF 5-methyl-THF concentration was observed compared to 
the reference samples obtained prior to any MTX therapy. However, the 
variability in the CSF concentration of the reduced folate was pronounced 
during this protocol probably due to the fact that the CSF samples were 
drawn after the start of a new MTX infusion. Since the infusion started 
approximately only one hour prior to sample collection there was not enough 
time to cause a significant depletion of the CSF concentration of 
5-methyl-THF.  
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Patients treated according to TOTAL XV received a similar MTX regimen 
during the consolidation block (see chapter 3.5.3). High-dose (2.5 or 
5.0 g/m2) and intrathecal MTX (8-12 mg) accompanied by folinate rescue (10 
or 15 mg/m2 5 times) were administered. Two weeks later a CSF sample was 
obtained. An intraindividual comparison (six patients) of the CSF 
5-methyl-THF concentrations during therapy revealed no significant difference 
between the reduced folate concentrations during consolidation therapy 
compared to samples obtained prior to any MTX therapy.  
It was shown in the PCNSL population who received a similar MTX regimen 
during block A and B that the depleted CSF concentrations of 5-methyl-THF 
significantly increased after administration of calcium folinate rescue. 
Moreover, Thyss et al.158 observed an accumulation of 5-methyl-THF in the 
CSF after several high-dose MTX courses followed by rescue. Since the CSF 
samples of ALL patients in this study were drawn weeks after the 
administration of folinate rescue the result of normal CSF 5-methyl-THF 
concentration two weeks after therapy was not surprising.  
In contrast to protocol M (concomitant systemic infusion) patients receiving 
intrathecal MTX had a significantly decreased CSF 5-methyl-THF during 
protocol I 12 days after the first MTX administration compared to 
pretreatment. After further intrathecal administration of MTX during protocol 
I and II/III, somewhat higher concentrations of 5-methyl-THF were determined 
and they were not significantly different from the inital values obtained prior 
to therapy. In addition, in three cases an intraindividual comparison prior to 
first intrathecal administration and twelve days later was possible. In two out 
of three cases the concentration of the reduced folate was decreased after 
twelve days, but it was already low prior to therapy. Moreover, intraindividual 
comparison between the start and end of protocol I revealed slightly higher 
CSF concentrations of the reduced folate at the end of the protocol. 
Interestingly, Surtees et al.136 reported similar findings in an ALL children 
collective after intrathecal MTX therapy. They also observed a significant 
decrease of the CSF 5-methyl-THF concentration initially which was not 
present later-on although patients continued receiving intrathecal MTX 
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therapy. Quinn et al.106 observed a decreased CSF concentration of 
5-methyl-THF seven days after the last intra-Ommaya MTX administration 
(2 mg/day on three subsequent days). Six days later the concentration was 
almost as high as the pretreatment value. In another study these authors also 
observed a significant decrease of 5-methyl-THF in the CSF within 7 days 
after oral MTX prior to delayed calcium folinate rescue104 (see also Table 5.4).  
A decrease of the CSF reduced folate concentrations which persists for some 
time is evident after intrathecal MTX administration without rescue. However, 
it is unclear why concentrations of 5-methyl-THF tend to increase during 
protocol I. Certain, the small number of evaluated samples could lead to an 
erroneous conclusion since it is possible that a significant decrease of the 
CSF 5-methyl-THF concentration at later time-point during protocol I and II/III 
could not be shown due to the sample number. Nevertheless, the 
intraindividual data indicate a trend which cannot be explained with the 
present knowledge and therefore further investigation of CSF 5-methyl-THF if 
concentrations in shorter time-intervals after MTX therapy would be valuable. 
In the pediatric ALL population treated according to ALL BFM 2000 receiving 
a high-dose infusion followed by intralumbar MTX administration and 
calcium folinate rescue in protocol M, no significant change in the CSF SAM 
concentration was found compared to the concentration of the methyl donor 
before drug treatment. In contrast, significantly decreased CSF 
concentrations of SAM were determined during protocol I and II or III in which 
intrathecal MTX was administered without calcium folinate rescue. Although 
the number of samples which were included in the statistical analysis was 
small an intraindividual comparison was possible in seven patients prior to 
the first intrathecal administration and twelve days later. In all of them a 
decrease of the SAM concentration was observed. Kishi et al.137 reported 
decreased CSF SAM concentration in ALL patients who were treated with 
high-dose and intrathecal MTX followed by rescue. The findings of Surtees et 
al.136 who observed a significant decline of the CSF SAM concentration in ALL 
patients who received intrathecal MTX without calcium folinate compared 
Discussion 
 151
Table 5.4: Overview of literature data of CSF 5-methyl-THF concentrations 
after MTX therapy without concomitant rescue. 
Authors MTX therapy Result  
Quinn et 
al.106 
2 mg i.cv. on three 
subsequent days 
Decreased concentrations one 
day and nine days after the first 
MTX administration (25 nM vs. 
75 nM) 
Quinn et 
al104. 
MTX p.o. (exact dose not 
stated)  
Significantly decreased 
concentrations within a week of 
therapy  
(54.2 nM vs. 82.8 nM) 
Surtees et 
al.136 
7.5-12.5 mg i.th. Decreased concentrations in 
initial protocol phases 
3 mg i.cv. on four 
subsequent days 
(PCNSL patients) 
Significantly decreased 
concentrations on the fifth day 
(23.2 nM vs. 73.8 nM) 
This work 
8-12 mg i.th. 
(ALL patients) 
Decreased concentrations 12 
days after first therapy course  
(24.2 nM vs. 56.4 nM) 
 
to patients who received high-dose MTX followed by rescue were similar to 
those in this work. An overview of literature data of CSF SAM concentrations 
after MTX therapy is presented in Table 5.5. It can be postulated that the CSF 
SAM concentrations decrease only after a persistent exposure to decreased 
CSF 5-methyl-THF concentrations which probably occurs after intrathecal 
MTX administration without concomitant rescue. The decreased SAM 
concentrations one to three weeks after intrathecal administration support 
such hypothesis. However, it was observed in this study that concentrations 
of SAM were decreased on day 17/38 of protocol II/III. Since these samples    
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Table 5.5: Overview of literature data of CSF SAM concentrations after MTX 
therapy. 
Authors MTX therapy Result 
Quinn et 
al.106 
2 mg i.cv. No rescue. 
~threefold lower 
concentrations one day after 
drug administration 
Kishi et 
al.137 
2 g/m2 i.v. + 12 mg/m2 i.th. + 
rescue 15 mg/m2 x 8 
~threefold lower 
concentrations 10 days after 
therapy course 
Surtees et 
al.136 
6-8 g/m2 i.v. + 7.5-12.5 mg i.th. 
+ rescue (dose not stated) 
7.5-12.5 mg i.th., no rescue 
 
No significant difference to 
reference samples 
Significantly lower 
concentrations 
This work 
5 g/m2 i.v. + 8-12 mg i.th.+  
rescue 15 mg/m2 x 2  
(Protocol M, ALL BFM 2000) 
8-12 mg i.th., no rescue 
(Protocol I, ALL BFM 2000) 
 
No significant difference 14 
days after therapy course 
compared to reference 
Significantly lower 
concentrations 12-21 days 
after therapy  
 
 
were collected prior to intrathecal MTX administration and more than a 
month after a rescued high-dose and intrathecal combination the result was 
surprising. The reason for the decreased SAM concentration remains unclear 
but it is probably not MTX-related.  
Since the concentration of SAH was quantified in only 23% of the obtained 
CSF sample no conclusions could be drawn from these data. However the 
available results suggest no major change in SAH concentrations following 
MTX treatment. 
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ALL patients with neurotoxicity  
Two patients treated according to ALL BFM 2000 developed signs of 
subacute neurotoxicity approximately ten days after receiving a high-dose 
and intrathecal MTX therapy course followed by calcium folinate rescue. In 
one patient (case 1) low SAM concentrations were determined in all collected 
samples whereas the level of 5-methyl-THF was low only shortly after the 
toxic episode. In contrast, in case 2 the reduced folate concentration was low 
in all samples whereas the level of SAM was decreased only just after toxicity. 
The common finding in both cases was that decreased concentrations of 
both substances together were observed only briefly after the toxicity 
episode which was almost two weeks after the MTX treatment course. 
Moreover, it was shown in this work that non-toxic patients had normal 
concentrations of 5-methyl-THF and SAM two weeks after the same MTX 
treatment. SAH could be quantified in all samples of both patients. Since 
most SAH concentrations in the non-toxic ALL population were below LLOQ a 
quantitative comparison was not possible.  
Low CSF 5-methyl-THF levels were also reported by Quinn et al.105 in one 
pediatric ALL patient who developed signs of subacute neurotoxicity four 
days after receiving the first course of triple intrathecal therapy which 
included 8 mg MTX. This patient presented with seizures and CSF was 
obtained by lumbar puncture shortly afterwards. The analysis revealed a 
concentration decrease of the reduced folate from 80 nM (prior to therapy) to 
11 nM. In addition, an increase of concentrations of homocysteine and of the 
excitatory amino acids homocysteic and cysteine sulphinic acid was 
observed.  
An overview of literature data regarding CSF 5-methyl-THF, SAM and SAH 
concentration in patients with manifest MTX-related neurotoxicity is 
presented in Table 5.6. 
It is possible that both patients in this study developed toxicity due to 
MTX-related biochemical alterations. Interesting is the fact that both patients 
received intrathecal MTX (a total of 60 mg) during protocol I which was well  
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Table 5.6: CSF concentrations of 5-methyl-THF, SAM and SAH in patients with 
MTX-associated neurotoxic symptoms. 
Author Toxicity 
CSF 5-methyl-
THF conc. 
(nM) 
CSF SAM 
conc. 
(nM) 
CSF SAH 
conc. 
(nM) 
Quinn et 
al.105  
1 case of 
subacute toxicity 
11.0  
Not 
reported 
Not 
reported 
Kishi et 
al137. 
2 cases of chronic 
toxicity 
Not 
reported 
32.9  
65.8 
27.5  
34.4  
2 cases of 
subacute toxicity 
19.1  
27.5 
79.3 
74.8 
8.6  
10.4  
This work 
2 cases of chronic 
toxicity 
29.3-31.8  
18.7-27.7 
<25-184.5 
34.1-47.6 
7.5-14.3 
5.0-11.4 
 
tolerated. Toxicity occurred after receiving a combination of high-dose 
infusion and intrathecal MTX followed by rescue. In contrast, Strunk et al.185 
reported a patient treated according to the same protocol with a similar 
neurotoxicity episode which occured after intrathecal therapy in protocol I 
indicating that the development of toxicity is independent of the time of 
treatment.  
It was shown in the PCNSL collective that the high-dose (5 g/m2) MTX infusion 
induces a more extensive depletion of the 5-methyl-THF concentration than 
intraventricular MTX. After 3-4 infusions of calcium folinate (30 mg/m2) 
rescue which followed the systemic high-dose MTX infusions the 
concentration of 5-methyl-THF was replenished. The ALL patients received 
usually two infusions of 15 mg/m2 calcium folinate. Nevertheless, the 
non-toxic ALL population had normal CSF levels of reduced folates two weeks 
after the high-dose indicating a complete repletion of the pool of reduced 
folates. If it is postulated that in both patients rescue failed for some reason 
to restore the pool of reduced folates after the high-dose MTX infusion then 
it is possible that very low CSF 5-methyl-THF persisted for some time. This 
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could have induced the impairment of folate-related biochemical pathways 
leading further to manifest signs of toxicity.  
The third patient with MTX-related chronic toxicity had an approximately 
twofold lower CSF 5-methyl-THF concentration in all three obtained samples 
compared to the non-toxic patients. The SAM level was more than fourfold 
decreased in two of the three samples but it has to be mentioned that the 
patient had an overt infection and hyperbilirubinemia at the time of the third 
sample collection and it cannot be excluded that it influenced the CSF 
concentration of the compound. The CSF SAH concentration was quantified in 
all three obtained samples similar as in the two patients with subacute 
neurotoxicity. The patient received high-dose and intrathecal MTX therapy 
six and sixteen years prior to toxicity and at the time of first diagnosis 
cranial irradiation was performed as well. However, signs of MTX-related 
neurotoxicity never occurred during the therapy with the drug. Due to the 
long time period between last MTX therapy and sample collection it is 
uncertain whether the observed biochemical alterations are a consequence of 
MTX treatment. Nevertheless, the observed changes were similar as in the 
other patients with signs of neurotoxicity.  
 
 
5.5 Correlation between MTX, reduced folates, SAM 
and SAH concentrations in the CSF 
The CSF concentrations of MTX, 5-methyl-THF, SAM and SAH of PCNSL 
patients were examined for potential correlations in order to get a better 
insight into the biochemical alterations of the folate and one-carbon 
metabolism after MTX therapy. 
There was no significant correlation between CSF MTX, 5-methyl-THF, SAM 
and SAH concentrations in PCNSL patients after MTX therapy. It was shown in 
studies that there is no significant correlation between the concentrations of 
5-methyl-THF and SAM in the CSF or blood in a reference population of 
healthy children and adults whereas a correlation existed between SAM and 
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SAH in plasma but not in erythrocytes151, 186. However, since it is probable 
that time is required for the decrease of the SAM concentration after reduced 
folate depletion it cannot be excluded that a correlation between the 
metabolite concentrations exists after MTX therapy but was not evident at 
the same time during this monitoring. 
The lack of correlation between the CSF concentrations of reduced folates, 
SAM and SAH in healthy humans as well as in MTX-treated patients makes the 
assessment of biochemical alterations due to therapy more difficult. 
Moreover, it indicates that MTX-induced changes in the homocysteine 
pathway are probably multifactorial and cannot be predicted only by 
monitoring MTX and reduced folates in plasma and CSF.  
 
5.6 Potential clinical consequences of biochemical 
alterations after MTX treatment  
It was shown in PCNSL as well as in ALL patients that MTX induces 
biochemical alteration of the folate pathway. Moreover, the methyl-transfer 
pathway is impaired as well after administration of intrathecal MTX without 
concomitant rescue. However, the question arises what the clinical relevance 
of such biochemical alteration is in terms of MTX-related neurotoxicity. 
It was shown in PCNSL patients that both high-dose and intrathecal MTX 
induces a depletion of 5-methyl-THF in the CSF. In all patients of this study 
with clinical signs of MTX-related neurotoxicity decreased CSF 5-methyl-THF 
concentrations were observed both during and shortly after toxicity. Low CSF 
reduced folate levels have been associated with neurological complications 
involving seizures, cerebellar ataxia and psychomotor retardation115. 
Moreover, axonal neuropathy, myelopathy and leukoencephalopathy 
characterised by demyelinating lesions of the white matter were associated 
with folate deficiency187-190. However, the pathogenetic mechanism by which a 
decrease of the reduced folate concentrations could induce neurotoxicity 
remains unclear. It was postulated that a depletion of the pool of reduced 
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folates mediates toxicity indirectly by inducing a biochemical alteration of 
the folate-linked metabolic pathways44, 191, 192. It was shown in PCNSL patients 
that the decrease of the CSF levels of 5-methyl-THF was associated with the 
increase of the homocysteine concentration after intrathecal MTX 
administration140. Decreased CSF 5-methyl-THF and SAM concentrations were 
observed in ALL patients after administration of intrathecal MTX in this study. 
Also an alteration of the adenosine and biopterin pathway was associated 
with reduced folate deficiency80, 115, 193. Moreover, it has been postulated that 
neurotoxicity occurs after a delayed CSF excretion of MTX37, 194, 195. A 
prolonged MTX exposure in the CSF may hence induce a more extensive 
depletion of the pool of reduced folates. Furthermore, calcium folinate which 
replenishes the CSF concentration of 5-methyl-THF has been shown to be 
beneficial in preventing and reversing MTX-induced toxicity in some    
cases196, 197. In view of the above presented facts a simultaneous monitoring 
of the CSF concentration of 5-methyl-THF and MTX could be useful in 
establishing the role of the folate depletion in drug-associated neurotoxicity.  
It was postulated that a decrease of CSF SAM concentrations occurs after 
MTX therapy44, 136, 137, 192. In ALL patients of this study a decrease of the SAM 
concentrations was observed in protocols in which MTX had been 
administered without concomitant rescue. Decreased CSF SAM 
concentrations have been reported in patients with depression, HIV and 
subacute combined degeneration of the spinal cord117, 130-132, 134, 198. In all 
these patient collectives demyelination was observed which was associated 
with the methyl-transfer pathway impairment117, 129, 133, 134, 159. An impairment 
of the myelin sheath has been observed also in MTX-treated patients without 
clinical signs of neurological complications. It was shown in studies that 
9-50% of the patients treated with high-dose and intrathecal MTX followed by 
rescue develop subclinical transient changes of the white matter 
characterised as demyelination58, 73, 74, 199. Such findings were associated with 
the administration of intrathecal MTX and remyelination occurred after 
discontinuation of therapy58. The clinical impact of the transient white matter 
changes remains unclear.  
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Approximately 60% of childhood ALL survivors had a decreased overall and 
verbal intelligence quotient and/or arithmetic achievement after MTX therapy 
without concomitant cranial irradiation73, 200. There was no clear correlation 
between these findings and white matter changes. Nevertheless, there are 
indices that patients with white matter changes may be more susceptible to 
certain neuropsychological deficits, primarily involving attention74, 201. The 
results of neuropsychological testing and diagnostic imaging indicate that 
although clinically not worrisome pathologic changes of the white matter 
occur in a large number of patients treated with MTX especially when it is 
administered intrathecally. Since this route of administration was associated 
with decreased CSF SAM concentrations in this study, a potential correlation 
between the decrease of the SAM concentrations and the subclinical transient 
changes observed with MRI remains an interesting topic for further 
investigation.  
Two patients in this study presented with signs of transient subacute 
neurotoxicity characterised by hemiparesis and speech disorders after 
receiving high-dose and intrathecal MTX followed by calcium folinate rescue. 
Several cases with similar symptomatology were reported in the literature in 
which toxicity was associated with high-dose MTX43, 45, 52, 202, 203. Nevertheless, 
the same clinical picture was observed after intrathecal MTX administration 
as well54, 185, 204, 205 indicating that both routes of drug administration may 
induce similar alteration. Transient subacute neurotoxicity was associated 
with changes of the white matter in MRI which indicated damage of the 
myelin sheath45, 52, 56, 58, 73, 185, 203, 205, 206. However, severe necrosis of the white 
matter resulting in tissue loss is not associated with such disorder58. In 
accordance to the literature, some changes in the white matter were 
observed in the two patients with subacute transient neurotoxicity in this 
study as well. The analysis of a CSF sample obtained shortly after toxicity 
revealed in both patients an approximately twofold lower SAM concentrations 
compared to the ALL population prior to treatment. One of the patients had 
decreased SAM levels more than two months prior to toxicity as well. Due to 
these facts it is possible that the alteration of the methyl-transfer pathway 
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played an important role in the genesis of neurological complications in both 
patients.  
Two patients in the present work had signs of severe chronic neurotoxicity. 
Clinically, signs of cognitive dysfunction dominated. Cases of severe 
MTX-associated chronic neurotoxicity have been reported in the     
literature57, 207-212. Usually such toxicity was observed after combined MTX 
therapy and cranial irradiation47, 196, 207, 210, 213 which was administered in one 
of the cases in this study as well. However, cases of toxic 
leukoencephalopathy were observed after MTX regimens which were not 
accompanied by radiotherapy as well57, 208, 212. This was the case in the PCNSL 
patient in this study. MRI scans in both patients revealed 
leukoencephalopathy characterised by severe demyelination. These findings 
are common in patients presenting with this form of neurological 
complications63, 209, 214. CSF analysis of both patients revealed the lowest SAM 
concentrations measured in this study. Both patients had a more than 
fourfold lower SAM concentration compared to non-toxic patients at the 
time-point when toxicity was clinically present. Compared to the patients 
with subacute neurotoxicity lower CSF SAM concentrations and a much more 
pronounced demyelination were encountered in the leukoencephalopathic 
patients, a further indication that the impairment of the methyl-transfer 
pathway is involved in the development of MTX-associated neurotoxicity. 
However, further studies are necessary to provide a better understanding of 
the relationship between the decrease of CSF SAM concentrations, the degree 
of demyelination and clinical symptoms. For that purpose a monitoring of the 
CSF SAM concentrations in patients receiving intensive MTX therapy seems to 
be useful. Furthermore, it was shown that the CSF SAM concentrations were 
increased following the administration of oral SAM130, 198, 215. The question 
arises whether patients who have low CSF SAM concentrations i.e. after 
administration of intrathecal MTX without calcium folinate rescue could profit 
from such substitution. In this way the methylation capacity may be 
preserved without compromising the efficacy of MTX. 
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6 Summary 
The introduction of intrathecal (3-12 mg) and/or intravenous high-dose 
(≥ 1 g/m2) MTX administration followed by calcium folinate rescue into 
therapy protocols has significantly improved cure rates of malignancies such 
as ALL, PCNSL, medulloblastoma and osteosarcoma. Nevertheless, this 
therapy is associated with an increased frequency of neurotoxicity which is 
classified as acute, subacute and chronic according to clinical symptoms and 
time of their appearance. Usually acute and subacute toxicity is reversible 
whereas the chronic form which involves leukoencephalopathy characterised 
by demyelination may be present in a severe form ending with coma or even 
death. Due to the potential severity of neurotoxicity the elucidation of the 
pathogenesis remains an important topic in order to develop prevention 
strategies and increase the safety of MTX treatment.  
It was postulated that MTX by interfering with the folate metabolism induces 
an alteration of the folate-related metabolic pathways which may further lead 
to the genesis of neurological complications. Moreover, the supposed 
depletion of the only cellular methyl-donor SAM may result in the decreased 
methylation of choline which further leads to malformation of the neuronal 
myelin sheath (demyelination).  
The aim of this work was to get a better insight into the biochemical 
alterations of the folate and methyl-transfer pathway in the CSF after 
administration of MTX and to investigate whether these alterations are 
related to neurological complications. For this purpose analytical methods 
were developed and CSF samples from adult PCNSL patients and pediatric 
ALL patients were collected and analysed.  
The effect of MTX and calcium folinate rescue therapy on the folate 
metabolism was assessed by the quantification of 5,10-methylene-THF and 
5-methyl-THF. The four compounds were determined simultaneously using 
HPLC with UV and fluorescence detection. The method was validated 
according to the FDA guideline for validation of bioanalytical methods. The 
main advantage of the method is the simple sample preparation due to the 
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natural fluorescence of the reduced folates which enables the use of the 
method in the routine monitoring of the compounds. 
SAM and SAH were also determined by HPLC with the use of fluorescence 
detection. The method was validated according to the FDA guideline as well. 
The compounds were quantified as their 1,N6-etheno derivatives after 
incubation with chloroacetaldehyde. An appropriate selection of the 
stationary phase was crucial in obtaining the desired selectivity and 
sensitivity of the method. The main advantage of the developed method is 
the simultaneous separation of both analytes in an acceptable run time 
(35 min). 
Method development and validation was followed by the analysis of patient 
CSF samples. Five adult PCNSL patients whith an implanted Ommaya 
reservoir and treated according to the Bonn protocol were included in the 
study. One of them received an intensified calcium folinate rescue initiated 
one hour after the end of the high-dose MTX infusion (3 g/m2) and it was 
possible to monitor the drug and reduced folates within 24 h after the end of 
the high-dose infusion. 5,10-methylene-THF and calcium folinate could be 
determined in the CSF of the patient. In the same time period MTX decreased 
rapidly whereas an increase of the 5-methyl-THF concentration was observed 
as a consequence of rescue. From the other four patients CSF samples were 
obtained on four or five subsequent days during a treatment block enabling 
close monitoring after therapy. In some blocks patients received high-dose 
MTX (3-5 g/m2) infusions followed by calcium folinate rescue and 
intraventricular MTX administration (3 mg/day) while in others MTX was 
administered only intraventricularly and was not accompanied by rescue. 
This enabled a distinction between the two treatment modalities regarding 
biochemical alterations. It was observed that high-dose MTX caused a 
massive depletion of the CSF 5-methyl-THF concentration determined at the 
end of infusion which was repleted after rescue administration. The 
5-methyl-THF concentrations decreased to a lower extent 24 h after 
intraventricular MTX administration. However, at the end of the block the 
reduced folate concentration was 2-3 fold lower compared to the beginning. 
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The low reduced folate concentrations persisted for some time since no 
calcium folinate was administered. In contrast to the depletion of folates an 
alteration of the SAM and SAH concentration was not observed during blocks. 
Nevertheless, in one patient lower CSF SAM concentrations were observed 
approximately two weeks after the treatment block with intraventricular MTX 
suggesting that the SAM concentrations decreased only after a persistent 
depletion of 5-methyl-THF. One patient had clinical signs of chronic toxicity 
in form of leukoencephalopathy. Low 5-methyl-THF concentrations were 
determined in this patient throughout the therapy. The SAM concentrations 
decreased during therapy and were extremely low at the time of appearance 
of neurological complications whereas the SAH concentration did not alter 
significantly during therapy. 
CSF samples were also obtained from two pediatric ALL collectives. Sampling 
was performed one to three weeks after the last MTX therapy enabling an 
insight into the biochemical alterations of the folate and methyl-transfer 
pathway weeks after treatment. It was observed that the concentrations of 
5-methyl-THF and SAM were in the normal range two weeks after the 
treatment with high-dose (2.5 or 5 g/m2) and intrathecal (8-12 mg) MTX 
followed by calcium folinate rescue. In contrast, in protocols with intrathecal 
MTX (8-12 mg) not accompanied by folinate rescue the 5-methyl-THF 
concentrations were significantly decreased 12 days after the first intrathecal 
MTX administration but not later-on whereas SAM was significantly decreased 
throughout these protocols. Such results support the hypothesis that the 
depletion of SAM probably occurs only after persistently low 5-methyl-THF 
concentrations.  
Three ALL patients manifested signs of neurotoxicity. Two exhibited 
subacute neurotoxicity characterised by hemiparesis and speech disorder 
which resolved spontaneously. Both patients had low levels of 5-methyl-THF 
and SAM shortly after the toxic episode. One patient exhibited a 
leukoencephalopathy probably as a consequence of earlier MTX therapy. Low 
5-methyl-THF and SAM concentrations were found in this patient as well. 
Moreover, demyelination was present in all four neurotoxic patients 
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indicating that the low CSF SAM concentration may indeed contribute to this 
disorder. 
In conclusion, the results suggest that the biochemical alterations of the 
folate and methyl-transfer pathway may play an important role in the genesis 
of neurotoxicity of MTX. Nevertheless, further prospective studies with more 
patients are required to clarify the relationship between decreased SAM 
concentrations, demyelination and its role in subacute and especially chronic 
MTX-related neurotoxicity. In addition, the possible role of low reduced folate 
and SAM concentrations in the prediction of neurologic complications 
deserves further investigation. 
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Appendix 
 
Appendix A 
 
Results of the CSF analysis of reduced folates, MTX, SAM and SAH in PCNSL 
patients treated in the Department of Neurology, University Hospital, 
Rheinische Friedrich-Wilhelms-Universität, Bonn. 
 
Graphical presentation of the data of patient 2-5 in Fig. 1-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CSF concentrations of reduced folates, MTX, SAM and SAH in patients treated 
according to the Bonn protocol for PCNSL 
Pat. 
1 
 Concentration 
 
(h) after 
end of 
HD-MTX 
infusion 
5,10-MeTHF 
(nM) 
5-MTHF 
(nM) 
Ca-folinate 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
1 0  n.d. n.d. n.d. 2.9 - - 
1 1  n.d. n.d. n.d. 2.3 - - 
1 3.5  n.q. n.q. n.q. 1.7 - - 
1 7  22.0 28.0 n.q. 1.2 - - 
1 24  28.0 44.0 118.0 0.2 - - 
        
Time Concentration Pat. 
2 
 
Block/day 
5,10-MeTHF 
(nM) 
5-MTHF 
(nM) 
Ca-folinate 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
2 A1/3 n.d. 32.4 n.d. 2.6 236.2 n.q. 
2 A1/4 n.d. 22.7 n.d. 6.7 183.1 n.q. 
2 A1/5 n.d. 26.7 n.d. 1.6 220.2 n.q. 
2 B1/2 n.d. n.q. n.d. 0.7 182.9 n.q. 
2 B1/3 n.d. 65.6 n.d. 5.5 184.5 n.q. 
2 B1/4 n.d. 55.1 n.d. 18.7 170.8 n.q. 
2 B1/5 n.d. 44.2 n.d. 9.2 230.4 n.q. 
2 C1/3 n.d. 63.0 n.d. n.d. 229.8 n.q. 
2 C1/4 n.d. 47.2 n.d. 39.4 263.3 n.q. 
2 C1/5 n.d. 40.0 n.d. 8.3 245.2 n.q. 
2 C1/6 n.d. - n.d. 35.3 284.8 n.q. 
2 C1/7 n.d. 26.0 n.d. 30.8 280.1 n.q. 
2 B2/2 n.d. n.q. n.d. 0.9 199.7 n.q. 
2 B2/3 n.d. 44.4 n.d. 1.5 261.9 n.q. 
2 B2/4 n.d. 50.7 n.d. 2.5 217.2 n.q. 
2 B2/5 n.d. 82.2 n.d. 15.1 203.8 n.q. 
2 C2/3 n.d. 75.0 n.d. n.d. 271.9 n.q. 
2 C2/4 n.d. 62.5 n.d. 1.5 264.3 n.q. 
2 C2/5 n.d. 56.8 n.d. 2.1 250.3 n.q. 
2 C2/6 - - - - - - 
2 C2/7 n.d. 48.5 n.d. 3.4 221.6 n.q. 
 
 
 
 
Time Concentration Pat. 
 3 
 
Block/day 
5,10-MeTHF 
(nM) 
5-MTHF 
(nM) 
Ca-folinate 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
3 B1/2 - - - - - - 
3 B1/3 n.q. 97.9 n.d. 5.6 614.4 7.0 
3 B1/4 n.d. 35.9 n.d. 2.2 697.2 6.1 
3 B1/5 n.d. 71.3 n.d. 1.6 516.3 6.2 
3 C1/3 n.d. 59.5 n.d. n.d. 579.3 5.3 
3 C1/4 n.d. 32.8 n.d. 1.3 672.7 7.4 
3 C1/5 n.d. 21.0 n.d. 1.4 645.4 9.5 
3 C1/6 n.d. 12.0 n.d. 9.1 579.7 6.3 
3 C1/7 n.d. 15.3 n.d. 3.4 557.3 11.0 
3 A2/2 - - - - - - 
3 A2/3 n.d. 48.3 n.d. 20.3 148.1 5.0 
3 A2/4 n.q. 90.9 n.d. 3.5 210.4 7.0 
3 A2/5 n.d. 75.4 n.d. 2.3 358.7 6.2 
3 B2/2 n.d. n.q. n.d. 2.0 641.2 6.6 
3 B2/3 n.d. 63.8 n.d. 1.3 856.7 8.9 
3 B2/4 n.d. 84.8 n.d. 2.0 856.8 10.2 
3 B2/5 - - - - 798.3 12.5 
3 C2/3 n.q. 74.1 n.d. n.d. 903.0 7.8 
3 C2/4 n.d. 23.4 n.d. 1.5 966.6 8.0 
3 C2/5 n.d. 33.2 n.d. 1.3 899.1 8.3 
3 C2/6 n.d. 28.2 n.d. 1.5 854.3 8.2 
3 C2/7 n.d. 20.6 n.d. 2.2 866.8 9.1 
        
Time Concentration Pat. 
 4 
 
Block/day 
5,10-MeTHF 
(nM) 
5-MTHF 
(nM) 
Ca-folinate 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
4 A1/3 n.q. 122.4 n.d. 0.8 283.5 9.3 
4 A1/4 n.q. 75.9 n.d. 0.3 295.3 11.8 
4 A1/5 n.d. 30.0 n.d. 0.4 279.4 n.q. 
4 C1/3 n.q. 91.8 n.d. n.d. 409.1 6.4 
4 C1/4 n.d. 72.1 n.d. 0.7 362.6 7.1 
4 C1/5 n.d. 35.9 n.d. n.q. 182.4 5.3 
4 C1/6 n.d. 56.2 n.d. 0.3 376.2 6.4 
4 C1/7 n.d. 48.1 n.d. 0.2 357.1 5.7 
4 A2/2 n.d. n.d. n.d. 1.5 424.8 n.q. 
4 A2/3 n.d. 69.3 n.d. 0.5 261.3 n.q. 
4 A2/4 n.d. 83.7 n.d. 0.3 441.9 n.q. 
4 A2/5 n.d. 67.6 n.d. 0.4 144.3 n.q. 
 
 
 
 
 
Pat. Time Concentration 
 Block/Day 
5,10-MeTHF 
(nM) 
5-MTHF 
(nM) 
Ca-folinate 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
5 B1/2 n.d. 13.3 n.d. 1.1 127.4 7.2 
5 B1/3 n.d. 57.5 n.d. 1.9 122.1 9.4 
5 B1/4 n.d. 41.8 n.d. 1.3 119.0 5.6 
5 B1/5 n.d. 23.0 n.d. 2.6 90.8 6.5 
5 C1/3 n.d. 13.5 n.d. n.d. 44.7 6.5 
5 C1/4 n.d. 22.9 n.d. 3.2 54.2 7.9 
5 C1/5 n.d. 17.8 n.d. 1.4 48.9 7.1 
5 C1/6 n.d. 16.2 n.d. 2.8 51.3 7.5 
5 C1/7 n.d. 14.0 n.d. 1.8 48.7 7.3 
5 A2/2 - - - - - - 
5 A2/3 n.d. 18.8 n.d. 1.4 34.1 5.0 
5 A2/4 n.d. 27.8 n.d. 3.8 38.8 11.4 
5 A2/5 n.d. 14.0 n.d. 1.9 47.6 7.4 
 
n.d.:  not detected 
n.q.:  not quantified 
 -: sample not obtained 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.1: CSF concentration of MTX (A) and 5-methyl-THF (B) in patient 2.  
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Fig.2: CSF concentration of SAM (C) in patient 2. 
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Fig. 3: CSF concentration of MTX (A) and 5-methyl-THF (B) in patient 3.   
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Fig.4: CSF concentration of SAM (C) and SAH (D) in patient 3. 
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Fig. 5: CSF concentration of MTX (A) and 5-methyl-THF (B) in patient 4. 
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Fig. 6: CSF concentration of SAM (C) and SAH (D) in patient 4. 
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Fig. 7: CSF concentration of MTX (A) and 5-methyl-THF (B) in patient 5.  
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Fig. 8: CSF concentration of SAM (C) and SAH (D) in patient 5. 
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Appendix B 
 
Results of the CSF analysis of 5-methyl-THF, MTX, SAM and SAH in patients 
treated according to ALL BFM 2000. 5,10-methylene-THF and calcium folinate 
were not quantified in any of these samples. 
 
 
CSF concentrations of 5-methyl-THF, MTX, SAM and SAH in patients treated 
according to ALL BFM 2000. 
Pat. Time Concentration 
  
5-MTHF 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
1 Protocol I, day 1 65.3 n.d. 194.9 n.q. 
1 Protocol I, day 12 36.8 n.d. 143.4 n.q. 
1 Protocol I, day 45 42.0 n.d. 166.8 n.q. 
1 Protocol I, day 59 66.1 n.d. - - 
1 Protocol M, day 8 71.9 1.6 - - 
2 Protocol I, day 12 24.2 n.d. - - 
2 Protocol I, day 33 41.5 n.d. - - 
2 Protocol I, day 59 19.3 n.d. 104.6 n.q. 
2 Protocol M, day 8 12.0 3.8 77.4 n.q. 
2 Protocol M, day 22 41.5 n.q. 132.8 5.6 
2 Protocol M, day 50 - - 75.8 5.0 
2 Protocol II, day 38 108.3 n.d. - - 
2 Protocol II, day 45 76.9 n.d. - - 
3 Protocol I, day 1 - - 156.9 n.q. 
3 Protocol I, day 12 11.9 n.d. 86.1 n.q. 
3 Protocol I, day 33 13.3 n.d. 74.2 n.q. 
3 Protocol M, day 8 20.8 0.8 - - 
3 Protocol M, day 22 36.2 0.2 - - 
3 Protocol M, day 50 38.1 0.4 - - 
4 Protocol I, day 12 - - 108.2 6.0 
4 Protocol M, day 8 n.q. 0.3 - - 
4 Protocol M, day 22 32.8 0.5 151.1 5.3 
4 Protocol M, day 36 26.7 0.3 90.0 5.5 
4 Protocol II, day 45 27.9 n.d. - - 
5 Protocol I, day 1 35.2 n.d. - - 
5 Protocol I, day 12 40.7 n.d. - - 
5 Protocol I, day 45 57.8 n.d. - - 
5 Protocol I, day 59 44.2 n.d. - - 
5 Protocol M, day 8 28.5 0.3 131.8 8.3 
5 Protocol M, day 22  37.8 0.3 145.7 7.2 
5 Protocol M, day 36 54.2 0.3 200.7 6.1 
5 Protocol M, day 50 - - 131.8 8.5 
6 Protocol I, day 12 15.7 n.d. 67.4 n.q. 
6 Protocol I, day 45 80.2 n.d. 111.0 n.q. 
6 Protocol I, day 59 100.6 n.d. 77.5 n.q. 
6 Protocol M, day 8 55.7 0.6 246.2 n.q. 
6 Protocol M, day 22 88.1 0.3 - - 
6 Protocol M, day 36 - - 227.9 n.q. 
7 Protocol I, day 1 91.9 n.d. 175.2 n.q. 
7 Protocol I, day 33 68.6 n.d. 128.9 n.q. 
 
 
 
 Pat. Time Concentration 
  
5-MTHF 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
8 Protocol I, day 1 - - 224.4 n.q. 
8 Protocol I, day 12 17.5 n.d. 120.6 n.q. 
8 Protocol I, day 33 24.0 n.d. 120.9 n.q. 
8 Protocol I, day 45 - - 149.3 n.q. 
8 Protocol I, day 59 53.0 n.d. - - 
8 Protocol M, day 8 - - 199.7 n.q. 
8 Protocol M, day 22 23.6 0.7 219.4 n.q. 
8 Protocol M, day 36 43.6 0.7 182.5 n.q. 
8 Protocol M, day 50 - - 221.1 n.q. 
9 Protocol I, day 45 26.9 n.d. - - 
9 Protocol M, day 8 15.7 0.3 - - 
9 Protocol M, day 22 39.4 0.3 - - 
9 Protocol M, day 38 31.4 n.q. - - 
10 Protocol I, day 59 45.7 n.d. - - 
10 Protocol M, day 8 53.3 n.q. - - 
10 Protocol M, day 50 25.0 0.5 154.6 10.6 
10 Protocol II, day 38 72.8 n.d. 27.7 n.q. 
11 Protocol I, day 45 32.1 n.d. - - 
11 Protocol I, day 59 - - 205.5 n.q. 
11 Protocol M, day 8 - - 227.4 n.q. 
11 Protocol M, day 22 36.4 0.5 176.6 n.q. 
11 Protocol M, day 36 27.9 8.5 178.6 n.q. 
11 Protocol M, day 50 28.4 3.2 190.5 n.q. 
11 Protocol III, day 17 - - 111.3 n.q. 
11 Protocol III, day 24 - - 171.6 n.q. 
12 Protocol I, day 1 52.2 n.d. 201.9 n.q. 
12 Protocol I, day 12 - - 152.1 n.q. 
12 Protocol I, day 33 - - 182.8 n.q. 
12 Protocol I, day 45 - - 112.2 n.q. 
12 Protocol I, day 59 68.9 n.d. 108.1 n.q. 
12 Protocol III, day 24 92.5 n.d. 76.6 n.q. 
13 Protocol I, day 33 26.7 n.d. - - 
13 Protocol M, day 22 122.5 0.7 - - 
13 Protocol M, day 36 110.0 0.5 - - 
14 Protocol I, day 1 78.6 n.d. - - 
15 Protocol I, day 45 113.6 n.d. 56.4 n.q. 
16 Protocol M, day 36 66.3 0.6 - - 
17 Protocol I, day 1 59.6 n.d. 90.0 n.q. 
17 Protocol I, day 12 39.2 n.d. - - 
17 Protocol I, day 45 - - 72.0 n.q. 
17 Protocol III, day 17 - - 94.3 9.0 
17 Protocol III, day 24 - - 140.3 n.q. 
 
 
 
 Pat. Time Concentration 
  
5-MTHF 
(nM) 
MTX 
(µM) 
SAM 
(nM) 
SAH 
(nM) 
18 Protocol I, day 1 53.0 n.d. 232.4 5.0 
18 Protocol M, day 36 - - 199.7 n.q. 
18 Protocol M, day 50 - - 506.9 n.q. 
18 Protocol III, day 17 - - 93.7 n.q. 
18 Protocol III, day 24 - - 199.6 n.q. 
19 Protocol I, day 1 53.3 n.d. 129.3 n.q. 
19 Protocol I, day 59 70.0 n.d. 94.1 n.q. 
19 Protocol M, day 22 35.2 1.9 106.6 n.q. 
19 Protocol III, day 24 - - 94.7 n.q. 
20 Protocol M, day 22 - - 63.3 n.q. 
20 Protocol III, day 17 27.9 n.d. 85.7 5.2 
20 Protocol III, day 24 28.4 n.d. 81.2 15.5 
21 Protocol III, day 24 15.2 n.d. - - 
22 Protocol M, day 8 23.5 2.4 - - 
22 Protocol M, day 36 - - 186.0 n.q. 
22 Protocol M, day 50 66.4 0.1 138.3 7.5 
22 Protocol III, day 17 27.8 n.d. 89.7 n.q. 
22 Protocol III, day 24 18.5 n.d. 121.5 n.q. 
23 Protocol I, day 1 - - 278.4 n.q. 
23 Protocol I, day 12 - - 136.1 n.q. 
23 Protocol I, day 33 - - 144.8 n.q. 
23 Protocol I, day 45 - - 166.1 n.q. 
23 Protocol I, day 59 - - 115.8 n.q. 
24 Protocol III, day 45 - - 58.3 6.0 
25 Protocol M, day 8 - - 187.9 n.q. 
25 Protocol M, day 50 - - 336.7 n.q. 
26 Protocol I, day 1 - - 282.8 11.5 
26 Protocol I, day 12 - - 131.5 7.4 
26 Protocol I, day 59 - - 242.0 12.3 
26 Protocol M, day 22 - - 121.7 n.q. 
26 Protocol M, day 36 - - 106.8 n.q. 
27 Protocol I, day 1 - - 103.1 n.q. 
27 Protocol I, day 12 - - 89.5 n.q. 
27 Protocol I, day 33 - - 46.3 n.q. 
 
n.d.: not detected 
n.q.: not quantified 
-:  sample not obtained 
 
 
  
Appendix C 
 
Results of the CSF analysis of 5-methyl-THF in pediatric ALL patients 
treated according to the ‘TOTAL XV’ Protocol. 5,10-methylene-THF, 
calcium folinate and MTX were not quantified in any of these samples. 
 
 
CSF concentration of 5-methyl-THF in children treated according to TOTAL XV. 
Patient 
 
Time 
 
Conc. of 5-methyl-THF 
(nM) 
1 Remission/Induction, day 1 67.5 
1 Consolidation, day 1 67.1 
1 Consolidation, day 15 67.2 
2 Remission/Induction, day 1 62.7 
2 Consolidation, day 1 62.0 
2 Consolidation, day 15 66.4 
3 Remission/Induction, day 1 86.2 
3 Consolidation, day 1 84.6 
3 Consolidation, day 15 86.8 
4 Remission/Induction, day 1 59.8 
4 Consolidation, day 1 61.8 
4 Consolidation, day 15 56.2 
5 Remission/Induction, day 1 68.5 
5 Consolidation, day 1 68.1 
5 Consolidation, day 15 79.3 
6 Remission/Induction, day 1 43.0 
6 Consolidation, day 1 36.1 
6 Consolidation, day 15 43.5 
7 Consolidation, day 1 103.9 
7 Consolidation, day 15 88.2 
8 Consolidation, day 1 59.8 
8 Consolidation, day 15 69.5 
9 Consolidation, day 1 61.6 
9 Consolidation, day 15 17.8 
10 Consolidation, day 1 44.1 
10 Consolidation, day 15 56.5 
11 Consolidation, day 1 35.0 
11 Consolidation, day 15 36.7 
12 Consolidation, day 1 60.4 
12 Consolidation, day 15 46.7 
13 Consolidation, day 1 25.6 
13 Consolidation, day 15 52.9 
14 Consolidation, day 1 47.7 
14 Consolidation, day 15 53.1 
15 Remission/Induction, day 1 85.6 
15 Consolidation, day 1 56.7 
16 Remission/Induction, day 1 50.7 
16 Consolidation, day 1 57.5 
17 Remission/Induction, day 1 60.9 
17 Consolidation, day 15 43.0 
18 Remission/Induction, day 1 55.7 
18 Consolidation, day 15 58.6 
 
 
 
